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CHAPTER 1  
INTRODUCTION 
The steady rise in Western obesity rates has been closely linked to significant increases in a 
multitude of accompanying health problems including type II diabetes and non-alcoholic fatty 
liver disease (NAFLD). NAFLD severity ranges from simple steatosis to acute steatohepatitis, 
but the molecular mechanisms controlling progression of this disease are poorly understood (1). 
The liver plays a central role in whole-body lipid, amino acid and glucose metabolism and 
therefore impairments in hepatic function are detrimental to a variety of biological processes 
including lipoprotein export, lactate and nitrogen recycling, gluconeogenesis and overall 
physiological homeostasis. Hepatic dysfunction associated with NAFLD is thought to be 
triggered by elevated free fatty acid flux from either adipose tissue or diet that results in ectopic 
deposition of fat in the liver (2). It is known to be accompanied by increased signaling though 
cellular stress pathways, oxidative stress and hepatocyte apoptosis. This phenotype is 
collectively termed hepatic lipotoxicity (3, 4). 
Recent literature suggests that elevated free fatty acids (FFAs), especially saturated FFAs, play a 
central role in lipotoxic mechanisms, both in experimental models and in NAFLD patients (5). 
Relevant cellular processes that have been causally linked to lipid-induced apoptosis, known as 
lipoapoptosis, include endoplasmic reticulum (ER) stress, oxidative stress, mitochondrial 
dysfunction, and Jun N-terminal kinase (JNK) signaling (6-10).  In contrast, increased 
triglyceride synthesis has been shown to have a protective effect against lipotoxicity (5, 6, 8, 11), 
despite being one of the hallmark traits of NAFLD. The overarching theme of this dissertation is 
to examine how the degree of intrahepatic lipid saturation controls cell fate in response to an 
elevated FFA load and to identify the mechanisms though which these fatty acids promote 
hepatocyte dysfunction. Developing a more nuanced understanding of the molecular mechanisms 
underlying NAFLD progression will lead to more targeted and effective therapeutics for this 
increasingly prevalent disease, which to date has no proven pharmacologic treatment to prevent 
or reverse its course. 
Chapter 2 provides a summary review of pertinent background information that is important for 
understanding the motivation behind this dissertation. The review covers general metabolic 
syndrome and its hepatic manifestation of NAFLD and NASH, as well as experimental methods, 
both in vitro and in vivo, that have been used previously to gain insight into the molecular 
mechanisms involved in these diseases. 
Chapter 3 investigates differences between the effects that saturated fatty acids (e.g., palmitate) 
and unsaturated fatty acids (e.g., oleate) have on hepatic cells in vitro (Fig 1-1 A and B). We 
found that palmitate treatment resulted in lipotoxic cell death that was characterized by increased 
membrane phospholipid saturation, ER stress and eventual apoptosis. Oleate, however, increased 
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lipid accumulation but did not induce cell death. Furthermore, co-supplementation of oleate with 
palmitate protected cells from palmitate-associated lipotoxic phenotypes. Interestingly, in 
palmitate-supplemented cells we observed accumulation of lipid intermediates that are indicative 
of increased Kennedy pathway activity and phospholipid synthesis. Our data reveal that 
palmitate-supplemented cells exhibit increased abundance of saturated phospholipids and 
reduced triglyceride accumulation, a phenotype that is reversed by palmitate and oleate co-
treatment.  
 
 
Figure 1-1. Summary of proposed mechanisms investigated in Chapters 3 and 4. In Chapter 3, we 
investigated the mechanism by which the saturated fatty acid palmitate (PA) initiates ER stress and 
culminates in apoptosis (A) and how this changes with addition of the monounsaturated fatty acid oleate 
(OA) (B). In Chapter 5, we examined the effect that inhibiting triglyceride (TG) synthesis would have on 
PA-treated hepatic cells (C). 
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These findings led to the work described in Chapter 4, where we investigated whether it was 
oleate’s stimulatory effect on triglyceride synthesis that led to reversal of ER stress and cell 
death in palmitate-treated cells or if it was the desaturating effect it had on membrane 
phospholipids that led to the rescue. In these studies, we used siRNA targeted knockdown of 
DGAT1 and DGAT2, the rate limiting enzymes in triglyceride synthesis, to prevent oleate-
mediated increases in lipid droplet accumulation (Fig 1-1C). Interestingly, even with significant 
reductions in triglyceride synthesis, oleate co-supplementation still provided an equally strong 
rescue effect in palmitate-treated cells. Our data indicate that oleate supplementation enables 
hepatocytes to counteract palmitate’s saturating effect on membrane phospholipids and to 
renormalize fluidity in the lipid bilayer, thus rescuing palmitate-induced ER stress and 
lipoapoptosis.  
In Chapter 5, our aim was to examine whether channeling palmitate away from phospholipid 
incorporation and into alternative pathways of cellular utilization, such as β-oxidation, would 
reduce its toxic effect. A small molecule agonist (AICAR) and/or specific inhibitor (etomoxir) of 
β-oxidation was applied to our in vitro hepatic system to determine the effect that modulating 
this route of fatty acid disposal had on lipotoxic phenotypes (Fig. 1-2A). We determined that 
inhibiting β-oxidation provided no positive benefits in terms of the lipotoxic phenotype in 
palmitate-treated cells. Conversely, increasing oxidation of palmitate did provide some beneficial 
effects to normalize phospholipid saturation, ER stress and cell survival, although this might 
have been partially due to the pleiotropic effects of AICAR.  
We also sought to test whether direct intervention in phospholipid synthesis and remodeling to 
prevent palmitate-induced saturation would reduce lipotoxicity in the studies described in 
Chapter 6. Our method was to use a pharmacologic inhibitor of iPLA2 (PACOCF3) to prevent 
breakdown and remodeling of phospholipids via the Lands’ cycle as well as siRNA targeted 
knockdown of the rate limiting step (Pcty1α) in phosphatidylcholine synthesis to accomplish this 
task (Fig. 1-2B). Our hypothesis was that preventing incorporation of palmitate into 
phospholipids in either of these two pathways would reduce the membrane oversaturation that is 
characteristic of palmitate-treated cells and thereby relieve ER stress. While both methods did 
lead to some improvements in lipotoxic phenotypes in hepatic cells, neither was completely 
effective. This is likely due to the fact that we were targeting only specific routes of palmitate 
incorporation into the phospholipid pool and, therefore, were unable to fully normalize 
membrane saturation due to redundancy in these lipid biosynthetic pathways. 
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Finally, we were interested in developing an in vivo model system that would enable us to test 
specific hypotheses generated from our in vitro studies. We performed a pilot study that involved 
feeding rats a Western-style diet rich in saturated fats and cholesterol for up to 12 weeks. 
Unfortunately, this strategy did not prove to be effective at inducing a NASH-like phenotype 
with traits characteristic of human disease within the time-frame of our study. However, direct 
infusion of ethyl palmitate into the jugular vein of mice has yielded interesting initial results that 
appear to parallel the mechanisms we have previously identified in our in vitro hepatic models. 
The results of these pilot studies are described in Chapter 7, with an eye toward continued 
development of in vivo model systems for the study of NAFLD and NASH.  
Chapter 8 summarizes the overall findings of this dissertation and presents suggestions for 
future experimental work to further this research. 
 
 
  
Figure 1-2. Summary of proposed mechanisms investigated in Chapters 5 and 6. In Chapter 5, we asked 
whether modifying β-oxidation rates would impact PA-induced lipotoxicity using pharmacological modulators 
(A). In Chapter 6, we sought to determine the effects that blocking PA incorporation into phospholipids (PL) by 
inhibiting iPLA2 or Pcyt1α would have in PA-treated hepatic cells (B). 
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CHAPTER 2  
BACKGROUND AND SIGNIFICANCE  
Introduction 
As the global waistline continues to expand, the incidences of obesity and type II diabetes are 
reaching epidemic proportions. Insulin resistance and obesity are often associated with a cluster 
of other metabolic abnormalities including hypertension, dyslipidemia, and hyperinsulinemia, 
collectively termed the “metabolic syndrome.” The pathogenesis of this disease state is 
hypothesized to begin with abnormal accumulation of lipids in non-adipose tissues (steatosis) 
due to increased export of free fatty acids from adipose tissue. The hepatic manifestation of 
metabolic syndrome is known as non-alcoholic fatty liver disease (NAFLD), a chonic condition 
affecting approximately one-third of the US population (1). Because of its growing prevalence in 
Western society, NAFLD is currently the leading cause of referrals to hepatology clinics in the 
US. An estimated 10% of NAFLD patients will progress to a more severe condition known as 
nonalcoholic steatohepatitis (NASH), which involves liver inflammation and apoptotic cell death 
and can eventually result in cirrhosis and/or liver failure (2). Despite its prevalence and potential 
serious complications, the underlying molecular mechanisms that regulate NAFLD progression 
remain poorly understood, and further investigation is needed to identify targeted therapeutic 
approaches for prevention and treatment of this disease. Lack of such knowledge represents an 
important problem, because it limits the ability of biomedical researchers to develop novel 
nutritional and/or pharmacologic interventions to combat the effects of NAFLD and to prevent 
its progression toward NASH (3).   
 
Models of NASH and the role of free fatty acids 
Identifying and diagnosing individuals with pathological NASH relies on biopsies and blood 
plasma samples to determine disease severity. NAFLD/NASH progression identification is based 
on the NAFLD Activity Score (NAS) and indicators of liver fibrosis. NAS was created by the 
Pathology Committee of the NASH Clinical Research Network (4) as method to use 14 
histological features of NASH, including lobular inflammation, lipid accumulation (steatosis) 
and hepatocellular ballooning, to score the degree of liver disease and differentiate the severity 
of NAFLD progression in liver biopsies (NAS ≥5 indicates a diagnosis of NASH, NAS ≤3 
diagnosis “not NASH”). Plasma markers of liver disease have historically included elevated 
levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). While these 
plasma makers are commonly accepted as indicators of general liver disease, they are not reliable 
biomarkers of nor specific to NASH. In fact, there appears to be only a weak correlation between 
elevated AST/ALT levels and diagnosis of NASH, and is a poor metric for the independent 
diagnosis of NASH (5, 6).  
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Animal models are an important research tool for investigating pathological mechanisms of 
NASH development as diagnosis of human NASH in the medical setting is invasive and not 
always definitive and the scope of experimental interventions that can be applied clinical studies 
is limited. Larter et al provide an excellent review of a multitude of animal experimental models 
of NASH, including those that are induced though diet, genetics or pharmacological intervention 
(7). Each of these models, however, has its advantages, disadvantages and discrepancies that 
must be taken into consideration when making correlation to manifestations and mechanisms of 
human NASH.  
 
Common animals models used in obesity and diabetes research, such as leptin receptor deficient 
db/db and leptin deficient ob/ob mice, do not spontaneously develop NASH without further 
intervention, despite significant accumulations of hepatic lipids (8, 9). Rodent models often 
employ secondary assaults, such lipopolysaccharide  (10) or a methionine and choline deficient 
(MCD) diet (11), in order to induce clinical symptoms of NASH. The MCD diet has been 
particularly popular in the past because even wild-type animals on this diet will rapidly develop 
hepatic steatosis, inflammation and fibrosis (12-14), providing a model free of the confounding 
effects of insulin resistance (15). However, the etiological difference between MCD-induced 
rodent models of NASH and clinical human NASH raises questions about whether this model is 
ideal or relevant for determining mechanisms of the human disease (16). More recently 
developed rodent models of NASH, whereby genetically unaltered rodents are fed a “western” 
like diet of high calorie, saturated fat, cholesterol and/or fructose diet, appear to more closely 
mimic development and histological features of human NASH. These models include “cafeteria-
diet rats” (17), fed actual human “junk” food found in cafeterias, and the “fast-food mouse” (18), 
fed a specially formulated rodent feed designed to imitate a typical westernized diet. These 
animals develop features and symptoms of NASH gradually over a longer period of time making 
them less idea for the fast past laboratory environment, but appear to make more ideal models as 
they represent a more human-like manifestation of NASH.  
 
In vitro models offer an alternative to human and animal studies. Hepatic cell lines and primary 
hepatocytes provide a platform for exploring the detailed molecular mechanisms that regulate 
transition and severity of hepatic disease in vivo. Progressive liver and metabolic diseases have 
been associated with elevated plasma levels of free fatty acids and triglycerides (19). In vitro 
experiments have used free fatty acids supplemented to the media to mimic this environment and 
found that saturated fatty acid (SFA) overexposure promotes expression of pro-inflammatory 
cytokines, impairs inulin signaling and increases apoptotic signaling characterized by ER 
dysfunction and oxidative stress (20-24). On the other hand, monounsaturated fatty acids 
(MUFAs) increase steatotic accumulations of triglycerides but do not initiate the lipotoxic 
cascade culminating in apoptotic cell death (19, 20, 22, 25). Several putative mechanisms have 
been proposed to explain this phenomenon and how SFA overexposure may promote progression 
of NAFLD to NASH, including reactive oxygen species accumulation, increased endoplasmic 
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reticulum (ER) stress and elevated ceramide synthesis, but no definitive mechanism had been 
conclusively determined (26, 27). Ceramide formation and signaling would seem to be an easy 
and attractive explanation for the initiation of hepatic lipoapoptosis by SFAs because ceramides 
are synthesized de novo from palmitate and serine and have shown pro-apoptotic effects in 
myocytes (28). However, numerous pharmacologic and genetic intervention studies have 
demonstrated that SFA induced lipoapoptosis can occur independently of ceramide synthesis in a 
variety of cell types including CHO (19, 29), breast cancer cells (20) and hepatoma liver cells 
(30). This suggests that other mechanisms of SFA induced lipotoxicity, such as ER stress and 
ROS accumulation, present more important targets promotion of apoptosis. 
 
SFAs promote cellular dysfunction by activating ER stress pathways 
The ER is a specialized organelle that is integral in many cellular functions, particularly disulfide 
bond formation, proper protein folding, and synthesis and secretion of several critical 
biomolecules including steroids, cholesterol, and lipids (31). The ER also is the most important 
regulator of intracellular calcium (Ca
2+
) as a result of its large Ca
2+
 stores and Ca
2+
 ATPases, 
which are necessary for proper functioning of Ca
2+
-dependent chaperones that stabilize protein 
folding.  Very small changes in cellular redox state (32) or abnormal accumulation of unfolded 
proteins and/or toxic lipid species (33) can result in activation of compensatory response 
pathways, which comprise the unfolded protein response (UPR) (31, 34, 35). The UPR stress 
signaling pathway is initiated by thee main ER transmembrane proteins, protein kinase RNA-like 
endoplasmic reticulum kinase (PERK), inositol-requiring 1 (IRE-1), and activating transcription 
factor 6 (ATF6), which together promote transcription of genes designed to increase protein 
folding and degradation. Markers that are often assessed in order to demonstrate cellular ER 
stress include phosphorylation of the thee aforementioned transmembrane proteins as well as the 
splicing of X-box binding protein, initiated by IRE1 signaling, and CHOP, a pro-apoptotic 
protein downstream of PERK activation. The UPR initially serves a protective role to increase 
protein folding capacity and degrade any misfolded proteins already synthesized. However, 
excessive and/or prolonged stress can trigger apoptosis via JNK signaling and release of ER Ca
2+
 
stores (36) (see (35) for a comprehensive review of general ER stress pathways). The released 
Ca
2+
 is readily taken up by the mitochondria adjacent to ER Ca
2+
-release channels  (37). Acute 
Ca
2+
 overload results in changes in mitochondrial potential and opening of the permeability 
transition pore (PTP) (38), invoking a potent cellular death signal (32).  
 
Increasing empirical evidence points towards endoplasmic reticulum (ER) stress as an upstream 
signal in SFA-induced cellular dysfunction and apoptosis (Table 1). Clinical studies of patients 
suffering from metabolic syndrome disorders, such as NAFLD, have increased levels of ER 
stress markers in the liver and other tissues (39-41). In vivo data from male Wistar rats indicate 
that diets high in saturated, but not unsaturated, fat results in induction of hepatic ER stress and 
liver damage (42). SFAs have also demonstrated a potent ability to induce ER stress in a 
9 
 
multitude of cell types in vitro, including hepatocytes (42-44), pancreatic β-cells (45, 46), 
adipocytes (47) and CHO cells (48). Therefore, prior studies have sought to define the role of ER 
stress in mediating SFA-induced lipotoxicity. Pfaffenbach et al. (49) investigated the role of ER 
stress in palmitate (PA)-treated H4IIEC3 cells and found that although CHOP expression was 
increased in PA-treated cells, siRNA knockdown of CHOP did not attenuate apoptosis, 
demonstrating that CHOP was not critical for lipoapoptosis to occur.  Additionally they showed 
that CHOP
-/-
 mice and their wild-type counterparts displayed comparable levels of liver injury 
when both were fed a MCD diet, as assessed by alanine and aspartate aminotransferase levels.  
Similarly, another study found that CHOP inhibition via siRNA in PA-treated HepG2 cells had 
no effect on apoptosis (50).  These results confirm that palmitate alters ER function, but does not 
fully define how ER stress contributes to apoptosis, implying that alternate downstream targets 
of ER stress could mediate lipotoxicity. 
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 Type Model  Key Findings Reference  
In vitro/ 
in vivo 
H4IIEC3 rat 
hepatomas/ 
CHOP -/- 
mice 
Palmitate induced significant ER stress as assessed by CHOP expression, but 
CHOP knockdown did not attenuate apoptosis in vitro. Knockout of CHOP 
in C57BL/6J mice (CHOP -/-) did not reduce liver injury compared to wild-
type mice when fed a MCD diet. 
Pfaffenbach, et 
al 
2010 
In vivo 
Male Wistar 
rats 
Hepatic steatosis was associated with elevated SFAs, but not unsaturated 
fatty acids, and was characterized by increased liver injury and markers of 
ER stress. 
Wang, et al 
2006 
In vitro CHO-K1 
In lipotoxic conditions, palmitate was rapidly incorporated into microsomal 
membrane lipid components resulting in compromised ER membrane 
integrity and subsequent UPR stress signaling.  
Borradaile, et al 
2006 
In vitro HeLa 
Knockdown of SCD-1 resulted in increased SFA content in phospholipids 
and expression of ER stress signaling chaperones. Synergistic knockdown of 
SCD-1 and lysophosphatidyl acyltransferase 3, an enzyme associated with 
preferential incorporation of polyunsaturated fatty acids into phospholipids, 
further exacerbated UPR. 
Ariyama, et al 
2010 
In vitro 
NIH-3T3 
fibroblasts 
UPR-mediated splicing generates an active form of X-box binding protein-1. 
Activation of this transcription factor significantly increased the synthesis of 
phospholipids, particularly PC. 
Sriburi, et al 
2004 
In vivo S. cervisiae 
SFA incorporation into phospholipids increased the order of membranes due 
to the characteristic suboptimal shape they create within the bilayer. The 
detrimental effects can be relieved by incorporation of unsaturated fatty 
acids with a more optimized shape that restores membrane disorder. 
Deguil, et al 
2011 
In vivo/ 
in vitro 
Chang cells, 
ICR mice, 
human biopsy 
LPC is the death effector in cellular apoptosis resulting from SFA 
overexposure. SFA toxicity can be attenuated by the addition of 
phospholipase A2 inhibitors which prevent the generation of LPC species 
and ER stress. Direct administration of LPC in vivo induced significant 
hepatitis. LPC content was also found to be significantly increased in liver 
specimens from NASH patients. 
Han, et al 
2008 
In vitro 
Huh-7, 
mouse/human 
primary 
hepatocytes 
LPC content increased linearly with increasing exogenous SFA 
concentration. Substitution of LPC for SFA in models of lipotoxicty resulted 
in induction of ER stress, glycogen synthase kinase-3/JNK dependent 
apoptosis and p53 dysregulation. 
Kakisaka, et al 
2011 
In vivo 
C57BL/6 
genetically 
unaltered 
mice 
“Fast food diet” mouse model. Used a high saturated fat, high cholesterol 
and high fructose diet to mimic typical westernized diet. Mice on fast food 
diet demonstrated histological markers of clinical steatohepatitis including 
hepatocyte ballooning, inflammation, ER stress, lipoapoptosis and fibrosisin 
comparison to mice fed a simple “high fat” diet. 
Charlton, et al 
2011 
In vivo 
Male Wistar 
rats 
“Cafeteria diet” rat model. Rats were fed actual junk food (eg. Oreos, chips, 
etc) found in typical American dietary consumption and results were 
compared to simple high fat and standard chow diet. Cafeteria fed rats had 
significantly higher weight gain, hyperinsulinemia, hyperglycemia, glucose 
intolerance, inflammation, macrophage infiltration and fibrosis than either 
high fat or standard chow diets.  
Sampey, et al 
2011 
In vivo 
Male Wistar 
rats 
Rats were infused intravenously with either soybean (enriched with 
unsaturated fatty acids) or lard (enriched with saturated fatty acids) oil or a 
control emulsion. Animals infused with either oil demonstrated elevated ER 
stress and activation of inflammatory pathways compared to control 
infusions, but was increased to a much greater extent in lard infused animals 
compared to soybean infusions.   
Nivala, et al 
2013 
 
Table 2-1. The role of ER stress in SFA-induced lipotoxicity. Abbreviations: Endoplasmic reticulum 
(ER); Saturated fatty acid (SFA); Unfolded protein response (UPR); Steroyl-CoA desaturase-1 (SCD-1); 
Phosphatidylcholine (PC); Lysophosphatidylcholine (LPC); Non-alcoholic steatohepatitis (NASH); 
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Molecular mechanisms of SFA-induced ER stress 
Although there is no definitive mechanism explaining how SFAs induce ER stress, increasing 
evidence points to disordered phospholipid metabolism as one initiating factor. Unsaturated fatty 
acids are readily incorporated into inert TGs, but excess SFAs remain largely unesterified (30). 
Recent literature suggests that these free SFAs are rapidly assembled into saturated phospholipid 
species that are subsequently integrated into ER membrane bilayers (48). The degree of 
saturation in membrane phospholipids plays an important role in many membrane-associated 
functions. Abnormal incorporation of saturated phospholipid species can result in detrimental 
stiffening of cellular membranes and loss of functionality (51). The composition of the ER 
membrane is unique and typically contains unsaturated phosphatidylcholine (PC) as its major 
phospholipid component (48, 52, 53). This allows the ER to maintain a high degree of fluidity in 
order to carry out its critical role in maintaining proper protein folding and trafficking. Relatively 
small changes in ER homeostasis can result in the induction of UPR (34, 52). Therefore, even 
limited incorporation of saturated phospholipid species could be detrimental to the ER and lead 
to the increased UPR signaling observed in response to SFA overexposure. 
 
Borradaile et al. (48) published a comprehensive study investigating the mechanism leading to 
ER stress in palmitate-treated CHO cells.  Following exposure to deuterated palmitate for 1 h, 
the cells displayed a 1.5-fold and 3.0-fold increase in the saturation of membrane-bound PC and 
TG, respectively, in the rough microsomal fraction. Accompanying the increased saturation were 
markers of ER stress including the dissociation of protein-folding chaperones protein disulfide 
isomerase (PDI) and GRP78 from the membrane into the cytosol and presentation of a drastically 
dilated rough ER morphology, indicating severely impaired ER function. Similar effects were 
not observed in response to H2O2 treatment alone, demonstrating that ER stress induced by SFA 
overexposure was not solely the result of increased oxidative stress. The study also reported a 
rapid depletion of ER calcium stores in response to palmitate treatment, pointing to impairment 
of calcium ATPase activity associated with the ER membrane, a phenomenon that has been 
previously linked to increased saturation of phospholipid fatty acyl chains (54) and palmitate 
induced lipotoxicity (55).  
 
Another recent study explored the implications of increasing saturation of membrane 
phospholipids in HeLa cells (56). Specifically, they investigated the effects of inhibiting steroyl-
CoA desaturase 1 (SCD-1), the enzyme responsible for the desaturation of saturated fatty acids 
for lipid biosynthesis, and lysophosphatidylcholine acyltransferase 3 (LPCAT3), an enzyme that 
preferentially incorporates polyunsaturated fatty acids into PC. Even without SFA 
supplementation, both the SCD-1 knockdown and LPCAT3 knockdown cells demonstrated a 
significant increase in phospholipid saturation and UPR activation indicated by increased X-box 
binding protein splicing and PERK phosphorylation. These results were exacerbated by the 
simultaneous LPCAT3 /SCD-1 knockdown and further enhanced by palmitate supplementation. 
Overall, these experiments indicate that proper incorporation of unsaturated fatty acids into 
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phospholipids is of critical importance for maintaining normal ER membrane functionality, and 
that SFA overexposure may disrupt this process. Further investigation into the mechanism and 
effects of SFAs in controlling the phospholipid composition of cellular membranes will be 
important in formulating a complete picture of lipotoxic cell death. 
 
Generation of lysophospholipid species, and lysophosphotidylcholine (LPC) in particular, has 
also been implicated as an important mediator in the apoptotic response to SFAs. LPC is 
generated from phosphatidylcholine though cleavage of the fatty acid from the sn-2 position by 
the enzyme phospholipase A2. In two small-scale biopsy studies, concentrations of LPC in 
hepatic tissue samples were determined to be greater in livers of NASH patients than healthy 
controls (57, 58). Direct injection of LPC into the tail vein of ICR mice significantly increased in 
vivo AST/ALT levels, lobular hepatitis, and apoptosis without any evidence of steatosis (58). 
Using a variety of in vitro models, including Huh-7, Chang, and primary mouse and human 
hepatocytes, SFA lipotoxicity was shown to be significantly attenuated in the presence of the 
phospholipase inhibitors bromoenol lactone (BEL) and palmityl trifluoromethyl ketone 
(PACOCF3). This indicates that action of the phospholipase A2 enzyme may play an important 
role in the lipotoxic phenotype (58, 59). LPC content was also shown to be linearly correlated 
with the concentration of exogenous SFA supplied (59). Data from these same in vitro models 
also demonstrate that addition of exogenous LPC produces a similar lipotoxic phenotype as SFA 
overexposure, including markers of ER stress, caspase activation and apoptosis (58, 59). 
Kakisaka et al. (59) demonstrated that LPC-dependent lipoapoptosis is dependent on activation 
of caspase and glycogen synthase kinase-3/ JNK signaling, and is associated with p53 
upregulated modulator of apoptosis activation. Identifying the role of LPC accumulation in SFA-
induced lipotoxicity presents an interesting new avenue of investigation, but further work is 
needed to define if and how the two events are directly connected.  
 
Oxidative stress and β-oxidation 
The mitochondrion is the cellular powerhouse, as it is the main supplier of energy within the cell. 
This organelle consumes significant portions of the oxygen supplied to the cell for metabolism in 
the tricarboxylic acid cycle (TCA cycle) and electron transport chain (ETC). Oxidative 
phosphorylation, the major process for generating ATP in mitochondria, and ETC are coupled 
together by the proton gradient across the inner mitochondrial matrix created by electron flow 
along the ETC. Due to inherent ETC inefficiencies, premature leakage of electrons occurs, 
mainly at complexes I and III (60). Leaked electrons combine with oxygen to form reactive 
oxygen species (ROS) such as H2O2, ·O2- and ·OH. ROS are powerful oxidizing agents and can 
indiscriminately damage many cellular components including proteins, fatty acids and DNA (60) 
but are present only at low levels under normal physiologic conditions. However, ROS can 
become elevated in response to mitochondrial dysfunction, reduced antioxidant capacity or 
cellular stress, resulting in a state of oxidative stress. At elevated levels, ROS have been shown 
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to serve as triggers of pro-apoptotic pathways that initiate programmed cell death (61) though 
mechanisms including mitochondrial phospholipid peroxidation (62) and/or c-Jun N-terminal 
kinase (JNK) signaling (61, 63, 64). Evidence for oxidative stress in human patients and animal 
models of NASH includes the accumulation of oxidized lipids such as malodialdehyde (65). 
NASH-associated oxidative stress has also been attributed to a variety of mechanisms including 
upregulated levels of cytochome P450 2E1 (66), NADPH oxidase (67), and changes in 
mitochondrial function such as increased beta-oxidation (68-70).   
 
Hepatic oxidation of free fatty acids is elevated in obese individuals (71), but the role of 
enhanced beta-oxidation in promoting lipotoxic ROS accumulation is unclear. In β-oxidation, 
long chain fatty acyl-CoAs are activated in the cytosol by coupling to carnitine though the 
enzymatic activity of carnitine palmitoyl transferase-1 (CPT-1), the rate limiting step in β-
oxidation (72). Fatty acyl-carnitines are then shuttled across the inner mitochondrial membrane 
by carnitine-acylcarnitine translocase. Once inside the matrix, they are transformed back into 
fatty acyl-CoAs primed for oxidation (72). The fatty acids are broken down into two carbon 
acetyl-CoA units in successive cycles to feed into the TCA cycle for NADH and ATP production 
or into ketogenic pathways to generate ketone bodies (73). There has been speculation that the 
overexposure of hepatic cells to SFAs provides an enormous increase in substrate availability for 
β-oxidation and stimulation of this cycle may lead to increased downstream ROS production. 
Literature reports on the role of β-oxidation in lipotoxicity have been inconclusive, with some 
studies indicating that it is a major source of ROS (74) while others indicate that ROS 
overproduction is due to mitochondrial dysfunction resulting from an upstream target of SFA-
induced impairment (30). A recent in vivo study demonstrated that increased β-oxidation may 
actually confer a protective effect against NASH by enhancing lipid disposal.  Administration of 
a PPAR-α agonist to MCD mice resulted in attenuated NAS scores while simultaneously 
increasing peroxisomal beta-oxidation (75).  In vitro studies in pancreatic β-cells (76) and breast 
cancer cells (20) agree with these results. Reducing β-oxidation using the pharmacological agent 
etomoxir had no positive effect on palmitate-induced apoptosis (20, 76). Overall, these studies 
indicate that SFAs likely play a more complex role in initiating hepatic ROS accumulation and 
lipoapoptosis than simply oversupplying a substrate fuel for increased oxidative metabolism. 
This role could involve indirect effects to dysregulate normal mitochondrial function or a 
signaling cascade resulting from ER stress-induced Ca
2+
 release. In contrast, β-oxidation of SFAs 
may actually play a protective role is SFA-mediate liptoxicity. 
 
 
Triglyceride synthesis is a protective mechanism to prevent lipotoxicity  
The most widely regarded theory in NAFLD progression is the so-called “two hit hypothesis” 
(77). The first hit is a product of imbalanced fatty acid metabolism leading to hepatic triglyceride 
(TG) accumulation that is characteristic of NAFLD. The second hit is thought to involve 
14 
 
oxidative and/or metabolic stress as the liver attempts to compensate for prolonged alterations in 
lipid metabolism, which culminates in hepatic inflammation and cell death (77). However, 
questions remain as to whether the accumulation of intrahepatic TGs is actually the initial cause 
of progressive liver disease or merely an early adaptive response to increased lipid load. Recent 
literature points to the latter, suggesting that while TG synthesis is symptomatic of hepatic lipid 
overload, it is actually serving a protective role by providing a route to inertly dispose of excess 
fatty acids and prevent the formation of more toxic lipid intermediates (78).  
 
Data from in vitro experiments provide some important clues as to the role of TGs in hepatic 
lipotoxicity. For example, experiments with H4IIEC3 rat hepatomas demonstrate that palmitate-
induced ROS production and subsequent cell death occur in the absence of excess TG formation. 
Conversely, treatment with oleate causes significant TG formation with little ROS production or 
cell death (30). Interestingly, when palmitate is co-supplemented with oleate, the lipotoxic 
effects of palmitate are completely abolished with a coincident increase in lipid droplet 
formation. These experiments suggest that the increased toxicity of SFAs may be in large part 
attributable to the fact that they are less efficiently esterified into TGs. When the supply of 
unsaturated fatty acids becomes limited or there is insufficient capacity to dispose of SFAs by 
either TG synthesis or beta-oxidation, the resulting accumulation of saturated phospholipids and 
other toxic lipid intermediates may subsequently promote cellular dysfunction and apoptosis. 
Several different cell types including β-cells (46, 76) , cultured rat islets (79), Chinese hamster 
ovary (CHO) cells (19), breast cancer cells (20) and rat liver cells (30, 80, 81) have shown 
similar results: acute SFA lipotoxicity is inversely correlated with triglyceride synthesis.  
 
SCD-1 is the enzyme responsible for catalyzing the endogenous desaturation of SFAs, such as 
palmitate (16:0) and sterate (18:0), into their monounsaturated counterparts, palmitoleate (16:1) 
and oleate (18:1), respectively (82, 83). Altering the cellular capacity for fatty acid saturation can 
dramatically change the potential lipotoxic effects of SFA supplementation. Hepatic models with 
SCD-1 inhibition have previously been shown to display significant reductions in triglyceride 
content (84). Both primary C57BL/6 hepatocytes  and HepG2 cells with pharmacological and 
genetic siRNA inhibition of SCD-1 showed significantly increased sensitivity to palmitate-
mediated apoptosis compared to controls treated with palmitate alone (81). Alternatively, CHO 
cells overexpressing SCD-1 displayed significant increases in TG synthesis and labeled SFA 
incorporation into TG species and were almost completely resistant to SFA-induced apoptosis 
(19). 
 
The beneficial effects of partitioning FFAs into TGs demonstrated by in vitro models also 
translates to in vivo rodent models. Mice expressing SCD-1 (SCD-1
+/+
) had significantly 
increased levels of TG accumulation in the liver compared to both high fat diet (HFD) controls 
and SCD knockout mice (SCD-1
-/-
), but also significantly reduced markers of hepatic apoptosis 
and inflammation compared to SCD-1
-/-
 (81). Interestingly, in vivo rodent models of progressive 
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liver disease have demonstrated a highly suppressed expression level of SCD-1 (81, 85), 
suggesting a possible impairment in SFA esterification into TG, thereby implicating 
compromised and/or reduced TG synthesis as an instigator in the progressive pathology of 
NAFLD. 
 
Methods for overexpressing or inhibiting enzymes responsible for TG synthesis have also been 
utilized in order to investigate the relationship between hepatic TG synthesis and progressive 
liver disease. Yamaguchi et al. (86) studied male db/db mice on a MCD diet. These animals have 
a genetically defective leptin receptor and provide a useful model of severe obesity and type II 
diabetes, and develop NASH when placed on an MCD diet (9, 87). Their study sought to 
investigate whether inhibiting TG synthesis with a liver-specific knockdown of diacylglycerol 
acyltrasferase 2 (DGAT2) would prevent hepatic steatosis and protect the liver from further 
progression to NAFLD. DGAT2 is responsible for catalyzing the final step in hepatic TG 
biosynthesis (88); therefore, the antisense oligonucleotide suppression of this enzyme was 
successful in preventing hepatic steatosis resulting from MCD-induced accumulation of TGs. 
However, contrary to the investigators’ expectations, reduction of hepatic steatosis with DGAT2-
ASO did not protect the MCD-diet fed mice from hepatic inflammation and fibrosis. In fact, 
these mice experienced increased markers of inflammation and disease associated with NASH, 
including increased levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
lobular inflammation, FFA levels and oxidative damage as assessed by TBAR and 4-HNE levels, 
compared to MCD-diet controls (86).  An alternate study by Monetti et al. (89) investigated the 
link between hepatic steatosis and insulin resistance in mice overexpressing the DGAT2 gene in 
the liver (liv-DGAT2). Finding DGAT-mediated steatosis in the liver to be insufficient to cause 
insulin resistance in the tissue, they investigated markers of inflammation and ER stress 
previously shown to promote insulin resistance. Mice expressing a 2-fold increase in hepatic 
DGAT2 mRNA (Liv-DGAT2-low) displayed a ~5-fold increase in hepatic TG content, but 
interestingly had reduced levels of phosphorylated Jun-N-terminal kinase (JNK), nuclear factor 
kappa B (NF-κB), and PERK compared to the WT littermates when both groups were 
maintained on a high-fat diet (89). Together, these findings suggest that TG synthesis provides a 
protective mechanism to buffer against toxic accumulation of FFAs in the liver.   
 
Overall, recent literature points to a dissociation between hepatic triglyceride formation and 
progression towards severe fatty liver disease. While increased hepatic triglyceride formation is 
most certainly an early indicator of liver metabolic stress and disease, it does not appear to be the 
initiating factor in NASH, but instead serves as a protective metabolic mechanism to counter 
FFA overload (78). Triglycerides may serve as inert storage species for diverting FFAs away 
from toxic pathways and thus protecting the cell from lipoapoptotic effects. The degree of FFA 
saturation has also been demonstrated to have a strong effect on the tendency of the cell to store 
FFAs as TGs, where unsaturated FFAs are more likely incorporated into TGs and their saturated 
counterparts are channeled towards other cellular fates.  Once the ability of the cell to channel 
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FFAs away from other metabolic pathways leading to lipotoxicity and into neutral TGs becomes 
diminished and/or overwhelmed, cellular FFA levels increase, resulting in a diseased phenotype 
characteristic of NASH. 
 
From bench to bedside: clinical trials in NASH patients 
Investigations into the molecular etiology of NASH have provided potential therapeutic targets 
to both ameliorate and prevent hepatic apoptosis and inflammation.  For example, vitamin E was 
administered to insulin-tolerant patients to investigate antioxidants as a potential treatment for 
NASH (90).  Treatment with vitamin E resulted in reduced liver injury assessed by a reduction in 
serum alanine and aspartate aminotransferase levels.  Although fibrosis scores were unimproved, 
other histologic features such as lobular inflammation and hepatocellular ballooning were 
improved. Similarly, pentoxifylline has been utilized successfully in mouse models (91) and 
human clinical trials (92) for treatment of NASH. Pentoxifylline is a non-selective 
phosphodiesterase inhibitor that has well known effects to suppress production of pro-
inflammatory cytokines, such as TNF-alpha, as well as antioxidant properties that include 
reducing ROS production, scavenging free radicals (93, 94), and preventing the depletion of 
glutathione stores (95).  In the clinical trial, 55 patients with confirmed NASH received thee 
daily doses of pentoxifylline or placebo over a 1-year period. After the duration of treatment, 
analysis showed significantly more patients on pentoxifylline than placebo had NAS decrease by 
≥2 points. Steatosis, lobular inflammation and fibrosis also showed significant improvements 
although no change in hepatocellular ballooning was observed (92).The ameliorating effects of 
antioxidant therapy highlight the central pathogenic role oxidative stress has in NASH disease 
progression.   
 
Well-known anti-diabetic drugs, such as metformin and thiazolidinedione derivatives, have also 
been frequently utilized as NASH treatments in diabetic and non-diabetic patients alike. 
Metformin is a first-line treatment for type II diabetes that inhibits hepatic gluconeogenesis (96) 
and alters fatty acid metabolism (97), often resulting in patient weight loss. In a clinical trial of 
NASH, metformin was shown to improve liver histology and ALT levels in a significant portion 
of patients (30%), which could not be attributed to increases in insulin sensitivity (98). The 
beneficial effects on NASH appeared to be mediated partly by the ability of metformin to 
promote weight loss, where the most weight loss correlated with the most improvement in liver 
histology. In fact, reduction in body mass by itself has been described as an effective 
intervention in NALFD progression (99). Results from clinical studies indicate that reductions in 
body weight of just 5% to >7% result in significant reductions in steatosis, NAS, and other 
laboratory abnormalities associated with progressive NAFLD in children (100) and adults with 
NASH (101, 102), respectively. Studies (103-105) and reviews (106, 107) on the impact of 
weight loss due to bariatric surgery have demonstrated similar improvements. 
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Pioglitazone is a derivative of the thiazolidinedione class of drugs used to treat type II diabetes 
mellitus due to its ability to reduce insulin resistance by activating PPAR-γ and controlling 
glucose and lipid metabolism in peripheral tissues (108). A placebo-controlled clinical trial of 
pioglitazone in patients with NASH  revealed encouraging results, where patients receiving 
pioglitazone displayed significant improvements in ALT and AST levels as well as hepatic 
histological markers such as reduced steatosis, ballooning, necrosis and inflammation despite a 
small weight gain (109). However, fibrosis improvements were not significantly different than 
that of a placebo+dietary intervention group. The conclusions about the mediator of this marked 
NASH improvement in patients treated with pioglitazone were not attributable to a single factor, 
but speculation regarding several mechanisms was briefly discussed. Mechanisms postulated 
include the following two: (i) thiazolidinediones are known to increase insulin sensitivity and 
reduce peripheral lipolysis from adipose tissue (110), thus significantly decreasing the flux of 
free fatty acid substrates to the liver and (ii) pioglitazone has been shown to activate AMPK 
(110) and raise adiponectin levels in the liver (111), which may play an important role in 
mediating the effects of thiazolidinediones in the liver. The serum aminotransferase level and 
histological improvements demonstrated with some classic diabetes drugs in patients with NASH 
warrants further investigation into the metabolic mechanisms activated in order to develop more 
targeted therapies in the future.   
 
A new drug has recently made waves in the medical community when clinical trials for 
obeticholic acid (OCA) for treatment of NASH were stopped early for efficacy based on interim 
analysis that shows recipients have already met the primary endpoint of the trial. OCA is a 
farnesoid X receptor (FXR) agonist that was orally administered in a double-blind, placebo-
controlled clinical trial known as FXR Ligand OCA in NASH Treatment (FLINT) at a dosage of 
25 mg daily in biopsy-proven adult NASH patients over 72 weeks. OCA is essentially a semi-
synthesis bile acid that serves to activate FXR. FXR is a nuclear receptor that expressed at high 
levels in the liver and intestines and plays role in various metabolic pathways including bile acid, 
glucose and lipid metabolism (112). When lipophilic bile acids, such as OCA, bind to FXR it is 
activated and promotes decreased hepatic gluconeogenesis, circulating triglycerides, hepatic lipid 
synthesis and enhanced peripheral clearance of VLDL and HDL (113). Based on these metabolic 
attributes, pharmacological activation of FXR was targeted as therapeutic treatment for NASH. 
Results from the FLINT study demonstrate highly statistically significant reductions in NAS 
score of at least two points and no worsening of fibrosis compared to placebo treated patients 
(113). Of the OCA-treated patients, 45% had improved liver histology compared to 21% in the 
placebo group (113) which demonstrates promising results for future clinical treatment of high-
risk NASH patients.  
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Figure 2-1. Saturated fatty acids initiate cellular dysfunction in lipotoxicity/NAFLD. Lipolysis of 
subcutaneous and visceral adipose tissue gives rise to higher concentrations of free fatty acids in the blood 
resulting in ectopic fat storage within the liver. Upon entering the liver, FFAs are partitioned toward thee 
main lipid disposal pathways: β-oxidation, TG synthesis, and phospholipid synthesis/remodeling. 
Mitochondrial β-oxidation gradually breaks down fatty acids into two-carbon acetyl-CoA units, which are 
subsequently used to fuel the TCA cycle. Esterification of FFAs into TG and phospholipids provides an 
alternate route for disposing of elevated FFAs.  High concentrations of saturated fatty acids, however, 
avoid protective sequestration into triglyceride stores and/or β-oxidation. Instead, SFAs are channeled 
toward phospholipid incorporation. Increased saturation of ER phospholipids can compromise the 
integrity of the ER-membrane structure resulting in stimulation of UPR signaling pathways and disruption 
of mitochondrial function. Additionally, elevated SFAs deregulate TCA cycle metabolism leading to ROS 
accumulation. Both ER-stress pathways and mitochondrial dysfunction activate JNK stress signaling, thus 
leading to eventual apoptotic cell death. Abbreviations: Monounsaturated fatty acid (MUFA); 
Endoplasmic reticulum (ER); Protein kinase RNA-like endoplasmic reticulum kinase (PERK); Inositol-
requiring protein–1 (IRE-1); Xbox binding protein-1 spliced (XBS-1s); Activating transcription factor 6 
(ATF-6); Jun N-terminal kinase (JNK); Reactive oxygen species (ROS).   
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Conclusion 
Nonalcoholic steatohepatitis is the liver manifestation of obesity and the metabolic syndrome and 
is marked by lipid deposition, inflammation and apoptosis.  While triglyceride accumulation is a 
hallmark of NAFLD, several in vitro and animal models suggest triglyceride accumulation is a 
protective mechanism to delay the toxic effects of excess lipids. Altered composition of 
intrahepatic free fatty acids and phospholipid metabolites have instead been implicated as major 
contributors to acute liver dysfunction and apoptosis.  Many studies have demonstrated that 
saturated fatty acids are more toxic than their unsaturated counterparts, resulting in a progressive 
lipotoxic cascade (Fig. 2-1).  SFAs have been shown to increase the saturation of membrane 
phospholipids, thus initiating UPR and leading to ER stress.  SFAs also affect mitochondrial 
metabolism and promote ROS accumulation.  Furthermore, hepatocyte apoptosis has been shown 
to be dependent on the activation of JNK stress signaling pathways that respond to prolonged ER 
and oxidative stress. Despite these common molecular features of lipotoxicity, a unifying 
mechanism is still unclear and has prevented the development of novel treatments for NASH. 
However, recent literature provides strong evidence that fatty acid saturation plays a critical role 
in determining cell fate under lipotoxic conditions. Continued research in understanding these 
molecular mechanisms will provide direction for more targeted therapeutics for NAFLD and 
NASH patients in the future.    
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CHAPTER 3  
ENHANCED SYNTHESIS OF SATURATED PHOSPHOLIPIDS IS ASSOCIATED WITH ER 
STRESS AND LIPOTOXICTY IN PALMITATE TREATED HEPATIC CELLS  
Journal of Lipid Research (55) 2014, pp. 1478-1488 
Introduction 
Free fatty acids (FFAs) are involved in a diverse range of functions within hepatic cells, 
including esterification into triacylglycerols (TAGs), oxidation to fuel mitochondrial 
metabolism, synthesis and remodeling of phospholipids (PLs), and conversion to signaling 
molecules such as prostaglandins or leukotrienes. The effects of elevated FFAs have been 
previously studied in cultured hepatic cell lines as a model for recapitulating the lipotoxicity that 
has been observed in obese type 2 diabetes and nonalcoholic fatty liver disease (NAFLD) (1-5). 
In these disease states, ectopic accumulation of FFAs in non-adipose tissues such as liver, 
pancreas, and skeletal muscle can interfere with normal cellular function and induce apoptotic 
cell death. These lipotoxic effects have shown dependence on fatty acid chain length and 
saturation. Exposure to long-chain saturated fatty acids (SFAs), such as palmitate (PA) or 
stearate, leads to lipoapoptosis in many cell types including hepatocytes (2, 6, 7). In contrast, 
monounsaturated fatty acids (MUFAs), such as oleate (OA), are not acutely cytotoxic to hepatic 
cells and have been shown to exert a protective effect when combined with toxic loads of SFAs 
(8-10).  
The mechanism by which metabolism of specific lipid species results in apoptosis has not been 
fully elucidated. A prior in vivo study demonstrated the deleterious effects of increased dietary 
saturated fat by feeding mice a so-called “fast food diet” that was high in saturated fat and 
cholesterol. These mice developed pathological symptoms of non-alcoholic steatohepatitis 
(NASH), in contrast to mice fed a typical high-fat diet that only developed simple steatosis 
without NASH symptoms (11). In vitro lipotoxicity experiments in a variety of cell lines, 
including Chinese hamster ovary (CHO) cells (10, 12, 13), pancreatic beta cells (14, 15), breast 
cancer cells (16), and hepatic cells (6, 9, 17-19), have shown that SFA overexposure is 
characterized by expression of pro-inflammatory cytokines, endoplasmic reticulum (ER) 
impairment, elevated reactive oxygen species (ROS), and eventual apoptosis without significant 
TAG formation. In contrast, MUFAs and poly-unsaturated fatty acids (PUFAs) induce 
substantial TAG formation but do not initiate apoptosis (6, 10). These findings suggest that 
lipotoxicity does not correlate with accumulation of TAGs containing unsaturated FAs, and that 
other lipid classes may mediate responses to SFA overload. Ceramide accumulation has been 
postulated as a major contributing factor in palmitate-induced lipotoxicity due to the fact that PA 
and serine are substrates for de novo ceramide biosynthesis. Although previous work has 
demonstrated the ability of ceramides to activate apoptotic signaling in muscle cells (20), recent 
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studies have shown that SFAs promote ER stress (13, 17) and ROS accumulation (10) 
independently of ceramide synthesis in CHO and hepatic cells. Therefore, identifying specific 
lipid metabolites that induce lipotoxicity in hepatic cells, as well as strategies to circumvent them 
by diverting SFAs into non-toxic disposal pathways, represents a potential research area for 
prevention and treatment of NAFLD.  
Markers of ER stress, including CCAAT/enhancer-binding protein homologous protein (CHOP) 
and depletion of Ca
2+
 stores from the ER lumen, appear soon after exposure to SFAs but are not 
found in cells treated with MUFAs (21). ER Ca
2+
 depletion has been shown to occur in a range 
between one to four hours following SFA exposure (8, 13), indicating that the initial metabolism 
of SFA results in rapid perturbations to ER homeostasis and initiation of the compensatory ER 
stress pathway known as the unfolded protein response (UPR). Aberrant lipid metabolism has 
been previously linked to disruptions in ER homeostasis leading to chonic ER stress in obesity 
(22). Based on this recent literature, we hypothesized that dysfunctional PL metabolism and 
subsequent changes to fatty acid composition of membrane lipid species may play a critical role 
in initiating ER stress under conditions of lipotoxicity. The composition of the ER membrane 
typically contains unsaturated phosphatidylcholine (PC) as its major phospholipid component 
(23). This allows the ER to maintain a high degree of fluidity in order to carry out its critical role 
in preserving proper protein folding and trafficking. The degree of saturation of phospholipids 
plays an important role in many membrane-associated functions and homeostasis. Abnormal 
incorporation of saturated phospholipid species can result in detrimental stiffening of cellular 
membranes and loss of function (24). Relatively small changes in ER homeostasis can result in 
the induction of UPR and reduced capacity to transport calcium (25, 26). Therefore, even limited 
incorporation of SFAs into phospholipid species, particularly PC, could be detrimental to ER 
function and lead to the increased UPR signaling observed in response to SFA overexposure. 
In the present study, we investigated the mechanisms by which upstream SFA metabolism 
induces hepatic cell lipotoxicity in both the H4IIEC3 rat hepatoma cell line and freshly isolated 
primary hepatocytes. We demonstrated that exogenous PA induces dramatic and rapid alterations 
in ER morphology, indicative of compromised ER integrity confirmed by high-resolution 
cellular imaging with transmission electron microscopy (TEM). Palmitic acid treatment resulted 
in dramatic increases in 16:0 lysophosphatidic acid (LPA) and dipalmitoyl phosphatidic acid 
(32:0 PtdOH), suggesting de novo lipid biosynthesis via the Kennedy pathway (27). 
Diacylglycerols (DAGs) also show incorporation of PA and further conversion preferentially 
into membrane PLs as opposed to TAGs. The resulting changes in PL acyl chain composition are 
associated with an increase in markers of ER stress and characteristic indicators of lipotoxicity 
(mitochondrial dysfunction, caspase activation, and cell death). Co-treatment with OA was found 
to suppress dysfunction and dilation of the ER membrane, reduce PA incorporation into PLs, and 
restore overall membrane saturation. Supplementing PA-treated cells with varying 
concentrations of OA almost completely abolished 16:0 LPA and 32:0 PtdOH accumulations and 
rerouted DAG species away from PL synthesis and into TAG esterification. Reduction in 
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markers of ER stress and lipotoxicity were observed in those cases. To our knowledge, this is the 
first time that changes in phospholipid synthesis, phospholipid fatty acid composition and ER 
membrane structure have been directly linked to lipotoxicity initiation in hepatic cells. We 
demonstrate that MUFA supplementation reduces PA incorporation into PL species and restores 
a more balanced saturated:unsaturated membrane PL composition while increasing metabolic 
flux toward more benign TAG synthesis. 
 
Experimental Procedures 
Materials and Reagents  
Oleic and palmitic acids, bovine serum albumin (BSA), and Dulbecco’s modified Eagle’s 
medium (DMEM) were all purchased from Sigma-Aldrich (St. Louis, MO). CHOP primary 
(mouse) and goat anti-mouse secondary antibodies were purchased from Abcam (Cambridge, 
MA). β-Actin primary (goat) and donkey anti-goat secondary antibodies were procured from 
Santa Cruz Biotechnology. All other chemicals were purchased from standard commercial 
sources.  
Preparation of Fatty Acid Solutions 
Fatty acid treatments solutions were prepared by coupling free fatty acids to bovine 
serum albumin (BSA). Specifically, palmitate or oleate was fully dissolved in 200-proof ethanol 
for a concentration of 195 mM. This FFA stock solution was added to a pre-warmed BSA 
solution (10% w/w, 37°C) for a final FFA concentration of 3 mM, ensuring that the 
concentration of ethanol in the FFA solution did not exceed 0.5% by volume. The solution was 
fully dissolved by warming at 37°C for an additional 10 minutes. The final ratio of FFA:BSA 
was 2:1. Vehicle control treatments were prepared using stocks of 10% w/w BSA with an 
equivalent volume of ethanol added to match that contained in the final FFA stock. The final 
concentration of ethanol was less than 0.2% in all experiments.  
Cell Culture  
Rat hepatoma cells, H4IIEC3 (ATCC), were cultured in low-glucose Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin/glutamine (2mM). Measurements were done at 70-80% confluency. 
Primary Hepatocyte Isolation and Culture 
Sprague Dawley rats were purchased from Jackson Laboratories (Bar Harbor, ME) and 
housed in temperature- and humidity-controlled environment with 12:12 h light-dark cycle and 
fed standard CHOW diet ad libitum. Following a 1-week acclimation period, rats were used for 
primary hepatocyte isolation. Briefly, the hepatic cells of 5-6 week old rats were isolated using 
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collagenase perfusion and first incubated in DMEM-based attachment media containing 20 mM 
glucose, 100 nM dexamethasone and 5 nM insulin on collagen IV coated plates for 4 h 
(attachment period). The cells were washed once with PBS and the medium was changed to a 
DMEM-based growth medium containing 20 mM glucose, 100 nM dexamethasone and 1 nM 
insulin for 16h. Experimental treatments were performed after this period using the same growth 
medium.  All experimental protocols were approved by the Animal Care and Use Committee at 
Vanderbilt University. 
JCI Membrane Potential Measurement 
JC1 is a dye which exists in a monomeric form in non-polarized mitochondria and 
fluoresces in the green emission (530nm) spectrum when excited at 485 nm.   The dye 
accumulates in the mitochondria based upon the potential which results in formation of dye 
aggregates. The aggregation shifts the fluorescence to the red emission (590 nm) spectrum when 
excited at 485 nm.  Therefore, the ratio of red/green is determined and represents alterations in 
the mitochondrial potential between different cells and treatments.   
Cell Toxicity 
Toxicity was assessed using the dead cell dye propidium iodide as described previously 
(28). Propidium iodide is an intercalating dye that can only permeate dead cells. It becomes 
highly fluorescent when embedded in the double stranded DNA exposed after cell death. After 
culturing cells in 96-well plates with experimental treatments, the medium was removed and 
replaced with a solution of the dye and serum-free DMEM. Cells were incubated at 37°C for 1 h 
in the dark prior to the fluorescence measurement at ex/em wavelength of 530/645 nm.  
Caspase Activation  
The Apo-ONE Homogenous Caspase 3/7 Assay kit was used to measure apoptotic 
caspase activation.  Cells were cultured in 96-well plates and incubated with desired treatments 
for 6 hours.  The Apo-ONE kit uses a lysis buffer combined with a caspase 3/7 specific substrate 
(Z-DEVD-R110), which becomes fluorescent once these caspases remove its DEVD peptide.  
Fluorescence was measured at ex/em wavelength of 485/535 nm.  
Western Blotting 
Cells were lysed with ice-cold RIPA lysis buffer (sc-24948, Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA) supplemented with Na-orthovanadate, protease inhibitor cocktail, and 
PMSF for 30 min on ice. Samples were centrifuged at 16,100 rcf and 4°C for 20 min, and the 
resulting supernatants constituted the total protein extracts. Protein concentrations were 
determined by BCA assay (Thermo Fisher Scientific, Rockford, IL). Samples were added in 
concentrations of 30 μg/lane for SDS-PAGE western blotting. Dilutions of the primary 
antibodies were anti-CHOP (1:1000) and anti-β-actin (1:1000). 
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Phospholipid Fatty Acid Profiles 
Cells seeded in 10-cm Petri dishes at an initial density of 4 × 10
6
 cells per plate were 
incubated in standard medium until reaching ~70-80% confluency, at which time experimental 
treatments were administered.  Cells were then trypsinized for 3 min and scraped using cold 
PBS. Cell suspensions were pelleted by centrifugation and resuspended in fresh PBS. Fatty acyl 
lipid analysis was performed by the Vanderbilt Hormone Assay and Analytical Services Core 
using thin-layer chromatography (TLC) and gas chromatography-flame ionization detection 
(GC-FID) techniques. Briefly, lipids were extracted from the aforementioned cell pellets using a 
modified Folch separation. An internal standard (1,2-dipentadecanoyl-sn-glycero-3-
phosphocholine) for phospholipids was added to the lipid-containing chloroform phase. Total 
lipids were then extracted and separated by TLC using petroleum ether/ethyl ether/acetic acid 
(80/20/1, v/v/v) on silica plates. Spots corresponding to PLs, TAGs, and FFAs were visualized 
with rhodamine 6G in 95% ethanol and scraped individually into glass tubes for 
transmethylation. Transmethylation was performed using a boron trifluoride-methanol 10% 
(w/w) solution. Derivatized lipids were then analyzed using a GC-FID, where standardized 
calibration curves were used to analyze fatty acid content. 
3
H-Palmitate Lipid Class Incorporation 
Cells seeded in 6-well dishes at 1.5 × 10
6
 cells per well were incubated in standard 
medium until reaching ~70-80% confluency. Next, the cells were incubated for the indicated 
duration at 37°C in 400 μM [9,10-3H] palmitic acid (1 µCi 3H/µmol PA), either in the presence 
or absence of oleic acid. Lipids were extracted using a modified Folch procedure. Twice, 0.75 
mL chilled methanol was added to each well and cells were scraped into 1:1 chloroform:water. 
Once vortexed and centrifuged, the lipid-containing chloroform phase was vacuum dried without 
heat. Lipid classes were separated by TLC, as described above. Each TLC spot was added to an 
individual vial and radioactivity was assessed by scintillation counting. 
Electron Microscopy 
Cells were seeded in 10-cm dishes at 4 × 10
6
 cells per dish and incubated in standard 
medium until reaching ~70-80% confluency. Cells were then incubated with desired treatments 
at 37°C for the indicated time period and then washed thoroughly with 0.1M sodium cacodylate 
buffer (with 1% calcium chloride), pH 7.4. After washing, cells were fixed with a 2.5% 
glutaraldehyde solution in 0.1 M sodium cacodylate buffer for 1 h at room temperature followed 
by 23 h at 4°C. Samples were postfixed in 1.25% osmium tetroxide and subsequently stained 
with 2% aqueous uranyl acetate. Embedded cells were then thin-sectioned and viewed on a 
Philips/FEI T-12 high-resolution transmission electron microscope.  
Quantification of Electron Micrographs 
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Images produced from electron microscopy were loaded into the publically available software 
program Image J. The straight-line measurement function of this program was used to determine 
the relative length of the scale bar (in nm) embedded in the image. Four randomly selected 
images from each treatment type were then quantitatively analyzed by measuring 10 points on 
the ER membranes displayed (n=10/image). The relative ER widths of these data points could 
then be converted to an absolute value (in nm) using the relative multiplicative factor determined 
by measuring the scale bar. Once converted to an absolute value, all data points from the 
respective treatments were pooled together to calculate the mean and standard error.  
Phospholipid Analysis  
H4IIEC3 cells were grown in 6-cm dishes and treated with the indicated fatty acid(s) for 12 h 
before they were pelleted and immediately snap frozen using liquid nitrogen. 
Glycerophospholipids were extracted using a modified Bligh and Dyer procedure (29, 30). 
Briefly, each pellet was homogenized in 800 μL of ice-cold 0.1 N HCl:CH3OH (1:1) by 
vortexing for one minute at 4°C. This suspension was then vortexed with 400 μL of ice-cold 
CHCl3 for one minute at 4°C and the extraction proceeded with centrifugation (5 min, 4°C, 18 
000 × g) to separate the two phases. The lower organic layer was collected and solvent 
evaporated. The resulting lipid film was dissolved in 100 µL of isopropanol:hexane:100 mM 
NH4COOH(aq) 58:40:2 (mobile phase A). Quantification of glycerophospholipids was achieved 
by the use of an LC-MS technique employing synthetic odd-carbon diacyl and lysophospholipid 
standards. Typically, 200 ng of each odd-carbon standard was added per sample. 
Glycerophospholipids were analyzed on an Applied Biosystems/MDS SCIEX 4000 Q TRAP 
hybrid triple quadrupole/linear ion trap mass spectrometer (Applied Biosystems, Foster City, 
CA, USA) and a Shimadzu high pressure liquid chromatography system with a Phenomenex 
Luna Silica column (2 × 250 mm, 5-μm particle size) using a gradient elution as previously 
described (30, 31). The identification of the individual species, achieved by LC-MS/MS, was 
based on their chomatographic and mass spectral characteristics. This analysis allows 
identification of the two fatty acid moieties but does not determine their position on the glycerol 
backbone (sn-1 versus sn-2). Therefore, glycerophospholipids species are referred to thoughout 
using X:Y notation (X- total number of carbon atoms, Y – total number of double bonds in both 
FA, e.g. 36:1 PC). 
 Neutral Lipid Analysis 
Neutral glycerolipids (monoacylglycerol (MAG), DAG and TAG) were extracted by 
homogenizing cell pellets in the presence of internal standards (300 ng each 14:0 MAG  and  
24:0 DAG, and 600 ng 42:0 TAG) in 2 mL 1X PBS and extracting with 2 mL ethyl 
acetate:trimethylpentane (25:75). After drying the extracts, the lipid film was dissolved in 1 mL 
hexane:isopropanol (4:1) and passed though a bed of Silica gel 60 Å to remove remaining polar 
phospholipids. Solvent from the collected fractions was evaporated and lipid film was 
redissolved in 90 µL 9:1 CH3OH:CHCl3, containing 10µL of 100mM CH3COONa for MS 
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analysis essentially as described (32).  
Statistical Analysis  
All data are represented as mean ± standard error. Type I ANOVA (Student’s t test) was used to 
assess statistical differences involving multiple (two) treatments. ANOVA was followed with 
Tukey-Kramer post-hoc testing for 
3
H-labeled PA experiments. 
 
Results 
Treatment of hepatocytes with the saturated fatty acid PA is associated with perturbations in ER 
morphology and organelle stress 
We hypothesized that the lipotoxic effects of PA could be mainly attributed to its ability to 
destabilize the structure and function of key organelles, specifically the ER. Increased saturation 
of PL species has been previously associated with stiffening of cellular membranes (24, 33) and 
organelle dysfunction (13, 34). Therefore, we sought to examine the effect that fatty acid 
treatments have on the structure and morphology of hepatic cellular organelles. We were 
particularly interested in its impacts on the ER membrane, since the ER constitutes more than 
half of total membrane content in hepatocytes and smooth ER is the major site of cellular PL 
biosynthesis (35, 36). Furthermore, ER stress has been implicated as a critical mediator in the 
PA-induced lipoapoptotic cascade (8, 13, 21) and is involved in diseased states such as obesity 
(22, 37) and progressive liver disease (38, 39). The morphology of this organelle appears normal 
in TEM images of vehicle-treated cells, with tubular cisternae studded by the electron-dense dots 
characteristic of attached ribosomes (Fig. 3-1A and 3-2A). In contrast, both primary hepatocytes 
and H4IIEC3 cells treated with 400 μM PA for 12h and 4h, respectively, exhibited distended ER 
structures that were dramatically increased in size relative to those of vehicle-treated cells (Fig. 
3-1B and 3-2B). Quantification of ER expansion revealed that its average thickness increased 
significantly in cells treated with PA compared to vehicle-treated cells (Primary hepatocytes: 
40.22 ± 2.93 nm vs. 24.59 ± 1.00 nm, p<0.01, Fig. 3-1E; H4IIEC3: 64.08 ± 2.39 nm vs. 25.79 ± 
0.90 nm, p<0.01, Fig. 3-2E;). The drastic dilation in ER morphology is indicative of ER stress 
and dysfunction in PA-treated cells (40). There does not appear to be any indication of 
significant changes in mitochondrial structure between treatments at this time point.  
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Figure 3-1. Incubation of freshly isolated 
primary hepatocytes with PA results in 
expansion of the ER membrane while co-
treatment with OA blocks PA-induced dilation.  
Primary hepatocytes were incubated for 12 h with 
(A) BSA vehicle, (B) 400 μM PA, (C) 400 μM OA 
or (D) 400 μM PA + 400 μM OA. Changes in ER 
morphology were observed by high-resolution 
imaging with transmission electron microscopy. 
Arrowheads point towards ER cisternae. M, 
mitochondria; LD, lipid droplets. Average ER 
diameter was quantified using  ImageJ length 
analysis and results are displayed in (E). Scale bars 
= 500 nm; 
b
,p < 0.01 versus cells treated with BSA.  
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Figure 3-2. Incubation of H4IIEC3 cells with 
PA results in expansion of the ER membrane 
while co-treatment with OA blocks PA-induced 
dilation. H4IIEC3 were incubated for 4 h with (A) 
BSA vehicle, (B) 400 μM PA, (C) 400 μM OA or 
(D) 400 μM PA + 400 μM OA. Changes in ER 
morphology were observed by high-resolution 
imaging with transmission electron microscopy. 
Arrowheads point towards ER cisternae. M, 
mitochondria; LD, lipid droplets. Average ER 
diameter was quantified using ImageJ length 
analysis and results are displayed in (E). Scale 
bars = 500 nm; 
b
,p < 0.01 versus cells treated with 
BSA.  
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Neither primary hepatocytes nor H4IIEC3 cells treated with 400 μM OA experienced any 
significant changes in ER morphology compared to vehicle-treated cells, despite carrying the 
same fatty acid load as those treated with PA alone (Fig. 3-1C and -32C). Quantification of ER 
thickness revealed no significant differences between OA- and vehicle-treated primary 
hepatocytes (23.6 ± 0.64 nm vs. 24.59 ± 1.00 nm, Fig. 3-1E) or H4IIEC3 cells (25.63±0.77 nm 
vs. 25.79 ± 0.90 nm, Fig. 3-2E).  OA-treated cells, conversely, did demonstrate significant 
increases in lipid droplet accumulation, composed primarily of TAGs, compared to those treated 
solely with PA, as indicated by the white, spherical droplets appearing on the electron 
micrographs (labeled “LD”). Co-incubation of PA-treated cells with 400 μM OA reversed the 
distended ER morphology observed in cells exposed to PA alone; the ER structure of these co-
treated cells closely resembled that of control cells both in terms of visual morphology (Fig. 1D 
and 2D) and quantified thickness (Fig. 3-1E and 3-2E) in both primary hepatocytes and H4IIEC3 
cells, respectively. All other subcellular structures appear normal and similar at this time point 
amongst all treatment groups. Taken together, there is clearly a substantial difference in ER 
morphology between hepatic cells treated with saturated versus monounsaturated fatty acids. 
Additionally, the structural changes in the ER associated with PA exposure can be completely 
reversed by co-treatment with OA. 
Changes in levels of ER stress markers associated with PA, but not PA+OA co-supplementation, 
closely followed trends in ER morphological alterations corresponding to the same treatments in 
H4IICE3 cells. We used CHOP/GADD153 as a marker of ER stress due to its known function as 
a pro-apoptotic protein up-regulated during the ER stress response. Based on a time course of 
CHOP protein levels (Supplementary Fig. 3-8S A), 8h was determined as an optimal point for 
assessing differences in CHOP expression in response to PA treatment. The intensity of CHOP 
expression increased in a concentration-dependent manner at 8h (Supplementary Fig. 3-8S B), 
similar to the increases in cell death (Supplementary Figure 3-6S A).  At this time point, 
H4IIEC3 cells treated with PA demonstrated significantly increased levels of CHOP, indicating 
substantial upregulation of UPR and confirming that ER stress is associated with PA-induced 
lipotoxicity (Fig. 3-3). This response was completely reversed by the addition of OA, a 
representative western blot of which is shown in Fig. 3-3.  
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Figure 3-3. PA-induced increases in CHOP expression was completely reversed by co-treatment 
with OA. H4IIEC3 were treated with 400 μM PA with or without OA supplementation for 8 h. Levels of 
CHOP expression were assessed using Western blotting techniques and quantified with ImageJ 
densiometric analysis. Upper panel, Representative blot; Lower panel, Quantification of CHOP/Actin. 
Thapsigargin (Thaps) was used as a positive control. Data represent mean ± SE of n=3. 
a
, P<0.05, vs cells 
treated with PA.  
 
Oleic acid (OA) co-supplementation modifies PA partitioning into intracellular lipid pools 
Due to the dramatic and differential effects that PA and OA had on ER structure and function, 
we sought to assess the consequences of PA treatment on intracellular lipid flux. There are two 
possible mechanisms by which OA could restore normal PL saturation: (i) by sequestering PA 
flux away from PL synthesis and into alternate lipid pathways or (ii) by competing with PA for 
esterification into the PL pool. We first examined the partitioning of 
3
H-PA into the five main 
classes of cellular lipids: phospholipids, diacylglycerols, free fatty acids, triacylglycerols, and 
cholesterol esters. These data confirm that PL and TAG are the two major fates of exogenous 
PA, with diacylglycerols (DAGs) also prominent in primary hepatocytes. Primary hepatocytes 
treated with only PA incorporated ~22% of the exogenous PA into the phospholipid fraction (Fig 
4A). The addition of 100 μM and 400 μM OA significantly reduced the PA incorporation into 
PLs after 24h by approximately 50% and 64%, respectively (~11.6% total PA in PL with the 
addition of 100 μM OA and ~7.9% with 400 μM OA, versus 21.9% with PA treatment alone). 
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The redistribution of PA appeared to mainly be channeled towards incorporation into the TAG 
fraction. In H4IIEC3 cells treated for 12h with PA alone, ~36% of intracellular PA was 
partitioned into PLs, with nearly all of the remainder incorporated into TAGs (Fig. 3-4B). 
Additionally, since primary hepatocytes and H4IIEC3 cells achieved similar  degrees of gross 
phenotype and cellular dysfunction based on analysis of TEM images at differing times (Figs. 3-
1 vs 3-2, respectively), it is not surprising that molecular partitioning processes achieve similar 
scales of change at different times shown in Fig. 3-4A vs 3-4B. 
 
Figure 3-4. OA supplementation reduces PA incorporation into phospholipids while increasing 
TAG synthesis and PA incorporation in the TAG fraction. Cells were treated with 400 μM 3H-PA 
with or without OA supplementation for 24h in primary hepatocytes (A) or 12h in H4IIEC3 cells (B). 
Lipid class incorporation was determined using TLC separation and scintillation counting of each lipid 
spot. PL, phospholipid; DG; diacylglyceride; FFA, free fatty acid; TG, triglyceride; CE, cholesterol ester. 
Data represent mean ± SE of n=3. *, p < 0.05; **, p < 0.01 vs. cells treated with PA.  
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As we hypothesized, co-supplementation with OA resulted in a concentration-dependent 
reduction in PA incorporation into PLs and a corresponding increase in its TAG esterification in 
both primary hepatocytes and H4IIEC3 hepatic cells. Thus, in the presence of PA alone, hepatic 
cells incorporated a higher percentage of exogenous PA into structural and signaling 
phospholipids than cells co-supplemented with OA. The addition of OA partially redirected the 
fate of exogenous PA away from PLs and toward incorporation into the more biologically inert 
TAGs.   
Palmitic acid is rapidly incorporated into cellular phospholipids and alters the composition of 
the phospholipid pool  
Due to the effects of OA treatment in modifying the intracellular partitioning of PA into different 
lipid pools and reversing PA-induced lipotoxicity, we evaluated the consequences of PA 
treatment on total cellular PL composition. The relative percentage of saturated acyl chain 
substituents on cellular PLs was found to increase significantly within 1 h of exogenous PA 
treatment in H4IIEC3 cells. The increase in PA incorporation was especially striking; in PA-only 
treated cells, there was more than a 50% increase in percent total composition PA in the PLs of 
the PA- versus vehicle-treated hepatomas within the first hour (Table 3-1). This increase in PA 
incorporation came mainly at the expense of monounsaturated 18:1 moieties, which were 
significantly reduced under PA treatment. These data indicate that treatment with 400 μM PA 
leads to rapid incorporation of exogenous PA into cellular PLs, resulting in increased PL 
saturation. After 6 h (Table 3-2) and 12 h (Supplementary Table 3-1S), the percentage of PA-
containing phospholipids continued to steadily climb in PA-treated cells.  By 12 hours, PA 
comprised approximately 43% of all phospholipid fatty acids in PA-treated cells (Supplementary 
Table 3-1S) compared to only approximately 13% in those treated with vehicle (BSA). These 
changes in cellular phospholipid composition were closely associated with the onset of PA-
induced decreases in mitochondrial membrane potential, apoptotic caspase activation, and cell 
death (Supplementary Fig. 3-6S and 3-7S).  
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Fatty 
Acid 
PA   PA+100OA   PA+400 OA   BSA   100 OA   400 OA   
 
14:0 0.65 ± 0.02  0.57 ± 0.01  0.50 ± 0.09  0.72 ± 0.05  0.60 ± 0.05  0.66 ± 0.06 
 
 
16:0 17.66 ± 0.15  
16.33 ± 0.07
a
 15.54 ± 0.63
a
 11.52 ± 0.25
a
 9.75 ± 0.17
a
 10.25 ± 0.08
a
 
 
16:1 5.93 ± 0.11  
5.36 ± 0.09
a
 4.99 ± 0.22
a
 5.39 ± 0.18  
4.29 ± 0.13
a
 4.45 ± 0.08
a
 
 
18:0 17.24 ± 0.19  16.61 ± 0.12  17.95 ± 0.62  18.33 ± 0.30  16.76 ± 0.14  16.55 ± 0.04 
 
 
18:1w9 29.88 ± 0.07  
32.80 ± 0.09
a
 35.80 ± 0.07
a
 33.11 ± 0.14
a
 39.42 ± 0.34
a
 42.36 ± 0.29
a
 
 
18:1w7 7.56 ± 0.02  
7.30 ± 0.01
a
 7.24 ± 0.06
a
 8.44 ± 0.04  
7.68 ± 0.02
a
 7.23 ± 0.03
a
 
 
18:2 2.92 ± 0.01  
2.80 ± 0.01
a
 2.76 ± 0.03
a
 3.14 ± 0.04
a
 2.83 ± 0.02
a
 2.75 ± 0.01
a
 
 
18:3 w3 0.46 ± 0.01  
0.49 ± 0.01
a
 0.00 ± 0.00
a
 0.53 ± 0.02
a
 0.50 ± 0.00
a
 0.20 ± 0.17
a
 
 
20:3w6 0.94 ± 0.01  0.92 ± 0.01  0.85 ± 0.03  0.95 ± 0.02  0.89 ± 0.01  0.79 ± 0.00 
 
 
20:4 11.75 ± 0.03  
11.63 ± 0.10  
9.21 ± 0.42
a
 12.48 ± 0.14
a
 11.94 ± 0.10  
10.64 ± 0.01
a
 
 
22:5w3 2.06 ± 0.03  2.15 ± 0.04  1.88 ± 0.09  2.21 ± 0.09  2.21 ± 0.03  1.69 ± 0.01 
 
 
22:6 2.96 ± 0.03  3.04 ± 0.05  2.72 ± 0.14  3.16 ± 0.12  3.14 ± 0.04  2.42 ± 0.02 
                                                     
 
%SFA 35.54 ± 0.05  
33.51 ± 0.14
a
 33.99 ± 0.15
a
 30.58 ± 0.19
a
 27.11 ± 0.19
a
 27.46 ± 0.12
a
 
 
%UFA 64.46 ± 0.05  
66.49 ± 0.14
a
 66.01 ± 0.15
a
 69.42 ± 0.19
a
 72.89 ± 0.19
a
 72.54 ± 0.12
a
 
 
Table 3-1. Phospholipid fatty acid composition of H4IIEC3 cells treated with PA and OA for 1 h (% 
of total composition). H4IIEC3 cells were incubated with 400 μM PA and/or 100μM or 400μM OA for 1 
h. Phospholipids were separated by thin layer chromatography and analyzed by gas chromatography-
flame ionization detection (GC-FID). Data represent mean fatty acid %± SE of n=4. 
a
, P<0.05 vs cells 
treated with PA alone. SFA, saturated fatty acids; UFA, unsaturated fatty acids. SFA, saturated fatty 
acids; UFA, unsaturated fatty acids. 
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Fatty 
Acid 
PA   PA+100 OA   PA+400 OA   BSA   100 OA   400 OA   
 
14:0 0.75 ± 0.02  
0.66 ± 0.03  
0.56 ± 0.07  
1.36 ± 0.07
a
  
1.13 ± 0.11  
0.72 ± 0.05
a
  
 
16:0 35.14 ± 0.42  
26.20 ± 0.08
a
  
23.32 ± 0.85
a
  
13.67 ± 0.16
a
  
11.43 ± 0.07
a
  
10.29 ± 0.25
a
  
 
16:1 6.83 ± 0.09  
6.37 ± 0.06
a
  
4.43 ± 0.09
a
  
6.09 ± 0.19
a
  
4.57 ± 0.08
a
  
3.32 ± 0.14
a
  
 
18:0 15.59 ± 0.12  
16.63 ± 0.14
a
  
14.87 ± 0.47  
19.52 ± 0.29
a
  
17.26 ± 0.33
a
  
16.96 ± 0.24
a
  
 
18:1w9 20.48 ± 0.21  28.82 ± 0.15  37.72 ± 1.06  31.71 ± 0.20  40.80 ± 0.17  48.38 ± 0.16  
 
18:1w7 4.46 ± 0.01  
4.44 ± 0.01
a
  
3.79 ± 0.07
a
  
7.20 ± 0.06
a
  
5.85 ± 0.01
a
  
4.93 ± 0.01
a
  
 
18:2 1.96 ± 0.00  
2.12 ± 0.01
a
  
1.95 ± 0.04  
2.84 ± 0.08
a
  
2.37 ± 0.04
a
  
1.87 ± 0.02
a
  
 
20:3w6 0.39 ± 0.23  0.56 ± 0.19  0.23 ± 0.23  0.42 ± 0.24  0.51 ± 0.17  0.54 ± 0.01  
 
20:4 9.72 ± 0.09  
9.67 ± 0.07  
9.24 ± 0.22  
11.85 ± 0.23
a
  
11.31 ± 0.24
a
  
9.30 ± 0.28  
 
22:4w6 1.16 ± 0.02  
1.14 ± 0.03  
0.90 ± 0.04
a
  
1.26 ± 0.02
a
  
0.96 ± 0.03
a
  
0.90 ± 0.04
a
  
 
22:5w3 1.49 ± 0.03  
1.49 ± 0.03  
1.30 ± 0.04
a
  
1.78 ± 0.03
a
  
1.58 ± 0.05  
1.14 ± 0.05
a
  
 
22:6 2.02 ± 0.05  
1.91 ± 0.03  
1.70 ± 0.07
a
  
2.29 ± 0.04
a
  
2.24 ± 0.07  
1.64 ± 0.08                                                      
 
%SFA 51.48 ± 0.56  
43.49 ± 0.26
a
  
38.76 ± 1.39
a
  
34.55 ± 0.53
a
  
29.82 ± 0.51
a
  
27.97 ± 0.54
a
  
 
%UFA 48.52 ± 0.72  
56.51 ± 0.56
a
  
61.24 ± 1.74
a
  
65.45 ± 1.09
a
  
70.18 ± 0.84
a
  
72.03 ± 0.77
a
   
Table 3-2. Phospholipid fatty acid composition of H4IIEC3 cells treated with PA and OA for 6 h (% 
total composition). H4IIEC3 cells were incubated with 400 μM PA and/or 100μM or 400μM OA for 6 h. 
Phospholipids were separated by thin layer chromatography and analyzed by gas chromatography-flame 
ionization detection (GC-FID). Data represent mean ± SE of n=4. 
a
, P<0.05 vs cells treated with PA 
alone. SFA, saturated fatty acids; UFA, unsaturated fatty acids. 
 
 
Oleic acid co-supplementation partially restores normal phospholipid composition 
We further conjectured that OA co-treatment would reverse PA-induced lipoapotosis by 
alleviating the oversaturation of PL membrane species. Therefore, we examined the effects of 
co-supplementing PA with OA at various ratios. We found that H4IIEC3 cells co-supplemented 
with OA incorporated significantly less PA into phospholipids after 1h of treatment (Table 3-1) 
and demonstrated substantial reductions in relative PA abundance after both 6 and 12 h (Table 3-
2, Supplementary Table 3-1S), which was accompanied by recovery of relative OA abundance 
back to levels approaching the vehicle-treated controls by 12 h. In particular, co-treatment with 
100 μM or 400 μM OA for only 6 h reduced PA abundance by ~25% and 33%, respectively, 
while overall PL saturation was reduced similarly by ~16% and 25%, respectively (Table 3-2). 
This significant drop in total saturation was mainly attributable to differences in the percentage 
of palmitic (16:0), palmitoleic (16:1), and oleic (18:1w9) fatty acyl components. Restoration of 
cellular phospholipid composition was closely associated with a reversal of PA-induced 
lipotoxicity markers (Supplementary Fig. 3-6S and 3-7S). 
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Palmitic acid treatment increases de novo lipid biosynthesis resulting in changes in DAGs and 
PLs while OA-supplementation ameliorates these changes by increased esterification into TAGs 
Additionally, we analyzed hepatic cells treated with defined fatty acid supplements in order to 
quantify the distribution of both neutral and phospho- lipids at 12h. H4IIEC3 hepatic cells 
treated with PA show significantly increased levels of 16:0 LPA (Fig. 3-5A) and both total and 
16:0-containing phosphatidic acid (Fig. 3-5B), specifically 32:0 PtdOH (Supplementary Fig. 3-
9S B), suggesting augmented de novo lipid biosynthesis though the canonical Kennedy pathway 
in response to SFA supplementation. PA treated cells accumulated increased quantities of total 
and 16:0-containing DAG (Fig. 3-5D), particularly 32:0 DAG (Supplementary Fig. 3-10S B) and 
had significantly higher levels of total phospholipid content, including an almost two-fold 
increase in the amount of PA moieties contained within the phospholipid pool (Fig. 3-5C).  
Additionally, the PA treated cells were not able to as effectively synthesize TAGs in comparison 
to cells supplemented with equimolar concentrations of the unsaturated fatty acid OA (Fig. 3-
5E). Alternatively, co-treatment with OA drastically shifted the incorporation of PA in glycero- 
and phospholipids. The presence of OA led to a dramatic reversal of PA-induced increases in 
16:0 LPA, PtdOH and DAGs (Fig. 3-5A, 3-5B and 3-5D, respectively), particularly PA-
containing 32:0 species within these classes (Supplementary Fig. 3-9S B and 3-10S A). 
Furthermore, OA supplementation significantly reduced both total and 16:0-containing PLs 
while simultaneously shifting incorporation of the PA toward TAG synthesis (Fig. 3-5C and 3-
5E, respectively).   
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Figure 3-5. PA treatment increases 16:0 lysophosphatidic acid, phosphatidic acid, PL and DAG, but 
not TAG, accumulation.  In contrast, co-treatment with OA substantially decreases PL while increasing 
TAG accumulation. H4IIEC3 cells were treated with 400 μM PA with or without OA supplementation for 
12h. Lipids were determined and quantified using a LC-MS method. Both total and 16:0 containing 
lysophosphatidic acid (A), phosphatidic acid (B), phospholipid (C) and DAG (D)  abundance was 
significantly increased in the presence of PA but was reversed by the addition of OA. Conversely, OA 
was much more readily incorporated into TAGs than the saturated PA, and co-supplementation with the 
two fatty acids synergistically increased overall triglyceride accumulation and 16:0 containing TAGs (E). 
Data represent mean ± SE of n=9; *, p < 0.05; **,p < 0.01 vs. cells treated with PA. 
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Discussion 
ER stress has been previously identified as a key mediator in the lipoapoptosis of CHO and 
hepatic cells (8, 13, 21). Other studies have demonstrated that ER stress precedes apoptosis in 
HeLa cells (34) and hepatic models of lipotoxicity (41). Borradaile et al. found a connection 
between ER stress and the degree of fatty acid saturation in membrane lipids of CHO cells 
supplemented with PA (13). Since the disruption of ER function appears to play an early and 
critical role in the response to SFA overload, we sought to better understand how lipid 
metabolism and partitioning of PA into specific lipid classes is affected by OA availability in 
hepatic cells.  We examined the effect that supplementing hepatic cells with PA and OA, alone 
or in combination, has on lipid metabolism, fatty acid composition of membrane phospholipids, 
and particularly on ER function.  
Species level analysis of the PL pool provides insight into mechanistic aspects of lipid synthesis 
in response to supplementation with differing fatty acids. Treatment of the H4IIEC3 hepatic cell 
line with PA resulted in dramatic increases in production of both 16:0 LPA and 32:0 PtdOH, 
strongly suggestive of de novo lipid biosynthesis characteristic of the canonical Kennedy 
pathway. This was not present in cells co-treated with both PA and OA or those grown in the 
absence of PA (Fig. 3-5A and Supplementary Fig. 3-9S B, respectively). Specifically, there was 
a dramatic increase in total PA esterified into PLs and DAGs that was significantly reduced by 
approximately 50% with the co-addition of only 100 μM OA (Fig. 3-5C and 3-5D, respectively). 
In contrast, the co-supplementation with OA resulted in significant increases in PA incorporation 
into TAGs. 
Palmitate treatment has been previously shown to increase DAG species in skeletal muscle 
models of FFA-induced insulin resistance (42-43). However, DAG accumulation in our hepatic 
cell model is secondary to even larger increases in overall PL synthesis, as evidenced by a strong 
and highly significant increase in both total and PA-containing phospholipids in cells treated 
with palmitate alone. This represents a significant finding that provides further context for a 
potential mechanism in which disordered PL metabolism is the initiator of palmitate-induced ER 
stress and downstream lipoapoptosis. In addition, observed differences in the molecular species 
distribution within distinct glycerophospholipid classes, particularly phosphatidylcholine (PC), 
phosphatidylinostitol (PI) and phosphatidylserine (PS), are in good agreement with results from a 
preclinical study of human liver samples from steatotic, cirrhotic and normal patients  
(Supplementary Fig. 3-9S C, G and H, respectively) (42). Such agreement provides evidentiary 
support for utilizing hepatocyte lipotoxicity experiments as models to explore remediation of 
human NAFLD progression.  
High-resolution TEM images of cells visually demonstrate the substantial divergence in cellular 
response to feeding hepatocytes saturated versus monounsaturated fatty acids. Supplementing 
cells with PA had a deleterious effect on the structural integrity of the ER membrane of both 
H4IIEC3 cells and primary hepatocytes after 4h and 12h of incubation, respectively, as indicated 
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by obvious dilation of the ER cisternae. This phenomenon has been previously observed in other 
cell types, specifically CHO (13) and C2C12 muscle cells (43) under similar PA-induced 
lipotoxic conditions.  An identical fatty acid load of OA, however, had no such effect on the ER, 
and the supplementation of PA-treated cells with OA reversed ER membrane distention and 
normalized ER morphology. Changes in ER morphology due to fatty acid treatment correlated 
with augmentation of the ER stress marker CHOP in the presence of exogenous PA (Fig. 3-3). 
As with ER dilation and distention, increases in markers of ER stress due to PA treatment were 
completely reversed by supplementing with OA (Fig. 3-3).  
Changes in ER morphology and function correlated with changes in PA partitioning among lipid 
classes. PA supplementation resulted in dramatic increases in PA incorporation into PL fatty acyl 
chains and overall PL saturation (Table 3-1, 3-2 and Supplementary Table 3-3S). OA co-
supplementation reduced PA incorporation into PLs at all examined time points in H4IIEC3 cells 
(1, 6, and 12 h).  This finding is supported by the differential changes in PA partitioning in 
response to supplementation alone or in combination with OA. We found that under PA/OA co-
treatment there was reduced partitioning into the PLs and increased incorporation into the TAG 
class. These data suggest that the ability of OA to reverse the lipotoxic effects of PA may be tied 
to its roles in altering the fate of PA away from PL incorporation and toward TAG synthesis 
and/or in restoring the saturation index of membrane phospholipids in compositionally sensitive 
organelles such as the ER.  
Overall, our data demonstrate that PA treatment caused increased de novo PL synthesis though 
the Kennedy pathway, which was not found in hepatocytes co-treated with PA and OA and, to 
our knowledge, has not been shown previously in models of hepatic lipotoxicity. Furthermore, 
we observed parallel trends in reversal of apoptotic cell death, Kennedy pathway flux and overall 
PL saturation, markers of ER stress, and physical ER dilation upon co-incubation of PA-treated 
cells with OA, indicating a strong association between these phenotypic responses. Notably, OA 
co-supplementation reduced levels of PA in the overall phospholipid composition, which in 
parallel diminished CHOP expression and ER distention, and reversed PA-induced markers of 
lipotoxicity in two hepatocyte models. Furthermore, the observed changes in PL composition and 
ER morphology preceded the onset of mitochondrial dysfunction, as assessed by changes in 
mitochondrial potential (JC1) and TEM images, as well as caspase activation, suggesting that ER 
stress may be a critical upstream mediator of the lipotoxic phenotype. This study demonstrates 
that increased phospholipid saturation is a hallmark and committed step of SFA lipotoxicity in in 
vitro hepatic models and that reversing saturation of membrane phospholipids may have a 
beneficial effect on hepatic cells exposed to a toxic SFA load. Treatments designed to limit the 
phospholipid saturation index may point towards novel strategies for improving hepatocyte 
function under these conditions.  
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Appendix: Supplementary Data 
 
Figure 3-6S. PA treatment induces cell death in a concentration dependent manner and co-
supplementation with OA reverses PA-mediated increases in cell death.   Cells were treated with 
increasing concentrations of PA for 12 h in H4IIEC3 cells (A) and 24h in primary hepatocytes (B). Cell 
toxicity was assessed using the fluorescent dye propidium iodide (PI) relative to control cells treated with 
BSA vehicle. Treatment with different concentrations of OA (100 μM OA and 400 μM OA) demonstrated 
no evidence of increased cell death while co-supplementing H4IIEC3 cells (C) and primary hepatocytes 
(D) with either concentration of OA reversed PA-induced cell death after 12h and 24h, respectively. Data 
represent mean ± SE of n=4. *, p < 0.05; **, p < 0.01 versus cells treated with BSA.  
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Figure 3-7S. Treatment of hepatic cells increases markers of apoptotic caspase activation and 
indicators of mitochondrial dysfunction though loss of membrane potential, all of which is reversed 
by co-treatment with OA. .   Hepatic cells were treated with 400 μM PA for 6 h in H4IIEC3 cells (A) 
and 12 h in primary hepatocytes (B) at which time caspase 3/7 activation was assessed by the ApoONE 
assay. Treatment with OA alone caused no significant increase in caspase 3/7 activation and co-treatment 
with OA completely reversed activation in PA treated cells. Indicators of mitochondrial dysfunction were 
determined by measuring loss of mitochondrial membrane potential using the JC-1 fluorescent dye and is 
depicted as the relative ratio between red and green fluorescent signals. PA treatment resulted in loss of 
mitochondrial potential in H4IIEC3 cells at 6h (C) and in primary hepatocytes at 12h (D). The addition of 
similar concentrations of OA demonstrated no deleterious effect on mitochondrial potential and its co-
supplementation significantly reversed losses induced by PA treatment in both cell types. Data represent 
mean ± SE of n=4. *, p < 0.05; **, p < 0.01 versus cells treated with BSA.  
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Figure 3-8S. PA treatment results in concentration- and time-dependent increases in CHOP expression.  (A) Western blot of PA-induced increases in CHOP 
expression over time in response to 400 μM PA. (B) PA concentration-dependent increases in CHOP expression at 8 h assessed by Western blot. Thapsigargin  
(Thaps) was used as a positive control. Data shown are a representative blot of n=3 western blots.  
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  Fatty Acid PA   PA+100 OA   PA+400 OA   BSA   100 OA   400 OA   
 
14:0 0.00 ± 0.00 
 
0.25 ± 0.12 
 
0.00 ± 0.00 
 
0.81 ± 0.02a 
 
0.73 ± 0.03a 
 
0.53 ± 0.01a 
 
 
16:0 43.12 ± 0.21 
 
33.58 ± 0.31a 
 
29.17 ± 0.28a 
 
12.71 ± 0.22a 
 
11.51 ± 0.10a 
 
9.01 ± 0.10a 
 
 
16:1 8.44 ± 0.13 
 
8.23 ± 0.14 
 
4.72 ± 0.09a 
 
4.88 ± 0.15a 
 
2.94 ± 0.02a 
 
1.75 ± 0.01a 
 
 
18:0 13.92 ± 0.22 
 
13.96 ± 0.52a 
 
13.68 ± 0.30 
 
19.75 ± 0.34a 
 
15.65 ± 0.09a 
 
13.49 ± 0.16 
 
 
18:1w9 12.77 ± 0.06 
 
22.57 ± 0.15a 
 
32.24 ± 0.27a 
 
28.80 ± 0.68a 
 
44.25 ± 0.12a 
 
54.31 ± 0.43a 
 
 
18:1w7 3.65 ± 0.02 
 
3.38 ± 0.01a 
 
3.01 ± 0.01a 
 
7.43 ± 0.17a 
 
6.03 ± 0.05a 
 
4.29 ± 0.04a 
 
 
18:2 1.96 ± 0.03 
 
2.17 ± 0.01a 
 
2.06 ± 0.03 
 
5.38 ± 1.93 
 
2.16 ± 0.01a 
 
2.18 ± 0.58 
 
 
20:3w6 0.88 ± 0.01 
 
0.83 ± 0.02 
 
0.71 ± 0.00a 
 
1.15 ± 0.02a 
 
0.35 ± 0.18 
 
0.14 ± 0.14a 
 
 
20:4 7.87 ± 0.06 
 
7.67 ± 0.21 
 
7.75 ± 0.17 
 
10.40 ± 0.18a 
 
8.52 ± 0.08a 
 
7.11 ± 0.04a 
 
 
20:5  0.15 ± 0.15 
 
0.46 ± 0.01 
 
0.45 ± 0.01 
 
0.00 ± 0.00a 
 
0.00 ± 0.00 
 
0.00 ± 0.00 
 
 
22:4w6 0.74 ± 0.01 
 
0.65 ± 0.03 
 
0.53 ± 0.01a 
 
1.18 ± 0.03a 
 
0.94 ± 0.43 
 
1.70 ± 0.07a 
 
 
22:5w6 0.98 ± 0.01 
 
1.02 ± 0.01a 
 
1.01 ± 0.02 
 
1.66 ± 0.04a 
 
1.30 ± 0.02a 
 
1.27 ± 0.02a 
 
 
22:5w3 2.50 ± 0.03 
 
2.35 ± 0.06 
 
2.11 ± 0.03a 
 
2.84 ± 0.07a 
 
2.46 ± 0.03 
 
1.81 ± 0.02a 
 
 
22:6 3.02 ± 0.03 
 
2.86 ± 0.03a 
 
2.56 ± 0.04a 
 
3.01 ± 0.07 
 
3.15 ± 0.04 
 
2.41 ± 0.02a 
                                                     
 
% SFA 57.03 ± 0.10 
 
47.79 ± 0.20a 
 
42.85 ± 0.14a 
 
33.27 ± 0.13a 
 
27.89 ± 0.05a 
 
23.03 ± 0.06a 
 
 
% UFA 42.97 ± 0.13 
 
52.21 ± 0.13a 
 
57.15 ± 0.13a 
 
66.73 ± 0.23a 
 
72.11 ± 0.14a 
 
76.97 ± 0.15a 
  
Table 3-3S. Phospholipid fatty acid composition of H4IIEC3 cells treated with PA and OA for 12 h (% of total composition). H4IIEC3 cells were incubated 
with 400 μM PA and/or 100μM or 400μM OA for 12 h. Phospholipids were separated by thin layer chromatography (TLC) and analyzed by gas chromatography-
flame ionization detection (GC-FID). Data represent mean fatty acid % ± SE of n=4. 
a
, P<0.05 vs cells treated with PA alone. SFA, saturated fatty acids; UFA, 
unsaturated fatty acids. 
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Figure 3-9S. Selected glycerophospholipid species distribution from H4IIEC3 hepatic cells treated for 12h. H4IIEC3 cells were treated with 400 μM 
PA with or without OA supplementation for 12h in H4IIEC3. Lipids were determined and quantified using a previously published LC-MS method. 
Selected species distributions of total glycerophospholipids, phosphatidic acid (PtdOH), phosphatidylcholine (PC),  phosphatidylethanolamine (PE), 
phosphatidylglycerol (PG),  Bis(monoacylglycerol)phosphate (BMP), phosphatidylinostitol (PI), phosphatidylserine (PS) and sphingomyelin (SM) are 
represented (A, B, C, D, E, F, G, H, and I respectively). Data represent mean ± SE of n=9.  
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Figure 3-10S. Selected glycerolipid species distribution from H4IIEC3 hepatic cells treated for 12h. .  H4IIEC3 cells were treated with 
400 μM PA with or without OA supplementation for 12h in H4IIEC3. Lipids were determined and quantified using a LC-MS method. 
Selected species distributions of triacylglycerols (TAG) and diacylglycerols (DAG) are shown (A and B, respectively). Data represent mean 
± SE of n=9. 
 
61 
 
CHAPTER 4  
INHIBITION OF TRIGLYCERIDE SYNTHESIS DOES NOT SENSITIZE HEPATIC CELLS 
TO LIPTOXICITY OR INTERFERE WITH OLEATE-MEDIATED RESCUE OF 
PALMITATE-TREATED CELLS 
Introduction 
Obesity has reached epidemic proportions both in the U.S. and abroad, creating ballooning 
healthcare costs. Metabolic diseases associated with obesity, including type 2 diabetes, non-
alcoholic fatty liver disease (NAFLD) and cardiovascular disease, have also seen concomitant 
increases in population incidence rates. NAFLD, the hepatic manifestation of metabolic 
syndrome, is characterized by chonic ectopic lipid accumulation in the liver and is estimated to 
affect over one-third of the U.S. general population and up to 80% of obese and diabetic 
individuals (1, 2). An estimated 10-25% of NAFLD patients progress to a more severe condition 
known as non-alcoholic steatohepatitis (NASH), characterized by chonic inflammation and 
hepatic cell death that can eventually lead to cirrhosis (3). Despite its high prevalence, the 
molecular mechanisms underlying the progression from NAFLD to NASH are not well 
understood and represent a critical area of investigation in order to develop more targeted and 
effective therapeutics for fatty liver disease. 
Unger et al. introduced the concept of lipoapotosis (4-6), which involves cellular dysfunction 
and death due to the overaccumulation of lipids in non-adipose tissues (7). Hepatocyte 
lipoapoptosis due to liver fat accumulation is one of the hallmark features of NASH in humans 
(2, 8). The large body of literature published since the introduction of this concept indicates that 
lipid-induced hepatocyte toxicity is most acute when cells are exposed to elevated saturated fatty 
acids (SFAs) such as palmitate (PA) (9-12). Clinical studies indicate that diets high in saturated 
fat may be linked to NASH progression while, conversely, unsaturated fat can impart a 
protective effect (7, 13). In vivo studies using rodent diets high in saturated fat have shown 
increased hepatic inflammation, cell death, and markers of liver injury compared to normal high 
fat and chow diets (14-16).  
In vitro experiments in a wide variety of cell types including Chinese hamster ovary (CHO) cells 
(17-19),  pancreatic beta cells (20-22), breast cancer cells (23), HeLa cells (24) and hepatic cells 
(9, 10, 12, 25-28) have consistently demonstrated the acute lipotoxic effects of saturated fatty 
acids, such as PA, but not unsaturated fatty acids. Palmitate-mediated lipotoxicity is 
characterized by endoplasmic reticulum (ER) stress, ER calcium release, reactive oxygen species 
(ROS) accumulation, caspase activation and cell death (11, 29). Cells treated with 
monunsaturated fatty acids (MUFAs), such as oleate (OA), exhibit none of these features but 
instead demonstrate significant increases in triglyceride (TG) synthesis and accumulation (9, 12, 
17).  
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Adding OA to PA-treated cells can fully reverse PA lipotoxicity though mechanisms that are not 
well defined but which have been previously attributed to increased TG accumulation and 
sequestration of PA into neutral lipid stores (17, 20, 21). However, this hypothesis has never 
been directly tested by experimentally modulating the relative partitioning of PA/OA between 
TGs and other lipid fates in hepatocytes. In this study, we test the alternative hypothesis that the 
rescue effect of PA/OA co-treatment (relative to treatment with PA alone) is due to its ability to 
normalize the composition of phospholipid membranes, rather than its ability to divert PA into 
neutral TG species. This hypothesis was suggested by our prior lipidomic profiling study that 
showed dramatic accumulation of saturated phospholipid species in response to PA treatment of 
liver hepatocytes, which was completely reversed by PA/OA co-treatment (9).  
The fatty acyl chain composition and degree of unsaturation in phospholipids determines the 
biophysical characteristics of cellular membranes, including fluidity and assembly, which in turn 
influence their function (30). The ER membrane typically contains unsaturated 
phosphatidylcholine (PC) as its major phospholipid component (31), and its composition is 
tightly regulated; even small changes in fatty acyl composition and saturation may induce ER 
stress. Recent literature suggests that not only do obese individuals have chonic underlying levels 
of ER stress (32-35), but that ER stress pathways, known collectively as the unfolded protein 
response (UPR), are activated in NAFLD and may play an important role in the development and 
progression of this disease (36, 37). Markers of ER stress, including CCAAT/enhancer-binding 
protein homologous protein (CHOP) downstream of PERK activation, appear rapidly after 
treatment with PA but not OA (9, 38). Aberrant phospholipid metabolism and composition has 
been previously postulated as the link between ER stress and lipotoxicity (9, 11, 24, 25, 
32).Abnormal incorporation of SFAs and subsequent oversaturation of the ER membrane can 
result in detrimental stiffening and loss of function leading to ER stress (30, 39). Increased 
phospholipid saturation may also impair the function of important membrane-bound proteins 
such as sarco-endoplasmic reticulum calcium ATPase (SERCA), which is critical for 
intracellular calcium homeostatsis (32, 40).  Interestingly, we have shown that increased Ca
2+
 
efflux from the ER can promote overactivation of mitochondrial metabolism leading to ROS 
accumulation and apoptosis in response to PA treatments (28).   
In this study we show that addition of OA to PA-treated hepatocytes decreases overall 
phospholipid saturation while rescuing PA-induced apoptotic cell death. As shown previously, 
this rescue effect is accompanied by enhanced TG synthesis and, specifically, increased 
incorporation of PA into TG stores. However, simultaneous knockdown of both liver isoforms of 
diacylglycerol acyltransferase (DGAT), the rate-limiting step in TG synthesis, significantly 
reduced TG accumulation but without altering the ability of OA to prevent PA lipotoxicity. In 
both wild-type and DGAT knockdown cells, co-treatment with OA significantly reduced overall 
phospholipid saturation in comparison to cells treated with PA alone. These data indicate that 
OA’s protective effects are mainly due to its ability to normalize the composition of cellular 
phospholipids in the presence of a PA load, rather than to divert toxic PA into inert TG stores.  
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Methods 
Materials and Reagents  
Oleic and palmitic acids, bovine serum albumin (BSA), and Dulbecco’s modified Eagle’s 
medium (DMEM) were all purchased from Sigma-Aldrich (St. Louis, MO). CHOP primary 
(mouse) and goat anti-mouse secondary antibodies were purchased from Abcam (Cambridge, 
MA). β-Actin primary (goat) and donkey anti-goat secondary antibodies were procured from 
Santa Cruz Biotechnology. Cleaved PARP primary (rabbit) and mouse anti-rabbit secondary 
antibodies were purchased from Cell Signaling (Danvers, MA). All other chemicals were 
purchased from standard commercial sources.  
Preparation of Fatty Acid Solutions 
Fatty acid treatment solutions were prepared by coupling free fatty acids BSA. Specifically, 
palmitate or oleate was fully dissolved in 200-proof ethanol for a concentration of 195 mM. This 
FFA stock solution was added to a pre-warmed BSA solution (10% w/w, 37°C) for a final FFA 
concentration of 3 mM, ensuring that the concentration of ethanol in the FFA solution did not 
exceed 0.5% by volume. The solution was fully dissolved by warming at 37°C for an additional 
10 minutes. The final ratio of FFA:BSA was 2:1. Vehicle control treatments were prepared using 
stocks of 10% w/w BSA with an equivalent volume of ethanol added to match that contained in 
the final FFA stock. The final concentration of ethanol was less than 1% in all experiments.  
Cell Culture and siRNA Transfections 
Rat hepatoma cells, H4IIEC3 (ATCC), were cultured in low-glucose Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin/glutamine (2mM). Measurements were obtained at 70-80% confluency. 
Hepatic cells were transfected with siRNA using Lipofectamine RNAiMAX (Invitrogen) 
according to the manufacturer’s protocol. The final concentration of siRNA was 25 nM.  
Cell Toxicity 
Toxicity was assessed using the dead cell dye propidium iodide as described previously (41). 
Propidium iodide is an intercalating dye that can only permeate dead cells. It becomes highly 
fluorescent when embedded in the double-stranded DNA exposed after cell death. After 
culturing cells in 96-well plates with experimental treatments, the medium was removed and 
replaced with a solution of the dye and serum-free DMEM. Cells were incubated at 37°C for 1 h 
in the dark prior to fluorescence measurement at ex/em wavelengths of 530/645 nm.  
Caspase Activation  
The Apo-ONE Homogenous Caspase 3/7 Assay kit was used to measure apoptotic caspase 
activation.  Cells were cultured in 96-well plates and incubated with desired treatments for 6 
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hours.  The Apo-ONE kit uses a lysis buffer combined with a caspase 3/7 specific substrate (Z-
DEVD-R110), which becomes fluorescent once these caspases remove its DEVD peptide.  
Fluorescence was measured at ex/em wavelengths of 485/535 nm.  
Western Blotting 
Cells were lysed with ice-cold RIPA lysis buffer (sc-24948, Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA) supplemented with Na-orthovanadate, protease inhibitor cocktail, and PMSF for 
30 min on ice. Samples were centrifuged at 16,100 rcf and 4°C for 20 min, and the resulting 
supernatants constituted the total protein extracts. Protein concentrations were determined by 
BCA assay (Thermo Fisher Scientific, Rockford, IL). Samples were added in concentrations of 
30 μg/lane for SDS-PAGE western blotting. Dilutions of the primary antibodies were Anti-
CHOP (1:1000), anti-β-actin (1:1000) and anti-cleaved parp (1:1000) all dissolved in 5% BSA. 
Secondary anti-bodies (anti-mouse, anti-goat and anti-rabbit, respectively) were all dissolved in a 
1:1 mix of TBST : 5% BSA at a dilution of 1:10,000.  
Total RNA Isolation and Quantitative Real-Time PCR 
Total RNA was isolated from cells using RNeasy Mini Kit (Qiagen, Germantown, MD) 
according to the manufacturer’s protocol and then reverse transcribed using a cDNA reverse 
transcriptase kit (BioRad, Hercules, CA). Quantitative real-time PCR was done using iQ SYBR 
Green Supermix (BioRad, Hercules, CA) and BioRad CFX96 Cycler (BioRad, Hercules, CA). 
The sequences of the primers were as follows: C/EBP homologous protein (CHOP) forward (5’-
CTCAGCTGCCATGACTGTA-3’) and reverse (5’-CGTCGATCATACCATGTTGAAGA-3’), 
ATF3 forward (5’-CGCCTCCTTTTTCTCTCATCT-3’) and reverse (5’-
CCATCCAGAACAAGCACCT-3’), ribosomal 18s forward (5’-CGGACAGGATTGACAGAT-
3’) and reverse (5’-CGCTCCACCAACTAAGAA-3’), diacylglycerol acyltransferase 1 
(DGAT1) forward (5’-TTACCGTGGTATCCTGAA-3’) and reverse (5’-
GCCATACTTGATAAGATTCTC-3’), diacylglycerol acyltransferase 2 (DGAT2) forward (5’-
AGACACCATAGACTACTT-3’) and reverse (5’-ATACCTCATTCTCTCCAA-3’). Target 
gene expression was normalized on the basis of 18s content.  
Phospholipid Fatty Acid Profiles 
Cells seeded in 10-cm Petri dishes at an initial density of 4 × 10
6
 cells per plate were incubated 
in standard medium until reaching ~70-80% confluency, at which time experimental treatments 
were administered.  Cells were then trypsinized for 3 min and scraped using cold PBS. Cell 
suspensions were pelleted by centrifugation and resuspended in fresh PBS. Fatty acyl lipid 
analysis was performed by the Vanderbilt Hormone Assay and Analytical Services Core using 
thin-layer chromatography (TLC) and gas chromatography-flame ionization detection (GC-FID) 
techniques. Briefly, lipids were extracted from the aforementioned cell pellets using a modified 
Folch separation. An internal standard (1,2-dipentadecanoyl-sn-glycero-3-phosphocholine) for 
phospholipids was added to the lipid-containing chloroform phase. Total lipids were then 
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extracted and separated by TLC using petroleum ether/ethyl ether/acetic acid (80/20/1, v/v/v) on 
silica plates. Spots corresponding to different lipid pools were visualized with rhodamine 6G in 
95% ethanol and scraped individually into glass tubes for transmethylation. Transmethylation 
was performed using a boron trifluoride-methanol 10% (w/w) solution. Derivatized lipids were 
then analyzed using GC-FID, where standardized calibration curves were used to analyze fatty 
acid composition and quantify total content. 
3
H-Palmitate Lipid Class Incorporation 
Cells seeded in 6-well dishes at 1.5 × 10
6
 cells per well were incubated in standard medium until 
reaching ~70-80% confluency. Next, the cells were incubated for the indicated duration at 37°C 
in 400 μM [9,10-3H] palmitic acid (1 µCi 3H/µmol PA), either in the presence or absence of oleic 
acid. Lipids were extracted using a modified Folch procedure; twice, 0.75 mL chilled methanol 
was added to each well and cells were scraped into 1:1 chloroform:water. Once vortexed and 
centrifuged, the lipid-containing chloroform phase was vacuum dried without heat. Lipid classes 
were separated by TLC, as described above. Each TLC spot was added to an individual vial and 
radioactivity was assessed by scintillation counting. 
Statistical Analysis  
All data are represented as mean ± standard error. Type I ANOVA (Student’s t test) was used to 
assess statistical differences involving multiple (two) treatments. ANOVA was followed with 
Tukey-Kramer post-hoc testing for 
3
H-labeled PA experiments and lipid fatty acyl chain 
composition . 
 
Results 
DGAT knockdown effectively reduces triglyceride synthesis in hepatic cells 
DGAT plays an important role in determining the rate of cellular TG synthesis. Therefore, we 
sought to examine how inhibiting the expression of DGAT affects PA-induced lipoapoptosis and 
cellular lipid composition. We chose to simultaneously inhibit both DGAT1 and DGAT2, since 
both isoforms have demonstrated activity in hepatocytes (42, 43). Simultaneous transfection of 
siRNAs targeted against rat DGAT1 and DGAT2 (siDGAT1/2) in H4IIEC3 cells efficiently 
reduced mRNA expression levels of both DGAT1 and DGAT2 by approximately 70% and 85%, 
respectively (Fig. 4-1A). Oleate is a potent activator of TG synthesis in hepatocytes though its 
binding and inactivation of the constitutive DGAT-inhibitory protein Ubxd8 (44). OA 
administration was used to demonstrate the functional inhibition of cellular TG synthesis in 
response to siDGAT1/2 transfection. siDGAT1/2 cells treated with 400 μM OA showed 
significantly less TG accumulation than cells transfected with a non-targeted siRNA control 
(NTC) vector (Fig. 4-1B). Despite these differences in TG synthesis, there was no difference in 
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cell death between siDGAT1/2 and NTC cells after treatment with OA (Fig. 4-1C). These data 
indicate that reduced TG synthesis capabilities do not sensitize hepatocytes to lipotoxicity in 
response to MUFA treatment. 
 
 
Figure 4-1. siRNA mediated knockdown of DGAT1/2 significantly reduced TG accumulation in 
H4IIEC3 cells but did not sensitize them to fatty acid lipotoxicity. Simultaneous siRNA mediated 
knockdown of DGAT1 and DGAT2  expression (siDGAT1/2) reduced mRNA transcript levels of both 
proteins (A). siDGAT1/2 cells demonstrated significantly reduced TG accumulation in comparison to 
non-targeted control (NTC) cells when supplemented with identical fatty acid loads (B). TGs were 
separated by thin layer chromatography and analyzed by gas chromatography-flame ionization detection 
(GC-FID). Amounts were normalized to mg protein for absolute quantification. Inhibition of TG 
synthesis did not sensitize siDGAT1/2 cells to OA lipotoxicity (C). Data represent mean ± SE of n=4. 
**
, 
P<0.05, vs. cells supplemented with the same treatment; 
a
, P<0.05, vs BSA-control cells with same 
genetic manipulation (NTC or siDGAT1/2); 
b
, P<0.05, vs cells with same treatment; ns, not significant.  
 
Inhibition of TG synthesis does not sensitize hepatic cells to FFA-induced apoptosis 
Previous work has shown that PA is toxic to a wide variety of cell types, including hepatocytes, 
while OA is not acutely toxic (6, 9, 11). In fact, co-supplementing PA-treated cells with OA 
effectively reverses all lipotoxic phenotypes associated with PA overload. Prior literature 
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suggests that this rescue is due to the ability of OA to induce TG synthesis and thereby sequester 
PA away from metabolic fates that promote cellular stress and dysfunction. Therefore, we sought 
to investigate how inhibition of TG synthesis affects the ability of OA to rescue PA-treated 
hepatic cells.  
Similar to prior studies, PA treatment of H4IIEC3 cells transfected with NTC siRNA resulted in 
significant increases in cell death while OA treatment did not initiate cell death (Fig. 4-2A). PA 
toxicity was associated with increased activity of caspases 3 and 7 (Fig. 4-2B) and accumulation 
of cleaved PARP (Fig. 4-2C), indicative of apoptosis-mediated cell death in PA-treated cells. Co-
supplementation of OA to PA-treated NTC cells completely abolished PA toxicity. Interestingly, 
knockdown of DGAT1/2 in H4IIEC3 cells did not alter the apoptotic response to PA and/or OA 
treatments. Palmitate was toxic to siDGAT1/2 cells while OA was not, and most surprisingly, 
cells supplemented with PA were still rescued by the addition of OA even in the absence of 
appreciable TG synthesis (Figure 4-2A). Furthermore, OA co-supplementation was still able to 
protect against caspase 3/7 activation and accumulation of cleaved PARP in siDGAT1/2 cells, 
indicating a rescue from PA-mediated cell apoptosis.   
 
Figure 4-2. OA-mediated rescue of PA-induced lipoapoptosis was not inhibited by siDGAT1/2 
knockdown. siDGAT1/2 cells demonstrated statistically identical responses to treatment with PA and/or 
OA (A) as assessed by propidium iodide (PI) staining of dead cells expressed relative to BSA-treated 
controls. Consistent trends were observed in cell apoptosis assessed by caspase 3/7 activity (B) and 
expression level of cleaved PARP (C). Data represent mean ± SE of n=4. **, P<0.05, vs cells 
supplemented with the same treatment. 
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DGAT1/2 knockdown does not affect palmitate- and oleate-induced markers of ER stress 
Next, we sought to examine whether DGAT1/2 knockdown affected other aspects of PA-induced 
lipotoxicity aside from cell death and apoptosis. Previous studies show that PA exposure induces 
acute ER stress, also known as unfolded protein response (UPR), as part of the lipotoxicity 
cascade (9, 38). The purpose of UPR is to respond to deleterious changes in ER function, which 
can result from accumulation of misfolded proteins (45) or changes in ER membrane 
composition (24, 25, 39). Thee transmembrane ER proteins, inositol-requiring 1 (IRE1), PERK 
and activating transcription factor 6 (ATF6), are upregulated during UPR. We measured 
expression of several genes associated with downstream and prolonged UPR, specifically CHOP 
and ATF3, as surrogate markers of ER stress during lipotoxic treatments. 
Quantitative real-time PCR analysis showed a marked increase in CHOP and ATF3 expression 
levels in response to PA but not OA treatment in both NTC vector and siDGAT1/2 transformed 
cells (Figure 4-3A). Co-treatment with OA in both control and knockdown cells restored these 
markers of ER stress to basal levels. The same trend was observed in measurements of CHOP 
protein expression (Figure 4-3B). These results indicate that elevated TG synthesis is not 
required for OA to inhibit PA-induced ER stress in hepatocytes.  
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Figure 4-3. PA-induced increases in markers of ER stress were completely reversed by co-treatment 
with OA regardless of DGAT expression level. Both NTC and siDGAT1/2 H4IIEC3 cells were treated 
with 400 μM PA with or without 400 μM OA supplementation to assess markers of ER stress. Relative 
mRNA transcript levels of CHOP (A) and ATF3 (B) were assessed at 6h. Levels of CHOP protein 
expression were assessed by Western blot at 8h, with one representative blot shown (C). Thapsigargin 
(Thaps) is a positive control. Data represent mean ± SE of n=3. **, P<0.05, vs cells treated w PA.  
 
DGAT1/2 knockdown alters palmitate distribution amongst lipid pools and modulates 
phospholipid composition 
We next examined the effects of siDGAT1/2 knockdown on PA incorporation into the main 
cellular lipid pools. As expected, DGAT knockdown significantly reduced partitioning of 
radiolabeled 
3
H-PA into the TG pool, both alone and in the presence of OA (Figure 4-4).There 
was a small, but significant, increase in accumulation of 
3
H-PA into the diacylglycerol pool in 
the siDGAT1/2 cells. However, the majority of the radiolabeled PA was alternatively channeled 
into the phospholipid pool in these knockdown cells. These results indicate that knockdown of 
DGAT1/2 alters the intracellular fate of exogenous fatty acids away from TG synthesis and into 
other lipid end-products. The vast majority of 
3
H-PA was alternatively incorporated into 
phospholipids. Interestingly, a higher percentage of total cellular 
3
H-PA was partitioned into the 
phospholipid fraction of siDGAT1/2 cells co-treated with PA+400μM OA than NTC cells treated 
with PA alone, and yet these cells were protected from lipotoxicity while the PA-treated NTC 
cells were not. This finding is inconsistent with the notion that oleate’s capacity to prevent PA 
lipotoxicity is simply a consequence of its ability to divert PA into TG synthesis. 
70 
 
 
Figure 4-4. Knockdown of DGAT1/2 repartitions PA into phospholipids and away from TGs. 
H4IIEC3 cells were treated with 400 μM 3H-PA with or without OA supplementation for 12h in both 
NTC and siDGAT1/2 knockdown cells . Lipid class incorporation was determined using TLC separation 
and scintillation counting of each lipid spot. PL, phospholipid; DG; diacylglyceride; FFA, free fatty acid; 
TG, triglyceride; CE, cholesterol ester. Data represent mean ± SE of n=3. **,p < 0.01 NTC vs siDGAT1/2 
cells with same treatment.  
Next, we measured the phospholipid composition in DGAT1/2 knockdown cells to see if the 
increased partitioning of PA into the phospholipid fraction was reflected in compositional 
changes (Table 4-1). Administration of PA resulted in significant increases in the abundance of 
palmitic acid (16:0) in phospholipids compared to BSA treatment in both NTC cells (48.73 ± 
0.62% versus 12.87 ± 0.14%) and DGAT1/2 knockdown cells (53.06 ± 2.66% versus 13.58 ± 
0.18%). This correlated with a significant increase in total phospholipid saturation in PA-treated 
cells versus BSA control cells. Similar to previous reports (9), PA/OA co-treatment of NTC cells 
significantly reduced both the abundance of PA in phospholipids (30.05 ± 0.24% versus 48.73 ± 
0.62%) and overall phospholipid saturation (40.80 ± 0.27% versus 61.55 ± 0.85%) compared to 
those treated with PA alone. Most interestingly, siDGAT1/2 cells exhibited similar shifts in PA 
abundance (30.77 ± 0.22% versus 53.06 ± 2.66%) as well as total saturation level of 
phospholipids (40.62 ± 0.24% versus 64.94 ± 2.77%) when PA/OA co-treated cells were 
compared to cells treated with PA alone. In fact, there were no statistical differences in 16:0 
abundance or phospholipid saturation level between the NTC and siDGAT1/2 cells administered 
the same fatty acid treatments. These data suggest that inhibition of TG synthesis does not alter 
oleate’s ability to normalize the composition of membrane phospholipids in PA-treated cells.   
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Fatty 
Acid 
NTC 
PA   
NTC 
PA+OA   
NTC 
BSA   
NTC 
OA   
siDGAT 
PA   
siDGAT 
PA+OA   
siDGAT 
BSA   
siDGAT 
OA   
14:0 0.00 ± 0.00 
 
0.00 ± 0.00 
 
0.89 ± 0.02 
 
0.48 ± 0.03 
 
0.00 ± 0.00 
 
0.00 ± 0.00 
 
0.69 ± 0.35 
 
0.00 ± 0.00 
 16:0 48.73 ± 0.62 
 
30.05 ± 0.23
a
 
 
12.87 ± 0.14
a
 
 
8.29 ± 0.10
a
 
 
53.06 ± 2.66
b
 
 
30.77 ± 0.22
a
 
 
13.58 ± 0.18
a
 
 
7.18 ± 0.11
a
 
 16:1 8.82 ± 0.24 
 
6.50 ± 0.06
a
 
 
6.71 ± 0.10
a
 
 
2.40 ± 0.08
a
 
 
9.70 ± 0.72 
 
5.37 ± 0.09
a
 
 
5.88 ± 0.05
a
 
 
1.47 ± 0.02
a
 
 18:0 12.82 ± 0.58 
 
10.75 ± 0.12
a
 
 
18.75 ± 0.55
a
 
 
12.64 ± 0.42 
 
11.88 ± 0.77 
 
9.84 ± 0.10
a
 
 
18.92 ± 0.31
a
 
 
10.77 ± 0.20 
 18:1w9 11.06 ± 0.07 
 
34.34 ± 0.40
a
 
 
28.19 ± 0.74
a
 
 
58.03 ± 0.05
a
 
 
12.28 ± 0.30 
 
37.68 ± 0.14
a,b
 
 
30.22 ± 0.66
a,b
 
 
66.40 ± 0.22
a,b
 
 18:1w7 3.22 ± 0.02 
 
2.83 ± 0.02 
 
8.01 ± 0.42
a
 
 
4.17 ± 0.08 
 
2.92 ± 0.09 
 
2.97 ± 0.02 
 
7.36 ± 0.20
a
 
 
4.00 ± 0.05 
 18:2 1.80 ± 0.08 
 
2.08 ± 0.01 
 
4.08 ± 0.14
a
 
 
1.75 ± 0.05 
 
1.10 ± 0.55 
 
1.76 ± 0.04
a
 
 
3.82 ± 0.14
a
 
 
1.42 ± 0.01
a
 
 20:3w6 0.66 ± 0.33 
 
0.96 ± 0.01 
 
1.51 ± 0.03 
 
0.60 ± 0.01 
 
0.00 ± 0.00 
 
0.00 ± 0.00 
 
0.85 ± 0.42 
 
0.00 ± 0.00 
 20:4 8.52 ± 0.07 
 
7.73 ± 0.14 
 
10.56 ± 0.03
a
 
 
6.64 ± 0.07 
 
6.72 ± 0.29 
 
7.30 ± 0.02 
 
10.51 ± 0.15
a
 
 
5.77 ± 0.11 
 20:5  0.00 ± 0.00 
 
0.12 ± 0.12 
 
0.34 ± 0.17 
 
0.00 ± 0.00 
 
0.00 ± 0.00 
 
0.00 ± 0.00 
 
0.00 ± 0.00 
 
0.00 ± 0.00 
 22:4w6 0.00 ± 0.00 
 
0.87 ± 0.05 
 
1.38 ± 0.01 
 
0.59 ± 0.01 
 
0.00 ± 0.00 
 
1.03 ± 0.09 
 
1.84 ± 0.05 
 
0.00 ± 0.00 
 22:5w6 0.00 ± 0.00 
 
0.00 ± 0.00 
 
0.65 ± 0.42 
 
1.05 ± 0.01 
 
0.00 ± 0.00 
 
0.00 ± 0.00 
 
0.81 ± 0.40 
 
0.51 ± 0.26 
 22:5w3 2.34 ± 0.09 
 
1.75 ± 0.05 
 
2.83 ± 0.03 
 
1.43 ± 0.01 
 
1.17 ± 0.59 
 
1.73 ± 0.01 
 
2.76 ± 0.04 
 
1.22 ± 0.03 
 22:6 2.02 ± 0.01 
 
2.01 ± 0.04 
 
3.23 ± 0.01 
 
1.91 ± 0.01 
 
1.74 ± 0.06 
 
1.56 ± 0.03 
 
2.78 ± 0.02 
 
1.25 ± 0.01 
 
 
  
 
  
                             % SFA 61.55 ± 0.85   40.80 ± 0.26a   32.52 ± 0.57a   21.42 ± 0.44a   64.94 ± 2.77b   40.62 ± 0.24a   33.18 ± 0.50a   17.96 ± 0.22a,b  
% UFA 38.45 ± 0.44 
 
59.20 ± 0.45
a
 
 
67.48 ± 0.98
a
 
 
78.58 ± 0.15
a
 
 
35.06 ± 1.16
b
 
 
59.38 ± 0.20
a
 
 
66.82 ± 0.93
a
 
 
82.04 ± 0.36
a,b
 
  
Discussion 
Currently, it is a widely held assumption that increases in TG accumulation are responsible for 
oleate’s ability to rescue cells from PA-induced lipotoxicity (17, 38, 44, 46, 47). This assumption 
is supported by the finding that Dgat1
-/- 
primary mouse embryonic fibroblasts (MEFs) showed 
increased sensitivity to OA toxicity (17). We therefore sought to examine the effects of OA 
supplementation on PA-treated H4IIEC3 cells with partial DGAT knockdown to assess whether 
corresponding decreases in cell viability would be observed in liver hepatocytes. Surprisingly, 
while DGAT knockdown effectively prevented TG accumulation (Fig. 4-1), it did not modify the 
differential effects of fatty acid treatments on cell viability or apoptosis (Fig. 4-2). In contrast to 
prior reports, these data suggest that increased TG synthesis is not necessary for OA-mediated 
rescue of PA lipotoxicity.  
Table 4-1. Phospholipid fatty acid composition of NTC and siDGAT1/2 H4IIEC3 cells treated with PA and/or 
OA for 12 h (% of total abundance). H4IIEC3 cells were incubated with 400 μM PA and/or 400 μM OA for 12 h. 
Phospholipids were separated by thin layer chromatography and analyzed by gas chromatography-flame ionization 
detection (GC-FID). Data represent mean fatty acid % ± SE of n=4. a, p<0.05 vs cells treated with PA alone and 
same genetic manipulation (NTC or siDGAT1/2); b, p<0.05 NTC vs siDGAT1/2 cells with same treatment. SFA, 
saturated fatty acids; UFA, unsaturated fatty acids.  
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We have shown previously (9) that addition of PA rapidly induces ER stress, which is correlated 
with increases in apoptosis and cell death. Addition of OA to PA-treated cells prevented ER 
stress and correlated with a change in PA distribution within cellular lipid pools: specifically, PA 
incorporation into the phospholipid fraction was reduced. We therefore examined the impact that 
inhibition of TG synthesis would have on PA partitioning and overall phospholipid composition 
in hepatic cells. DGAT knockdown cells incorporated a higher percentage of exogenous PA into 
the phospholipid fraction and less into TGs, even in the presence of OA, than vector control cells 
(Fig. 4-4). However, this change in relative PA partitioning had no impact on ER stress markers 
(Fig. 4-3). This is likely explained by the lack of any meaningful differences in phospholipid 
saturation between DGAT knockdown and vector control cells (Table 4-1). Most interestingly, 
there were no differences in relative PA abundance or overall saturation of phospholipid species 
between DGAT knockdown and vector control cells co-treated with equimolar concentrations of 
OA and PA. Although DGAT knockdown changed the relative partitioning of exogenous PA 
into cellular lipid pools, OA partitioning apparently adjusted in a proportional manner to 
maintain constant phospholipid composition. This ability of OA to counteract PA’s effects on 
phospholipid saturation correlated with a reduction in markers of ER stress and lipoapoptosis, 
irrespective of DGAT expression levels.  
The ER membrane is estimated to contain up to 50% of total cellular phospholipids and is 
characterized by a “disordered” composition; low concentrations of “ordering” cholesterol 
moieties and high concentrations of unsaturated fatty acids that increase membrane fluidity (30). 
Small changes in ER membrane fluidity can result in impaired ER function and initiation of 
UPR. Exogenous saturated fatty acids have been shown to rapidly incorporate into phospholipids 
of the ER membrane and alter its structure though increased order and reduced fluidity (9, 38, 
39, 48). The precise nature of the link between reduced membrane fluidity and ER stress has not 
been fully elucidated, but recent literature suggests that changes in lipid composition 
substantially affect ER membrane proteins (40). For example, the sarcoendoplasmic reticulum 
calcium ATPase (SERCA) pump is an ER-resident, membrane-bound protein that functions to 
maintain proper cellular calcium concentrations by sequestering excess cytosolic calcium into 
the ER lumen. Increased saturation of the ER membrane effectively inhibits the activity of the 
SERCA pump both in vivo (32) and in vitro (40), resulting in ER calcium depletion and initiation 
of the UPR. This dysfunctional ER calcium buffering may play a role in downstream events 
characteristic of PA-mediated lipotoxicity including mitochondrial dysfunction and apoptotic 
cell death (10, 28). Additionally, Volmer et al. have recently demonstrated that increased lipid 
acyl-chain saturation of the ER membrane can directly activate ER transmembrane proteins 
IREα and PERK, whose stimulation initiates two of the three main arms of the UPR (48). This is 
consistent with our results in PA-treated hepatic cells showing upregulation of ER stress markers 
CHOP and ATF3, both of which are activated though the PERK pathway in the UPR.  
The composition of fatty acyl chains of membrane phospholipids is determined though both de 
novo and remodeling pathways (49-51). De novo phospholipid synthesis though the canonical 
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Kennedy pathway begins with a glycerol-3-phosphate that is sequentially acylated to form 
phosphatidic acid, which serves as a precursor for downstream lipid products including 
diacylglycerol, phospholipids and TGs. In general, phospholipids produced though de novo 
synthesis contain a saturated fatty acid at the sn-1 position, typically 16:0 (PA), and an 
unsaturated fatty acid at the sn-2 position (52). Glycerophospholipid remodeling, known as the 
Lands’ cycle, involves tandem removal and re-acylation of fatty acyl chains to generate 
phospholipid diversity and to maintain homeostatic membrane composition and fluidity (51, 53-
56). In the presence of PA overload, hepatic cells readily incorporate the exogenous PA into 
phospholipids leading to increased saturation (Table 4-1) and initiation of ER stress (Fig. 4-3). 
When OA is supplemented to PA-treated cells, remodeling enzymes are able to efficiently 
balance PA and OA incorporation to achieve a more normal phospholipid composition (Table 4-
1).  
Our study demonstrates that any increased capacity for PA disposal via esterification into TGs is 
not necessary for OA to exert its protective effects. However, the results of this study seem to 
contradict the previous results, such as the Listenberger et al. study which demonstrated 
increased cellular sensitivity to all free fatty acids, including MUFAs, in response to triglyceride 
synthesis knockdown in MEFs (17). Additional studies in yeast screens for fatty acid sensitive 
strains seem to support those results (57, 58). There are several possible explanations for these 
seemingly contradictory findings. All of these studies were done in different cell types other than 
hepatocytes and thus have difference metabolic profiles. Additionally, the lipotoxicity 
experiments in these studies utilized complete knockdown models. Complete ablation of 
triglyceride synthesis may lead to toxic accumulation of lipid intermediates or death by a 
mechanism that is different from palmitate lipotoxicity. Another complication to point out is that 
some of the knockdowns, such as ARV1 in the yeast mutants (58), that lead to depressed 
triglyceride synthesis and FFA sensitivity actually demonstrate high levels of basal ER stress 
without fatty acid stress (59), a fact that complicates interpretation of these results in comparison 
to our own. Further studies are needed to fully elucidate the mechanism by which OA 
incorporation into phospholipids in enhanced in our model that leads to rescue from palmitate-
induced lipotoxicity. 
Saturated fatty acids induce lipotoxicity in a variety of cell types and are postulated to be a 
contributing factor to pathological disorders including metabolic syndrome, insulin resistance 
and type 2 diabetes (60, 61). Both in vitro and in vivo models (16, 19, 37) have been used to 
study the mechanisms of lipotoxicity and demonstrate the apoptotic inducing effects of saturated 
fatty acids. PA mediated lipotoxicity is typically characterized by increases in mitochondrial 
dysfunction, ROS accumulation and caspase activation that culminates in apoptotic cell death. 
Increasing evidence points toward ER stress as an integral player in both acute lipotoxicity and 
more chronic metabolic disease and that PA may act directly at the ER membrane to mediate this 
response. Specifically, PA rapidly incorporates in ER membrane phospholipids, increasing the 
saturation ratios and impairing ER integrity (9, 38). Measures intended to reverse palmitate-
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mediated saturation, such as overexpressing the LPCAT3 enzyme to increase unsaturated fatty 
acid incorporation in the phospholipids (25), have shown beneficial results for reducing ER 
stress. Our study demonstrates that co-supplementation with OA in PA treated cells may act in a 
similar manner, integrating into the membrane phospholipids, reversing oversaturation and 
preventing PA mediated ER stress and lipotoxicity. Although OA-mediated rescue has been 
traditionally attributed to its capacity to increase PA storage in TGs, our data shows its effect on 
phospholipid composition is sufficient to attenuate lipotoxicity. These findings suggest that more 
research directed toward understanding phospholipid composition and metabolism may represent 
a promising direction for developing therapeutic interventions for chronic metabolic diseases.  
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CHAPTER 5  
PHARMACOLOGICAL STIMULATION OF BETA OXIDATION EXERTS PROTECTIVE 
EFFECTS AGAINST, BUT DOES NOT FULLY REVERSE, PALMITATE-INDUCED 
LIPTOXOCITY  
Introduction 
Free fatty acid induced toxicity is used in in vitro hepatic models to recapitulate the lipotoxicity 
characteristic of obesity, type 2 diabetes and other diseases associated with metabolic syndrome 
(1-4). Under normal conditions, free fatty acids provide substrate for critical functions in 
hepatocytes including esterification into triglycerides and phospholipids, oxidation in β-
oxidation and as part of signaling pathways and other biochemical pathways. However, during 
chonic exposure or high-concentration acute exposure, certain free fatty acids can induce 
hepatocyte dysfunction and death. Specifically, long-chain saturated fatty acids (SFAs) such as 
palmitate (16:0) and sterate (18:0) are known to induce a pro-apoptotic effect (5-7), while 
monounsaturated fatty acids (MUFAs) such as oleate (18:1) do not cause apoptosis and actually 
provide a protective mechanism to detoxify harmful concentrations of SFAs.  
The mechanism by which SFAs, but not MUFAs, induce lipoapoptosis is not fully understood. In 
vitro experiments in a variety of cell types, including Chinese hamster ovary (CHO) (8-10), 
pancreatic beta cells (11, 12) and hepatic cells (6, 13-17), among others, have demonstrated that 
acute exposure to high concentrations of SFAs is characterized by endoplasmic reticulum (ER) 
impairment, elevated ROS and eventual apoptosis. In contrast, mono- and poly-unsaturated fatty 
acids (MUFAs and PUFAs, respectively) induce significant triglyceride (TG) formation but do 
not initiate apoptosis (6, 9).  
Under stress, the ER induces a cascade known as the unfolded protein response (UPR) to 
mitigate the stress and restore ER homeostasis. SFA overexposure has been shown to rapidly 
induce this ER stress cascade, including depletion of Ca
2+
 stores from the ER lumen (10, 18) and 
increased expression levels of CCAAT/enhancer-binding protein homologous protein (CHOP), 
but evidence of UPR has not been found in cells treated with MUFAs alone (19).  
Although there is no definitive mechanism for how SFAs induce ER stress, increasing evidence 
points to disordered phospholipid metabolism as a key initiating factor. Unsaturated fatty acids 
are readily incorporated into inert TGs, but excess SFAs remain largely unesterified (6). Recent 
literature suggests that these free SFAs are rapidly assembled into saturated phospholipid species 
that are subsequently integrated into ER membrane bilayers (10). The degree of saturation in 
membrane phospholipids plays an important role in many membrane-associated functions and 
homeostasis. Atypical accumulations of saturated fatty acids or other species known to have a 
membrane ordering effect, such as cholesterol (20), can result in deleterious stiffening of 
organelle membranes and subsequent loss of function (21). Under normal physiological 
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conditions, the ER membrane is composed mainly of unsaturated phosphatidylcholine (PC) (10, 
22) as its major phospholipid component (23). ER membrane composition is tightly monitored 
such that even seemingly small changes in membrane fluidity can trigger ER stress response 
mechanisms (i.e., UPR) and dysregulated calcium sequestration (22, 24). Therefore, even limited 
incorporation of saturated phospholipid species into the membrane lipid bilayer could impair ER 
function and lead to the ER stress response and signaling that is observed in SFA lipotoxicity.  
Alternative pathways of lipid metabolism, such as β-oxidation and TG esterification, may play 
significant roles in mitigating this response. Long-chain fatty acids, such as palmitate (PA), enter 
the cell and are immediately transformed into their activated form, long-chain fatty acyl 
coenzyme-As, by fatty acyl-CoA synthetase. For use as substrates in cellular energy production, 
long chain fatty acyl-CoAs must be transported into the mitochondria by carnitine palmitoyl 
transferase 1 (CPT1) and then undergo subsequent β-oxidation.  It would seem that overexposure 
of hepatic cells to SFAs provides a large increase in substrate availability for β-oxidation and 
stimulation of this cycle may lead to increased downstream ROS production. However, literature 
reports on the role of β-oxidation in lipotoxicity have been inconclusive, with some studies 
indicating that it is a major source of ROS (25) while others indicate that ROS overproduction is 
due to mitochondrial dysfunction resulting from an upstream target of SFA-induced impairment 
(6).  Understanding whether β-oxidation plays a protective or inflammatory role in PA-induced 
lipotoxicity is important as it may open up a novel method for redirecting PA flux toward an 
oxidative use and away from other toxic pathways.  
In the present study, we sought to examine the effects of modulating the initial steps of lipid 
metabolism on PA-induced hepatic cell lipoapoptosis in H4IIEC3 rat hepatomas. β-oxidation 
was stimulated with the AMP-activated protein kinase (AMPK) activator AICAR and inhibited 
by treatment with the CPT-1 inhibitor etomoxir. The effects of these metabolic modulations on 
PA-induced cell death were characterized by examining key lipotoxic responses including ROS 
accumulation, 3/7 caspase activation and cell death. Because we expect that disordered 
phospholipid metabolism and altered membrane composition  plays a critical role in triggering 
ER stress and the lipoapoptosis cascade, we also measured markers of ER stress and 
phospholipid composition.  Total membrane phospholipid data were used as a proxy for ER 
phospholipid composition as it is known that the ER constitutes more than half of total 
membrane in hepatocytes (26, 27). In this study, we demonstrate in our H4IIEC3 hepatic model 
that PA is rapidly and preferentially incorporated into membrane phospholipids in the absence of 
alternative pathways of fatty acid metabolism and that this is associated with an increase in 
markers of ER stress and lipotoxicity. Furthermore, redirecting the fate of PA to an alternative 
route of lipid metabolism, specifically the β-oxidation pathway, can reduce SFA incorporation 
into phospholipids and partially reduce markers of ER stress and lipotoxicity, suggesting that 
modulating lipid metabolism can have a beneficial effect on hepatocytes during SFA 
overexposure.  
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Methods 
Materials and Reagents 
AICAR, etomoxir, palmitic acid, albumin from bovine serum (BSA) and Dulbecco’s modified 
Eagle’s medium (DMEM) were all purchased from Sigma-Aldrich (St. Louis, MO). CHOP 
primary and goat anti-mouse secondary antibodies were purchased from Abcam (Cambridge, 
MA). β-Actin primary and donkey anti-goat secondary antibodies were procured from Santa 
Cruz Biotechnology. All other chemicals were purchased from standard commercial sources.  
Cell Culture  
Rat hepatoma cells, H4IIEC3 (ATCC), were cultured in low glucose DMEM supplemented with 
10% fetal bovine serum and 1% penicillin/streptomycin/glutamine (2mM). Measurements were 
obtained at 70-80% confluency. 
ROS Measurement 
Intracellular ROS production was measured using 2’,7’-dichlorodihydrofluoresceindiacate 
(H2DCFDA, Invitrogen) as described previously (28). H2DCFDA is a non-polar compound that 
readily passes though the cell membrane where intracellular esterases remove the acetate groups 
resulting in a non-fluorescent dichlorodihydrofluorescein dye that is strongly retained by the cell. 
In the presence of ROS production, dichlorodihydrofluorescein is oxidized and becomes highly 
fluorescent. After indicated treatments were applied to cells cultured in 96-well plates, the 
medium was removed and cells were washed twice with Hanks’ balanced salt solution (HBSS). 
Cells were then incubated at 37°C for 1 h in the dark in a 10 M solution of H2DCFDA in 
HBSS. The fluorescence intensity was measured at an excitation/emission wavelength of 
485/530 nm using a Biotek FL600 microplate analyzer. 
Cell viability and toxicity 
Toxicity was assessed using the dead cell dye propidium iodide (PI) as described previously 
(29). PI is an intercalating dye that can only permeate dead cells and becomes highly fluorescent 
when it is embedded in the double-stranded DNA exposed after cell death. After indicated 
treatments were applied to cells cultured in 96-well plates, the medium was removed and 
replaced with a solution of PI and serum-free DMEM. Cells were incubated at 37°C for 4 h in 
the dark before fluorescence measurement with the microplate analyzer at an excitation/emission 
wavelength of 530/645.  
Caspase Activation  
The Apo-ONE Homogenous Caspase 3/7 Assay kit was used to measure markers of apoptotic 
activation.  H4IIEC3 hepatoma cells were cultured in 96-well plates and then incubated with 
indicated treatments for 6 hours.  The Apo-ONE kit uses a lysis buffer combined with a caspase 
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3/7 specific substrate (Z-DEVD-R110), which becomes fluorescent once these caspases remove 
its DEVD peptide.  Fluorescence was then measured at ex/em of 485/535.  
Western Blotting 
H4IIEC3 cells were lysed with ice-cold RIPA lysis buffer (sc-24948, Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA) supplemented with DTT (15 μl/ml) for 30 min on ice. Samples were 
centrifuged at 13,200 rpm/4°C for 20 min and the resulting supernatants constituted the total 
protein extracts. Protein concentrations were determined by BCA assay (Thermo Fisher 
Scientific, Rockford, IL). Samples were added in concentrations of 30 μg/lane for SDS-PAGE 
Western blotting. Dilutions of the primary antibodies were anti-CHOP (1:1000) and anti-β-actin 
(1:1000). 
Lipid Profiles 
Cells seeded in 100-mm Petri dishes at 4  106 cells per dish were incubated in standard medium 
until reaching ~70-80% confluency. Upon reaching this point, they were incubated for the 
specified duration of time at 37°C in standard medium with or without BSA-bound palmitate 
and/or oleate (400 μM or 100 μM, respectively) in the presence of indicated chemical 
modulators. Cells were trypsinized for 3 min then quenched and scraped using cold PBS. Cell 
solutions were pelleted by centrifugation and resuspended in fresh PBS. Lipid analysis was then 
provided by the Vanderbilt DRTC Lipid Lab (DK20593) using TLC and GC-FID techniques. 
Briefly, lipids were extracted from the aforementioned cell pellets using a modified Folch 
separation. An internal standard (1,2-dipentadecanoyl-sn-glycero-3-phosphocholine) for 
phospholipids was added to the lipid-containing chloroform phase. Total lipids were then 
extracted and separated by thin layer chromatography using petroleum ether/ethyl ether/acetic 
acid (80/20/1, v/v/v) on silica TLC plates. Spots corresponding to PLs, TGs and FFAs were 
visualized with rhodamine 6G in 95% ethanol and scraped individually into glass tubes for 
methylation. Methylation was completed using a boron trifluoride-methanol 10% (w/w) solution. 
Transmethylated lipids were then analyzed using GC-FID, where standardized calibration curves 
were used to assess the lipid content. 
 β-Oxidation Measurements 
Cell cultures fed tritiated fatty acid produce 
3
H2O at a rate proportional to that of mitochondrial 
beta oxidation (30). Albumin-bound [9,10-
3
H(N)] palmitic acid  (4 µCi 
3
H/µmol palmitate) was 
added to cells grown to confluency in 6-well dishes at 400 μM. The final volume of media 
solution, including inhibitors/activators and palmitate, was adjusted to exactly 2 mL per well. 
After 6 hours of incubation, 1.5 mL of media was removed directly from each well and collected 
in individual round-bottom snap-top tubes. Then 75 μL of 60% perchloric acid was added to 
each sample for deproteinization to remove albumin-bound un-oxidized PA from the sample 
media. The deproteinization reaction continued overnight at 4°C. 
84 
 
Following deproteinization, samples were centrifuged for 30 min. Then 1.2 mL of sample was 
collected into a new centrifuge tube and 5 μL of pH indicator dye and 36 μL of 5M K2CO3  were 
added for neutralization. This reaction was allowed to continue overnight at 4°C. After 
neutralization, samples were centrifuged for 30 min. To remove remaining PA, 0.8 ml of 
neutralized sample was applied to an individual AG 1-X8 Resin (BioRad, Hercules, CA) column 
and the column was allowed to empty under gravity flow. Each column was flushed twice with 
0.6 mL of distilled water. The initial charge (0.8 ml) and all subsequent washes (1.2 ml) were 
collected in a scintillation vial (PerkinElmer, Waltham, MA). 10 mL of EcoLite scintillation 
cocktail fluid (MP Biomedical, Santa Ana, CA) was added to each sample vial, shaken 
vigorously and read in a scintillation counter. 
Statistical Analysis  
Data from fluorescence plate readers were converted to mean ± S. E. Student’s t-test was used to 
determine statistical differences between two samples (p < 0.05). Statistical differences between 
multiple treatments were assessed using Type I ANOVA with Tukey-Kramer post hoc testing.  
 
Results 
ROS accumulation and apoptotic cell death characterize H4IIEC3 liver cell exposure to PA 
treatment 
We examined the lipotoxic effects of varying PA concentrations on H4IIEC3 hepatomas using 
the fluorescent stain propidium iodide to quantify cell death at 24 hours. Cell death increased in a 
concentration-dependent manner (Fig. 5-1A), and a concentration of 400 μM PA was found to 
significantly increase cell death while remaining within a physiologically acceptable range (31). 
PA-induced cell death was primarily due to apoptosis as indicated by increased caspase 3/7 
activity as early as 6 h (Fig. 5-1B), which also varied with PA in a concentration-dependent 
manner (Fig. 5-1C). ROS accumulation peaked at 6 hours, after which time it began to decrease 
presumably due to increases in cell death (Fig. 5-1D).  
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Figure 5-1. PA-induced cell death, caspase activation and ROS accumulation in H4IIEC3 cells.  A, 
H4IIEC3 cells were treated with increasing concentrations of PA for 24 h. Cell toxicity was assessed 
using the fluorescent dye propidium iodide (PI). B, Caspase 3/7 was activated in a time-dependent 
manner starting at 6 h as measured by the Apo-ONE kit.  C, At 6 h, caspase 3/7 demonstrated a PA 
concentration-dependent activation as measured by the Apo-ONE kit. D, ROS accumulation also 
displayed time dependency, peaking at 6 h and falling off quickly thereafter. ROS was measured using the 
fluorescent probe H2DCFDA. All data represent mean ± SE of n=4. *, P<0.05; **, P<0.01 vs. cells treated 
with BSA alone. 
 
Enhanced fatty acid oxidation prevents PA-induced cell death and ROS accumulation in liver 
cells.  
The impact of β-oxidation in hepatic oxidative stress and lipotoxicity remains disputed (6, 25), 
and the molecular mechanism defining its role has yet to be fully elucidated. However, data from 
studies in β-cells indicate that increased fatty acid oxidation (FAO) may serve a protective role in 
PA-induced lipotoxicity. Pharmacological inhibition of FAO with etomoxir (32) or siRNA-
mediated knockdown of CPT-1 (12) augmented PA-induced cell death, while genetic CPT-1 
overexpression reduced the lipotoxic effects of PA (33). Therefore, we sought to investigate the 
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effects of modulating FAO on PA-induced cell death. Etomoxir (Eto) is a specific inhibitor of 
CPT-1 and, consequently, of mitochondrial fatty acid β-oxidation (34). The AMP kinase 
activator 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) has been used 
previously as a stimulant of FAO (10, 35).  The pharmacologic modulation of FAO with Eto and 
AICAR was directly determined by measuring H
3
-labeled water produced from H
3
-labeled PA. 
FAO stimulation with 500 μM AICAR doubled the oxidation rate of PA while 250 μM Eto 
significantly decreased the rate of FAO (Fig. 5-2A). Eto treatment was also able to effectively 
block the FAO stimulation provided by AICAR,  reducing the oxidative rate of the combined 
AICAR+Eto+PA treatment down to the level Eto+PA alone (Fig. 5-2A).  These data 
demonstrated that AICAR and Eto were able to positively and negatively modulate the rate of 
PA oxidation, respectively.  
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Figure 5-2. Enhancing mitochondrial β-oxidation reduces lipotoxicity while inhibiting β-oxidation 
has no positive effects on the PA-induced phenotype. A, H4IIEC3 were treated with 400 μM 3H-PA 
with or without 500 μM AICAR and/or 250 μM etomoxir (Eto) for 6 h. PA oxidation rate was determined 
by the measurement of 
3
H2O produced. Data represent mean ± SE from thee independent experiments. *, 
P<0.05, **, P<0.01 vs cells treated with PA; B, PA-induced ROS accumulation at 6 h with AICAR and/or 
Eto co-treatment as measured by H2DCFDA. C, After 24 h, the effect of modulating β-oxidation on cell 
toxicity with AICAR and/or Eto was assessed by PI. D, Caspase 3/7 activation after 6 h of treatment was 
measured with the Apo-ONE kit. B-D data represent mean ± SE of n=4. *, P<0.05 vs BSA; **, P<0.01 vs 
BSA. 
 
We then examined the question of whether modulating FAO could affect PA-induced lipotoxic 
responses including ROS accumulation, caspase activation and cell death.  Treatment with 
AICAR significantly reduced all three of these markers of lipoapoptosis; ROS accumulation and 
caspase 3/7 returned to vehicle-treated levels (Fig. 5-2B and D, respectively) and, 
correspondingly, there was a significant reduction in cell death at 24 hs (Fig. 5-2C). On the other 
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hand, Eto co-treatment had no effect on ROS accumulation (Fig. 5-3B), caspase activation (Fig. 
5-2D) or cell death (Fig. 5-2C). These data suggest that FAO inhibition may play a role in PA-
induced lipotoxicity and stimulation of this pathway could provide a protective effect in this 
setting. Surprisingly, however, Eto only partially reversed AICAR-induced protective effects on 
PA-mediated caspase activation (Fig. 5-2D) and cell death (Fig. 5-2C), in constrast to its ability 
to completely inhibit PA oxidation rate as described in Fig. 5-2A. This indicates that although 
AICAR significantly increases FAO in the presence of PA, its protective effects on PA-induced 
lipoapoptosis may be partially mediated by other off-target effects.   
PA treatment results in increased phospholipid saturation and ER stress 
ER stress has been implicated as a critical moderator in the PA-induced lipoapoptotic cascade 
(10, 18, 19). Increased saturation of the ER membrane has also been postulated as a possible 
cause of PA-mediated ER stress (10, 36).  Therefore, we sought to investigate the effect of PA 
treatment on the cellular phospholipid composition and changes in levels of CHOP, a 
proapoptotic protein up-regulated during the ER stress response. Previous work has shown that 
the intensity of CHOP expression increased in a concentration dependent manner (16), similar to 
the increases in cell death associated with changes in PA concentration described in Fig. 5-1. 
Based on a time course of increases in CHOP protein level (16), 8 h was determined as an 
optimal point for assessing the differences in ER stress due to PA-induced lipotoxicity. At this 
time point, H4IIEC3 cells treated with PA demonstrated significantly increased levels of CHOP 
indicating that cells were experiencing significant up-regulation of UPR in response to PA 
treatment alone and confirming that ER stress is involved in the PA-induced lipotoxic cascade.   
We then sought to assess the consequences of PA treatment on phospholipid composition, as this 
has been hypothesized to be an important contributing factor to PA-induced ER stress (37) and 
subsequent lipotoxicity (10, 36).  The relative percentage of saturated acyl chain substituents on 
phospholipids was found to increase significantly within 1 h of exogenous PA treatment. The 
increase in total percent PA (16:0) chains on cellular phospholipids was especially striking; there 
was over 50% increase in PA incorporation into phospholipids in the PA- versus control-treated 
cells within the first hour (Fig. 5-3A). This trend was further exaggerated after a 24-h incubation 
with PA. Cells supplemented with 400 μM PA contained ~75% more saturated fatty acid 
motieties than BSA control-treated cells; the proportion of PA contained in phospholipids was 
more than 3-fold higher in PA- versus control- treated cells (Fig. 5-3B). These data indicate that 
exogenous PA was rapidly incorporated into cellular phospholipids resulting in increased 
saturation of these species in H4IIEC3 cells treated with 400μM PA.  
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Figure 5-3. PA treatment rapidly alters phospholipid composition after 1 h and continues to 
increase after 24h. H4IIEC3 were treated with 400 μM PA or BSA for 1 h (A) and 24h (B) and 
phospholipid composition was subsequently determined using thin layer chromatography, FAME 
esterification and GC-FID. Data represent mean ± SE from n=4. *, P<0.05; **, P<0.01 vs cells treated 
with BSA.   
 
Increased fatty acid oxidation significantly reduces PA-induced ER stress and incorporation of 
SFAs into phospholipids 
We sought to determine if modulating catabolism of fatty acids though β-oxidation would result 
in changes in phospholipid composition. As described above, AICAR and etomoxir were used to 
stimulate and suppress, respectively, rates of mitochondrial β-oxidation. Phospholipid 
composition was subsequently determined at 1 and 24h, and CHOP expression levels were 
analyzed at 8h post-treatment. As shown in Table 5-1, PA was rapidly incorporated into 
phospholipids resulting in an over 1.5-fold increase in PA-containing species compared to 
vehicle-treated controls after just 1 h of PA treatment. The overall saturation of phospholipids 
was also increased after only 1 h of incubation time. In this time frame, AICAR significantly 
reduced PA-induced increases in both %PA composition (~20%) and total saturation of 
phospholipids (~35%) with respect to control BSA levels (Table 5-1). Etomoxir treatment alone 
had no effect on fatty acid composition of phospholipids but partially reversed the effectiveness 
of AICAR administration. A similar trend held after 24h of incubation: PA treatment resulted in 
large increases in both PA incorporation and overall phospholipid saturation while 
supplementing cells with AICAR significantly reduced both markers of lipotoxicity. Etomoxir 
alone had no statistically significant effect on either of these factors (Table 5-2), but co-
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administration of AICAR and etomoxir with PA treatment partially reversed the rescue effects 
imparted by AICAR. Similarly, ER stress at 8h was significantly reduced by AICAR treatment, 
as assessed by western blotting of CHOP expression levels (Fig. 5-4). As with phospholipid 
composition, etomoxir alone had no significant effect on CHOP expression levels, but co-
treatment of AICAR+Eto served to partially reverse the rescuing effect of AICAR on PA-
induced ER stress.  
 
  Fatty Acid  PA   PA+AICAR   
PA+AICAR+ 
Eto 
  PA+Eto   BSA   
 
14:0 0.71 ± 0.06 
 
0.74 ± 0.05 
 
0.74 ± 0.05 
 
0.61 ± 0.03 
 
0.81 ± 0.02a 
 
 
16:0 19.52 ± 0.42 
 
17.94 ± 0.32a 
 
19.08 ± 0.28b 
 
19.23 ± 0.15 
 
12.25 ± 0.12a 
 
 
16:1 6.09 ± 0.15 
 
8.00 ± 0.32a 
 
7.36 ± 0.27a 
 
6.63 ± 0.25 
 
6.02 ± 0.13 
 
 
18:0 17.63 ± 0.16 
 
16.65 ± 0.28a 
 
16.74 ± 0.26a 
 
17.26 ± 0.19 
 
17.94 ± 0.09 
 
 
18:1w9 29.75 ± 0.17 
 
30.85 ± 0.44 
 
31.10 ± 0.27a 
 
31.07 ± 0.48 
 
33.01 ± 0.16a 
 
 
18:1w7 7.30 ± 0.08 
 
7.20 ± 0.05 
 
7.26 ± 0.09 
 
7.34 ± 0.10 
 
8.10 ± 0.01a 
 
 
18:2 2.87 ± 0.09 
 
2.71 ± 0.10 
 
2.55 ± 0.02 
 
2.59 ± 0.17 
 
3.39 ± 0.06a 
 
 
20:3w6 0.98 ± 0.02 
 
1.07 ± 0.01a 
 
1.01 ± 0.01b 
 
0.95 ± 0.01 
 
1.09 ± 0.01a 
 
 
20:4 9.92 ± 0.19 
 
9.97 ± 0.25 
 
9.63 ± 0.06 
 
9.46 ± 0.15 
 
11.21 ± 0.21a 
 
 
20:5 0.00 ± 0.00 
 
0.00 ± 0.00 
 
0.00 ± 0.00 
 
0.23 ± 0.13 
 
0.14 ± 0.14a 
 
 
22:5w3 2.20 ± 0.03 
 
2.02 ± 0.13 
 
1.84 ± 0.03a 
 
1.89 ± 0.10a 2.57 ± 0.06 
 
 
22:6 3.01 ± 0.04 
 
2.84 ± 0.12 
 
2.68 ± 0.06a 
 
2.74 ± 0.10 
 
3.47 ± 0.07a 
                                             
 
% SFA 37.87 ± 0.64 
 
35.33 ± 0.65a 
 
36.56 ± 0.03a,b 
 
37.10 ± 0.36 
 
31.01 ± 0.23a 
 
 
% UFA 62.13 ± 0.78 
 
64.67 ± 1.42a 
 
63.44 ± 0.03a,b 
 
62.90 ± 1.35 
 
68.99 ± 0.71a 
  
Table 5-1. Phospholipid composition of cells treated with PA with or without AICAR and/or 
etomoxir after 1 h. H4IIEC3 cells were incubated with 400 μM PA with or without 500 μM AICAR 
and/or 250 μM etomoxir (Eto) for 1 h. Phospholipids were separated by thin layer chromatography and 
analyzed by gas chromatography-flame ionization detection (GC-FID). Data represent mean ± SE of n=4. 
a
, p<0.05 vs cells treated with PA alone; 
b
, p<0.05 vs cells treated with PA+AICAR. 
  
91 
 
  Fatty Acid PA   PA+AICAR   
PA+AICAR+ 
Eto 
  PA+Eto   BSA   
 
14:0 0.63 ± 0.04 
 
0.42 ± 0.02a 
 
0.16 ± 0.16 
 
0.21 ± 0.21 
 
0.34 ± 0.03a 
 
 
16:0 46.10 ± 1.76 
 
38.78 ± 0.37a 
 
40.07 ± 0.72a 
 
41.13 ± 0.29 
 
9.01 ± 0.24a 
 
 
16:1 12.40 ± 1.33 
 
17.09 ± 0.42a 
 
9.69 ± 0.80b 
 
7.30 ± 0.60a 
 
5.76 ± 0.19a 
 
 
18:0 14.81 ± 0.19 
 
11.87 ± 0.28a 
 
16.08 ± 0.44b 
 
18.53 ± 0.38a 
 
20.94 ± 0.14a 
 
 
18:1w9 11.17 ± 0.23 
 
13.64 ± 0.16a 
 
13.78 ± 0.39a 
 
12.84 ± 0.26a 
 
36.68 ± 0.09a 
 
 
18:1w7 3.17 ± 0.06 
 
3.06 ± 0.04 
 
3.68 ± 0.05a,b 
 
3.79 ± 0.08a 
 
8.46 ± 0.07a 
 
 
18:2 1.86 ± 0.05 
 
2.31 ± 0.03a 
 
2.08 ± 0.02a,b 
 
1.94 ± 0.03 
 
2.79 ± 0.03a 
 
 
20:3w6 0.77 ± 0.02 
 
0.90 ± 0.01a 
 
0.29 ± 0.29 
 
0.33 ± 0.33 
 
1.05 ± 0.02a 
 
 
20:4 6.34 ± 0.06 
 
7.75 ± 0.08a 
 
9.84 ± 0.67a 
 
9.39 ± 0.47a 
 
9.34 ± 0.19a 
 
 
20:5 0.00 ± 0.00 
 
0.00 ± 0.00a 
 
0.00 ± 0.00 
 
0.00 ± 0.00 
 
0.49 ± 0.01a 
 
 
22:4w6 0.00 ± 0.00 
 
0.57 ± 0.01a 
 
0.00 ± 0.00b 
 
0.00 ± 0.00 
 
0.68 ± 0.02a 
 
 
22:5w3 1.02 ± 0.05 
 
1.50 ± 0.02a 
 
1.63 ± 0.11a 
 
1.78 ± 0.10a 
 
1.69 ± 0.05a 
 
 
22:6 1.72 ± 0.05 
 
2.30 ± 0.05a 
 
2.68 ± 0.16a 
 
2.76 ± 0.14a 
 
2.76 ± 0.09a 
                                             
 
% SFA 61.55 ± 1.64 
 
51.07 ± 0.32a 
 
56.32 ± 0.16a,b 
 
59.87 ± 0.18 
 
30.29 ± 0.16a 
 
 
% UFA 38.45 ± 1.64 
 
48.93 ± 0.32a 
 
43.68 ± 0.16a,b 
 
40.13 ± 0.18 
 
69.71 ± 0.16a 
  
Table 5-2. Phospholipid composition of cells treated with PA with or without AICAR and/or 
etomoxir for 24 h. H4IIEC3 cells were incubated with 400 μM PA with or without 500 μM AICAR 
and/or 250 μM etomoxir (Eto) for 24 h. Phospholipids were separated by thin layer chromatography and 
analyzed by gas chromatography-flame ionization detection (GC-FID). Data represent mean ± SE of n=4. 
a
, p<0.05 vs cells treated with PA alone; 
b
, p<0.05 vs cells treated with PA+AICAR. 
 
92 
 
 
Figure 5-4. Stimulation of β-oxidation in PA-treated H4IIEC3 cells reduces CHOP expression, a 
marker of ER stress. PA-induced increases in CHOP abundance were reversed by increasing β-
oxidation with AICAR but inhibiting PA oxidation with Eto had no positive effect on CHOP expression. 
H4IIEC3 hepatocytes were treated with 400 μM PA alone or in the presence of 500 μM AICAR and/or 
250 μM Eto for 8 h in three independent experiments. Levels of CHOP abundance were assessed using 
Western blotting techniques. Thapsigargin (Thaps) was used as a positive control. 
 
Discussion 
This study was designed to examine the effect that modulating β-oxidation has on PA-induced 
hepatic lipoapoptosis. Stimulation of the fatty acid β-oxidation pathway by the AMPK agonist 
AICAR served to significantly reduce PA-induced H4IIEC3 ROS accumulation and apoptotic 
cell death. Inhibition of β-oxidation by the CPT-1 specific inhibitor etomoxir had no effect on 
PA-promoted ROS accumulation and cell apoptosis. These data suggest that PA-induced 
lipotoxicity can be regulated by modulating rates of FFA disposal though alternative routes of 
lipid metabolism such as β-oxidation. 
We investigated how modifications in lipid metabolism affect PA-induced UPR activation 
because ER stress has been shown to be a key mediator in the lipoapoptosis cascade (10, 18, 19). 
Borradaile et al. postulated a connection between ER stress and degree of fatty acid saturation in 
the membrane of CHO cells, implicating this connection as a potentially critical mediator of 
SFA-induced lipotoxicity (10). In their experimental model, PA was rapidly incorporated into 
saturated phospholipids and TGs resulting in drastic dilatation and disruption of the ER structure 
and loss of functional integrity. Markers of ER impairment have been shown as early as 30 
minutes post-PA treatment (10) while our data indicates that significant increases in ROS 
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accumulation does not occur until at least 6 h after PA supplementation. Additionally, previous 
TEM images from our lab (16) show changes in ER structure at 4 h in response to PA while 
there are no significant changes in mitochondrial structure. These data suggest that SFA 
incorporation into the ER membrane is a key event initiating ER impairment and stress 
connected to the subsequent lipotoxic cascade and was not just a by-product of downstream 
events such as oxidative stress (e.g., ROS production). Other studies have also indicated that ER 
stress in hepatic models of lipotoxicity precedes apoptosis, indicating that disruption of ER 
function plays an early and key role in SFA overload (38), and this ER response is mediated by 
changes in membrane phospholipid saturation (10, 36). Therefore, understanding the partitioning 
of PA into specific lipid classes may better elucidate the mechanism by which SFAs induce ER 
stress and subsequent lipoapoptosis. Therefore, we examined the effect of lipid metabolism on 
both ER stress and fatty acid composition of cellular phospholipids. PA treatment alone 
progressively augmented expression levels of the ER stress marker CHOP and total phospholipid 
saturation as incubation time increased (Fig 5-4 and Tables 5-1 and 5-2).  
Our study indicates that stimulation of mitochondrial β-oxidation can significantly prevent 
increases in phospholipid saturation and reduce CHOP expression levels in response to PA 
treatment. Consistent with previous studies, AICAR-mediated stimulation of β-oxidation 
prevented PA-induced lipoapoptosis (10, 32, 35, 39) and ER stress (10) (Fig. 5-2). We expanded 
upon these observations by demonstrating that increasing the partitioning of PA towards β-
oxidation resulted in a significant reduction in PA content in membrane phospholipids (Tables 5-
1 and 5-2). In contrast, inhibition of β-oxidation with etomoxir had no effect on PA-mediated 
increases in CHOP expression or overall membrane phospholipid saturation.  Curiously, 
although etomoxir completely repressed AICAR-mediated stimulation of β-oxidation, etomoxir 
did not fully block AICAR’s ability to suppress phospholipid alterations or CHOP expression. 
This may be the result of AMPK’s effects on other pathways besides beta-oxidation and/or non-
AMPK-dependent effects of AICAR. Previous research has demonstrated that either AICAR-
stimulated or constitutively activated AMPK can alleviate lipid-induced ER stress and 
lipoapoptosis though AMPK-induced expression of the ER-associated chaperone, 150-kDA 
oxygen regulated protein (ORP150) (40). Other groups have also found that AICAR mediates 
inhibition of phospholipid synthesis which is independent of AMPK activation (41, 42). 
Therefore, these off-target effects may be partially responsible for AICAR’s ability to rescue 
palmitate lipotoxicity.  
In summary, this study indicates that alterations in lipid metabolism can modulate PA-induced 
markers of lipotoxicity as well as ER stress response and phospholipid composition/saturation. 
We also found that these changes appear to be positively correlated. For example, reduced PA 
incorporation into phospholipids was accompanied by diminished CHOP expression and reversal 
of PA-induced ROS accumulation, caspase activation and cell death. While it is not possible 
from these data to eliminate a concomitant effect of PA directly on the mitochondria, another key 
organelle implicated in lipotoxicity, our data indicate that the impact of initial SFA metabolism 
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on the ER is a critical mediator in this phenotype. Our results, combined with consistent data 
from other studies, suggest that perturbations in lipid metabolism resulting from SFA 
overexposure initiate a potent cellular death signal that originates at the ER and involves 
functional impairments of this important organelle. This study demonstrates that modulating 
specific pathways of lipid metabolism can have beneficial effects on the response of hepatic cells 
to SFA overexposure and may point towards therapeutic strategies for improving hepatocyte 
function under these conditions. In particular, interventions designed to increase oxidative 
metabolism of free fatty acids through β-oxidation in clinical applications may represent an 
important treatment option for patients.  
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CHAPTER 6  
INHIBITION OF PHOSPHOLIPID SYNTHESIS AND REMODELING SHOWS LIMITED 
PROTECTION AGAINST PALMITATE LIPOTOXICITY IN HEPATIC CELLS 
Introduction 
Phospholipids are arguably the most important component of biological membranes as they are 
integral for both extracellular and intracellular compartmentalization in living cells (1). They 
facilitate a wide array of essential physiological processes including signal transduction, 
vesicular trafficking, molecular transport, and biosynthesis. Phospholipids can themselves be 
used as substrates in reactions for generation of active signaling molecules including 
diacylglycerol and lysophosphatidic acid (2).  
Phospholipids display a vast diversity in both structure and fatty acyl composition. The head 
group moiety determines species shape while both chain length and degree of saturation of the 
fatty acid chains determine the biophysical properties of the membrane (3, 4). The relative 
degree of fluidity in the membrane associated with the ratio of unsaturated and saturated fatty 
acids is crucial for many membrane associated proteins including ion channels such as the sacro-
endoplasmic reticulum calcium ATPase (SERCA) (5, 6). Alterations in the degree of membrane 
saturation and structure can have detrimental effects on membrane functionality, and in 
particular, are thought to contribute to ER dysfunction and induction of a stress response (5, 7-
10). Deguil et al. demonstrated that the capacity of particular fatty acids to induce or relieve ER 
stress in yeast is dependent on their ability to directly incorporate into phospholipid species and 
to destroy or restore, respectively, optimal membrane organization (11). This ER stress response 
has been implicated in a wide variety of diseased states including obesity, diabetes, fatty liver 
and heart disease, among others (6, 12-15). 
Phospholipids, along with other biologically relevant lipids, are synthesized de novo though the 
Kennedy pathway (16) (Fig. 6-1). Newly synthesized phospholipids undergo significant 
remodeling via fatty acyl deacylation (via phospholipases) and reacylation (via lysophospholipid 
acyltransferases, LPLATs) though a pathway known as Lands’ cycle (17) (Fig. 6-1). 
Phosphatidylcholine (PC) is the most abundant phospholipid in cellular membranes, accounting 
for approximately 50% of total cellular phospholipid mass (1, 18, 19),  and is known to play a 
significant role in ER structure and function (19). The CDP-choline pathway produces the 
choline headgroup that is esterified with diacylglycerol (DAG) from the Kennedy pathway to 
form PC. The rate limiting step in PC production is generally accepted to be the transfer of 
cytidine monophosphate (CMP) from cytidine triphosphate (CTP) to phosphocholine to form 
CDP-choline, which is catalyzed by the enzyme CTP:phosphocholine cytidylyltransferase  
(CCT) and encoded by the gene  Pcyt1 (Fig. 6-1). CCT is activated though phosphorylation and 
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binding events and is translocated to the ER membrane in response to changes in lipid 
composition to regulate PC synthesis flux (19). 
 
 
 
Figure 6-1. Kennedy pathway lipid synthesis and Lands’ cycle phosphatidylcholine recycling. 
Abbreviations are as follows: GPAT, glycerol-3-acyltransferase; AGPAT, acylglycerophosphate 
acyltransferase; PAP, phosphatidic acid phosphatase; DGAT, diacylglycerol acyltransferase; CK, choline 
kinase; CCT, CTP:phosphocholine cytidylyltransferase; CPT, choline phosphotransferase; PLA2, 
phospholipase A2; LPCAT, lysophosphatidylcholine acyltransferase; FA-CoA, fatty acyl CoA. 
 
The deacylation enzyme thought to play a major role in membrane phospholipid remodeling is 
calcium-independent phospholipase A2 (iPLA2), which cleaves at the sn-2 position of 
phospholipids releasing a lysophospholipid and a fatty acid as products (19-21). Remodeling 
though the Lands’ cycle is responsible for the creation of significant diversity in fatty acyl chain 
composition as acylation enzymes in the de novo synthesis pathway have little substrate 
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specificity with regard to saturation or chain length (22). LPLATs demonstrate considerably 
higher substrate specificity  in regards to fatty acyl donors and lysophospholipid acceptors (23). 
For example, lysophosphotidylcholine acyltransferase 1 (LPCAT1) almost exclusively 
incorporates saturated fatty acids, such as palmitate (16:0), into PC (24, 25)  while LPCAT3 has 
broader specificity for incorporating polyunsaturated fatty acids (PUFAs) and some 
monounsaturated fatty acids in membrane PC (7, 23, 26).  
Several groups (7-9, 11, 22, 27) have been in interested in the impact of incorporation of specific 
fatty acids and overall remodeling of PLs in relation to lipotoxicity. Most of the investigations 
have focused on the changes that result due to fatty acid supplementation (8, 9, 27) (us, borr, 
yeast ER) or changes in LPCAT3 expression (LXR and PL unsaturation). Others have looked at 
the effect inhibiting iPLA2 has lysophospholipid levels (28, 29). Focusing on preventing PA 
incorporation into PLs by inhibiting specific pathways in PL metabolism specifically has not 
been fully explored and represents an important gap in knowledge that must be more fully 
understood in order to accurately describe the connection between PA-induced apoptosis and 
phospholipid saturation, ER stress and the lipotoxic cascade.  
Increased ER stress and lipotoxicity have shown strong association with elevated phospholipid 
saturation in models of palmitate (PA) mediated lipotoxicity (7-9, 22, 30). In this study, we 
investigate methods for modulating phospholipid synthesis and remodeling in order to inhibit PA 
incorporation into phospholipid species that results in oversaturation of membrane bilayers. Our 
aim was to prevent PA-induced lipotoxity by targeting both phospholipid synthesis and 
remodeling pathways in attempt to reduce ER stress and subsequent lipoapotosis. Our results 
show that impeding deacylation of existing phospholipids (remodeling) using a pharmacological 
inhibitor of iPLA2, palmityl trifluoromethyl ketone (PACOCF3), did impart some positive 
benefits for PA-treated hepatic cells. We demonstrate small reductions in membrane saturation 
and ER stress that led to depressed markers of lipoapoptosis. Similarly, genetic knockdown of 
Pcyt1a, the regulatory step in PC synthesis, also resulted in decreases in membrane saturation 
and other downstream markers of lipotoxicity, though the effect was small. Overall, 
manipulations designed to more effectively reduce saturated fatty acid incorporation into 
membrane phospholipids presents an interesting target for preventing lipotoxicity and its 
physiological consequences.  
 
Methods 
Materials and Reagents 
Oleic and palmitic acids, bovine serum albumin (BSA), Dulbecco’s modified Eagle’s medium 
(DMEM), and palmityl trifluoromethyl ketone (PACOCF3) were all purchased from Sigma-
Aldrich (St. Louis, MO). CHOP primary (mouse) and goat anti-mouse secondary antibodies 
were purchased from Abcam (Cambridge, MA). β-Actin primary (goat) and donkey anti-goat 
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secondary antibodies were procured from Santa Cruz Biotechnology. siRNA was purchased in 
the TriFECTA kit from Integrated DNA Technologies (Coralville, IA). All other chemicals were 
purchased from standard commercial sources.  
Preparation of fatty acid solutions  
Fatty acid solutions were prepared by coupling free fatty acids to bovine serum albumin (BSA). 
Specifically, palmitate or oleate was fully dissolved in 200-proof ethanol for a concentration of 
195 mM. This FFA stock solution was added to a pre-warmed BSA solution (10% w/w, 37°C) 
for a final FFA concentration of 3 mM, ensuring that the concentration of ethanol in the FFA 
solution did not exceed 0.5% by volume. The solution was fully dissolved by warming at 37°C 
for an additional 10 minutes. The final ratio of FFA:BSA was 2:1. Vehicle control treatments 
were prepared using stocks of 10% w/w BSA with an equivalent volume of ethanol added to 
match that contained in the final FFA stock. The final concentration of ethanol was less than 
0.2% in all experiments.  
Cell Culture and siRNA transfections 
Rat hepatoma cells, H4IIEC3 (ATCC), were cultured in low-glucose Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin/glutamine (2mM). Measurements were obtained at 70-80% confluency. 
Hepatic cells were transfected with siRNA using Lipofectamine RNAiMAX (Invitrogen) 
according to the manufacturer’s protocol with a final volume of 10 μL of Lipofectamine 
RNAiMAX per 2 mL media solution. The final concentration of siRNA was 25 nM.  
Total RNA Isolation and Quantitative Real-Time PCR 
Total RNA was isolated from cells using RNeasy Mini Kit (Qiagen, Germantown, MD) 
according to manufacturer’s protocol and then reverse transcribed using cDNA reverse 
transcriptase kit (BioRad, Hercules, CA). Quantitative real-time PCR was performed using iQ 
SYBR Green Supermix (BioRad, Hercules, CA) and BioRad CFX96 Real-Time PCR Detection 
System (BioRad, Hercules, CA). The sequence of the primers were as follows: C/EBP 
homologous protein (CHOP) forward (5’-CTCAGCTGCCATGACTGTA-3’) and reverse (5’-
CGTCGATCATACCATGTTGAAGA-3’), ATF3 forward (5’-
CGCCTCCTTTTTCTCTCATCT-3’) and reverse (5’-CCATCCAGAACAAGCACCT-3’), 
ribosomal 18s forward (5’-CGGACAGGATTGACAGAT-3’) and reverse (5’-
CGCTCCACCAACTAAGAA-3’), CTP: phosphocholine cytidylyltransferase 1, alpha (Pcyt1a) 
forward (5’-CTTTACCTTATCAACTCGTTCTTGC-3’) and reverse (5’-
TCCGTGACTATGATGTGTATGC-3’). Target gene expression was normalized on the basis of 
18s content.  
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ROS 
Intracellular ROS production was measured using 2’,7’-dichlorodihydrofluoresceindiacate 
(H2DCFDA, Invitrogen) as described previously (31). H2DCFDA is a non-polar compound that 
easily passes though the cell membrane where intracellular esterases remove the acetate groups 
resulting in a non-fluorescent dichlorodihydrofluorescein dye that is strongly retained by the cell. 
In the presence of ROS production, dichlorodihydrofluorescein is oxidized and becomes highly 
fluorescent. After indicated treatments for cells cultured in 96-well plates, the medium was 
removed and cells were washed twice with Hanks’ balanced salt solution (HBSS). Cells were 
then incubated at 37°C for 1 h in the dark in a 10 M solution of H2DCFDA in HBSS. The 
fluorescence intensity was measured at an excitation/emission wavelength of 485/530 nm using a 
Biotek FL600 microplate analyzer. 
Cell Toxicity 
Toxicity was assessed using the dead cell dye propidium iodide as described previously (32). 
Propidium iodide is an intercalating dye that can only permeate dead cells. It becomes highly 
fluorescent when embedded in the double-stranded DNA exposed after cell death. After 
culturing cells in 96-well plates with experimental treatments, the medium was removed and 
replaced with a solution of the dye and serum-free DMEM. Cells were incubated at 37°C for 1 h 
in the dark prior to the fluorescence measurement at ex/em wavelengths of 530/645 nm.  
Caspase Activation  
The Apo-ONE Homogenous Caspase 3/7 Assay kit was used to measure apoptotic caspase 
activation.  Cells were cultured in 96-well plates and incubated with desired treatments for 6 
hours.  The Apo-ONE kit uses a lysis buffer combined with a caspase 3/7 specific substrate (Z-
DEVD-R110), which becomes fluorescent once these caspases remove its DEVD peptide.  
Fluorescence was measured at ex/em wavelengths of 485/535 nm.  
Western Blotting 
Cells were lysed with ice-cold RIPA lysis buffer (sc-24948, Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA) supplemented with Na-orthovanadate, protease inhibitor cocktail, and PMSF for 
30 min on ice. Samples were centrifuged at 16,100 rcf and 4°C for 20 min, and the resulting 
supernatants constituted the total protein extracts. Protein concentrations were determined by 
BCA assay (Thermo Fisher Scientific, Rockford, IL). Samples were added in concentrations of 
30 μg/lane for SDS-PAGE western blotting. Dilutions of the primary antibodies were anti-CHOP 
(1:1000) and anti-β-actin (1:1000). 
Phospholipid Fatty Acid Profiles 
Cells seeded in 10-cm Petri dishes at an initial density of 4 × 10
6
 cells per plate were incubated 
in standard medium until reaching ~70-80% confluency, at which time experimental treatments 
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were administered.  Cells were then trypsinized for 3 min and scraped using cold PBS. Cell 
suspensions were pelleted by centrifugation and resuspended in fresh PBS. Fatty acyl lipid 
analysis was performed by the Vanderbilt Hormone Assay and Analytical Services Core using 
thin-layer chromatography (TLC) and gas chromatography-flame ionization detection (GC-FID) 
techniques. Briefly, lipids were extracted from the aforementioned cell pellets using a modified 
Folch separation. An internal standard (1,2-dipentadecanoyl-sn-glycero-3-phosphocholine) for 
phospholipids was added to the lipid-containing chloroform phase. Total lipids were then 
extracted and separated by TLC using petroleum ether/ethyl ether/acetic acid (80/20/1, v/v/v) on 
silica plates. Spots corresponding to phospholipids (PLs), triglycerides (TAGs), and free fatty 
acids (FFAs) were visualized with rhodamine 6G in 95% ethanol and scraped individually into 
glass tubes for transmethylation. Transmethylation was performed using a boron trifluoride-
methanol 10% (w/w) solution. Derivatized lipids were then analyzed using a GC-FID, where 
standardized calibration curves were used to analyze fatty acid content. 
Transmission electron microscopy 
Cells were seeded in 10-cm dishes at 4 × 10
6
 cells per dish and incubated in standard medium 
until reaching ~70-80% confluency. Cells were then incubated with desired treatments at 37°C 
for the indicated time period and then washed thoroughly with 0.1M sodium cacodylate buffer 
(with 1% calcium chloride), pH 7.4. After washing, cells were fixed with a 2.5% glutaraldehyde 
solution in 0.1 M sodium cacodylate buffer for 1 h at room temperature followed by 23 h at 4°C. 
Samples were postfixed in 1.25% osmium tetroxide and subsequently stained with 2% aqueous 
uranyl acetate. Embedded cells were then thin-sectioned and viewed on a Philips/FEI T-12 high-
resolution transmission electron microscope. 
Results 
Palmitate-induced ER stress is accompanied by formation of large phospholipid accumulations, 
known as myelin figures 
Results from prior work demonstrate that the lipotoxic effect of PA in various cell types, 
including hepatocytes, occurs by inducing cellular dysfunction and apoptosis-mediated cell death 
(8, 9, 33-39). We have shown previously that this PA-induced liptoxicity is characterized by 
increased saturation and disordered metabolism of phospholipids and induction of ER stress (9). 
TEM images of PA-treated hepatic cells, both H4IIEC3 rat hepatomas (Fig. 6-2) and freshly 
isolated primary rat hepatocytes (Fig. 6-3), revealed striking evidence of disordered phospholipid 
metabolism in vitro though the formation of lamellar structures known as myelin figures (Fig. 6-
2B, Fig. 6-3B). Myelin figures (MFs) are essentially concentric layers of phospholipid 
aggregates that are thought to indicate dysregulated phospholipid synthesis and metabolism in 
cells. Compared to hepatic cells treated with BSA-vehicle control (Fig 6-2A, Fig. 6-3A), cells 
treated with PA in vitro exhibited repeatable formation of MFs (Fig 6-2B, Fig. 6-3B). In contrast, 
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hepatocytes supplemented with equimolar concentrations of OA alone (Fig 6-2C, Fig. 6-3C) 
presented normal lipid droplet accumulations without any indication of myelin figure formation. 
 
C 
A 
0.5 
μm 
B 
LD 
M 
M 
M 
Figure 6-2. Incubation of H4IIEC3 cells with PA results in formation of myelin figures, which are 
absent from cells treated with BSA or OA. H4IIEC3 cells were incubated for 4 h with (A) BSA vehicle, 
(B) 400 μM PA, or (C) 400 μM OA. Changes in cellular morphology were observed by high-resolution 
imaging with transmission electron microscopy. Arrowheads point towards myelin figures. M, 
mitochondria; LD, lipid droplets 
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Figure 6-3.  Incubation of freshly isolated rat hepatocytes with PA results in formation of myelin 
figures, which are absent from cells treated with BSA or OA. Hepacotyes were incubated for 12 h 
with (A) BSA vehicle, (B) 400 μM PA, or (C) 400 μM OA. Changes in cellular morphology were 
observed by high-resolution imaging with transmission electron microscopy. Arrowheads point 
towards myelin figures. M, mitochondria; LD, lipid droplets 
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Pharmacological inhibition of iPLA2 activity results in small reductions in markers of palmitate-
induced lipotoxicity 
Our observations that disordered phospholipid metabolism plays a role in PA-induced 
lipotoxicity, particularly oversaturation of membrane phospholipids, led us to experiment with 
methods designed to alter PA incorporation into these integral cellular components. First, we 
aimed to prevent PA incorporation into phospholipids by targeting the Lands’ remodeling cycle. 
New phospholipids are primarily produced though the Kennedy lipid synthesis pathway, but 
extensive post-synthesis remodeling is thought to provide much of the diversity in acyl-chain 
composition and positional distribution on the glycerol backbone. In Lands’ cycle, 
phospholipases hydrolyze a fatty acid bonded to the phospholipid and acyltransferases re-esterify 
the specific moiety. Since we were interested in fatty acid composition, we examined enzymes 
involved in this remodeling cycle. Different phospholipases hydrolyze the sn-1 or sn-2 position 
of the phospholipid bond, releasing a lysophospholipid and a fatty acid. Lysophospholipid 
acyltransferases utilize the emancipated lysophospholipid as a substrate and reacylate the same 
position with a new fatty acid moiety thereby providing significant species diversity (2, 23). 
Calcium-independent phospholipase A2 (iPLA2) is an abundant enzyme in all tissues that 
hydrolyzes the fatty acid sn-2 position of phospholipids (40). We chose to inhibit this enzyme 
using the commercially available small molecule palmityl trifluoromethyl ketone (PACOCF3). 
This molecule has been previously shown to significantly inhibit iPLA2 activity (41) in other 
studies on different hepatic models (29).  
Pre-treating H4IIEC3 cells with PACOCF3 reduced PA-mediated markers of lipotoxicity 
including ROS, caspase 3/7 activation and cell death compared to cells treated with PA alone.  
After 6 hours, PA supplementation increased total cellular ROS levels by almost two-fold while 
pre-treatment with PACOCF3 reduced this accumulation by approximately 40% (Fig. 6-4A). 
Similarly, PA induced caspase 3/7 activity almost thee-fold after 8h and increased cell death 
two-fold after 12h over BSA-control treatments (Fig 6-4 B and C, respectively). 
Supplementation with the iPLA2 inhibitor PACOCF3 reduced these levels by approximately 35% 
in comparison to PA-only treated cells. Although PACOCF3 did not completely reverse PA-
mediated lipoapoptosis, the observed reductions were statistically significant and closely 
correlated with the observed reductions in ROS.  
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Figure 6-4. Induction of ROS accumulation, caspase 3/7 activation and cell death by palmitate 
treatment is partially reversed by co-treatment with the iPLA2 inhibitor PACOCF3. H4IIEC3 cells 
were incubated with indicated treatments (PA = 400 μM PA, PACOCF3 = 100 μM PACOCF3) and 
assayed for ROS accumulation at 6 h (A), activation of caspase 3/7 at 9 h (B) and cell death at 12 h (C). 
ROS was assessed using the fluorescent dye H2DCFDA, caspase 3/7 activation with Apo-ONE and cell 
toxicity via propidium iodide, all of which were normalized to control cells treated with BSA vehicle. 
Data represent mean ± SE of n=4. *, p < 0.05 vs. cells treated with BSA; ∆, p < 0.05 cells treated with 
PA+PACOCF3 vs. cells treated with PA alone. 
 
Next, we were interested to investigate if pre-treatment with PACOCF3 reduced PA 
incorporation into phospholipids and markers of ER stress. Examining the fatty acid composition 
of the phospholipid fraction after 6h and 24h of incubation revealed that, in comparison to PA-
only treated cells, co-treatment with PACOCF3 led to small, but significant, decreases in PA 
incorporation (~44% vs 34%, 24h) and total phospholipid saturation (~57.5% vs ~49.5%, 24h) 
(Table 6-1 and 6-2, respectively). This correlated to a small reduction in ER stress after 8 h, as 
assessed by reduction in CHOP levels (Fig. 6-5). These data indicate that while inhibition of 
iPLA2 did provide some positive benefits to PA-treated hepatic cells, it was unable to completely 
reverse the lipotoxic effects of PA treatment.  
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  Fatty Acid PA   PA+PACOCF3   BSA   BSA+PACOCF3   
 
14:0 0.56 ± 0.14 
 
0.61 ± 0.02 
 
0.69 ± 0.15 
 
0.63 ± 0.09 
 
 
16:0 32.13 ± 0.68 
 
27.56 ± 0.74
a
 
 
12.72 ± 0.43
a
 
 
13.14 ± 0.05
a
 
 
 
16:1 11.14 ± 0.28 
 
10.78 ± 0.44 
 
6.93 ± 0.39
a
 
 
5.78 ± 0.23
a
 
 
 
18:0 13.84 ± 0.18 
 
15.30 ± 0.17
a
 
 
18.54 ± 0.54
a
 
 
19.86 ± 0.42
a
 
 
 
18:1w9 20.11 ± 0.16 
 
22.43 ± 0.45a 
 
33.38 ± 0.32
a
 
 
30.39 ± 0.27
a
 
 
 
18:1w7 4.94 ± 0.05 
 
5.10 ± 0.05 
 
7.95 ± 0.08
a
 
 
8.08 ± 0.04
a
 
 
 
18:2 2.34 ± 0.03 
 
2.57 ± 0.06 
 
2.88 ± 0.00 
 
3.03 ± 0.08 
 
 
20:3w6 0.77 ± 0.24 
 
0.76 ± 0.01 
 
0.80 ± 0.03 
 
0.78 ± 0.01 
 
 
20:4 8.93 ± 0.21 
 
9.43 ± 0.17 
 
10.45 ± 0.05
a
 
 
11.91 ± 0.32
a
 
 
 
20:5 0.22 ± 0.21 
 
0.28 ± 0.01 
 
0.00 ± 0.00 
 
0.16 ± 0.09 
 
 
22:4w6 0.96 ± 0.26 
 
0.95 ± 0.01 
 
1.11 ± 0.01 
 
1.07 ± 0.01 
 
 
22:5w6 0.38 ± 0.00 
 
0.39 ± 0.01 
 
0.29 ± 0.13 
 
0.33 ± 0.11 
 
 
22:5w3 1.61 ± 0.04 
 
1.61 ± 0.02 
 
1.79 ± 0.05 
 
2.00 ± 0.05 
   22:6 2.05 ± 0.04   2.25 ± 0.06   2.49 ± 0.04   2.84 ± 0.10 
                  
 
% SFA 46.53 ± 1.01 
 
43.46 ± 0.76
a
 
 
31.95 ± 0.71
a
 
 
33.63 ± 0.43
a
   
 
% UFA 53.47 ± 0.72 
 
56.54 ± 0.66
a
 
 
68.05 ± 0.53
a
 
 
66.37 ± 0.52
a
 
  
Table 6-1. Phospholipid composition of cells treated with PA with or without PACOCF3 for 6 h. 
H4IIEC3 cells were incubated with 400 μM PA with or without 100 μM PACOCF3 for 6 h. Phospholipids 
were separated by thin layer chromatography and analyzed by gas chromatography-flame ionization 
detection (GC-FID). Data represent mean fatty acid %± SE of n=3. a, p<0.05 vs cells treated with PA 
alone. SFA, saturated fatty acids; UFA, unsaturated fatty acids.  
  
110 
 
 
Fatty Acid PA   PA+PACOCF
3
   BSA   BSA+PACOCF
3
 
  
14:0 0.41 ± 0.14 
 
0.52 ± 0.02 
 
0.55 ± 0.04 
 
0.82 ± 0.02 
 16:0 43.86 ± 0.68 
 
33.99 ± 0.37
a
 
 
11.29 ± 0.26
a
 
 
12.00 ± 0.12
a
 
 16:1 12.44 ± 0.28 
 
15.99 ± 0.18
a
 
 
6.87 ± 0.07
a
 
 
6.20 ± 0.05
a
 
 18:0 12.71 ± 0.18 
 
14.56 ± 0.29
a
 
 
19.98 ± 0.38
a
 
 
20.50 ± 0.06
a
 
 18:1w9 11.42 ± 0.16 
 
14.89 ± 0.22
a
 
 
32.79 ± 0.11
a
 
 
31.75 ± 0.11
a
 
 18:1w7 3.13 ± 0.05 
 
3.64 ± 0.05 
 
8.25 ± 0.07
a
 
 
8.66 ± 0.05
a
 
 18:2 2.17 ± 0.03 
 
2.31 ± 0.03 
 
3.02 ± 0.04
a
 
 
3.16 ± 0.03 
 20:3w6 0.72 ± 0.24 
 
0.84 ± 0.00 
 
0.92 ± 0.02 
 
0.85 ± 0.01 
 20:4 9.06 ± 0.21 
 
8.87 ± 0.12 
 
10.77 ± 0.18
a
 
 
10.47 ± 0.06
a
 
 22:4w6 0.77 ± 0.26 
 
0.90 ± 0.02 
 
1.26 ± 0.03 
 
1.11 ± 0.01 
 22:5w6 0.00 ± 0.00 
 
0.09 ± 0.09 
 
0.12 ± 0.12 
 
0.45 ± 0.00 
 22:5w3 1.36 ± 0.04 
 
1.36 ± 0.05 
 
1.73 ± 0.04 
 
1.62 ± 0.02 
 22:6 1.94 ± 0.04 
 
1.96 ± 0.06 
 
2.46 ± 0.05 
 
2.25 ± 0.02 
 
                 % SFA 56.99 ± 0.72  49.07 ± 0.47
a
  31.82 ± 0.46
a
  33.33 ± 0.14
a
  
% UFA 43.01 ± 0.84 
 
50.93 ± 0.35
a
 
 
68.18 ± 0.34
a
 
 
66.67 ± 0.19
a
 
  
Table 6-2. Phospholipid composition of cells treated with PA with or without PACOCF3 for 24 h. 
H4IIEC3 cells were incubated with 400 μM PA with or without 100 μM PACOCF3 for 24 h. 
Phospholipids were separated by thin layer chromatography and analyzed by gas chromatography-flame 
ionization detection (GC-FID). Data represent mean fatty acid % ± SE of n=3. a, p<0.05 vs cells treated 
with PA alone. SFA, saturated fatty acids; UFA, unsaturated fatty acids.  
 
 
Figure 6-5. Inhibition of iPLA2 in PA-treated H4IIEC3 cells reduces CHOP expression, a marker of 
ER stress. PA-induced increases in CHOP abundance were reduced by inhibiting iPLA2 with the small 
molecule specific inhibitor PACOCF3. H4IIEC3 hepatocytes were treated with 400 μM PA alone or in the 
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presence of 100 μM PACOCF3 for 8 h in independent experiments. Levels of CHOP abundance were 
assessed using Western blotting techniques. Actin was the loading control and thapsigargin (Thaps) was 
used as a positive control. 
 
Inhibition of phospholipid synthesis via siRNA knockdown of Pcyt1α results in a small reversal 
in ER saturation and markers of lipoapoptosis.  
Based on our previous data that showed increased phospholipid synthesis though the Kennedy 
pathway in the presence of PA (9), we were interested in investigating the effect of reducing 
phosphatidylcholine (PC) synthesis. PC constitutes the most abundant phospholipid in membrane 
bilayers (1), and therefore presents the best single phospholipid species to target.  PC is 
synthesized de novo though the CDP-choline pathway (Fig. 1) in which the rate limiting step, 
conversion from phosphocholine to CDP-choline, is regulated by the enzyme CCT encoded by 
the gene Pcyt1 (16, 42) . Two isoforms are known to exist (Pcyt1a and Pcyt1b). Pcyt1a is 
thought to be the predominant form in the liver (43) and has been shown previously to be 
stimulated  via translocation of the enzyme from the cytosol to the microsomal membrane by 
fatty acid treatment (44). Using siRNA, we knocked down Pcyt1a expression in H4IIEC3 
hepatic cells to determine if this genetic manipulation imparted any effect on lipotoxic 
phenotypes in PA-treated cells (Fig. 6-6A). 
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Figure 6-6. siRNA mediated knockdown of Pcyt1a expression trended towards reduced 
phospholipid synthesis without reductions in triglyceride synthesis in H4IIEC3 cells and partially  
reduced palmitate lipotoxicity. Knockdown of Pcyt1a  (siPcyt1a), the rate limiting step in de novo PC 
synthesis, reduced mRNA transcript levels of the gene regardless of treatment (A). H4IIEC3 cells 
transfected with siRNA targeted to Pcyt1a demonstrated a downward trend in phospholipid synthesis in 
comparison to non-targeting control siRNA treated cells (NTC), but the effect was not statistically 
significant (B). siPcyt1a partially reduced toxicity when combined with PA treatment (C). There were no 
statistically significant changes in TG accumulation between siPcyt1a and NTC groups (D). Data 
represent mean ± SE of n=4. **, P<0.05, vs. cells supplemented with the same treatment; ns, not 
significant.  
 
Knocking down Pcyt1a (siPcyt1a) resulted in a trend toward reduced phospholipid synthesis 
after 12h, but the differences between NTC and siPcyt1a cells were not statistically significant 
(Fig. 6-6B). However, Pcyt1a knockdown did reduce PA associated cell death in H4IIEC3 cells 
by approximately 40% (Fig. 6-6C). Manipulation of this gene had no effect on OA treated cells. 
Due to the known function of PC as a coating phospholipid for lipid droplets, we tested whether 
inhibition of Pcyt1a had any effect on triglyceride synthesis. Although there was a slight 
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downward trend, there were no statistical differences in triglyceride accumulation between NTC 
and siPcyt1a  cells with the same fatty acid treatments (Fig. 6-6D).  
Because inhibiting Pcyt1a resulted in significant reduction in PA-induced cell death, we were 
interested to see if it also reduced other facets of lipotoxicity including ER stress and 
phospholipid saturation that we had observed in prior studies. Changes in CHOP protein 
expression levels were inconclusive (Fig. 6-7B). Additionally, siPcyt1a cells demonstrated a 
decrement in the percentage of PA incorporated into phospholipids correlating to a small but 
significant decrease in overall percent saturation after 12h (Table 6-3). The PA (16:0) abundance 
in cellular phospholipids was reduced by ~18% in siPcyt1a cells compared to NTC cells treated 
with PA (42.56% ± 0.42 vs 48.73% ±0.62).  Total phospholipid saturation was reduced by ~25%. 
Overall, these data point toward knockdown of Pcyt1a expression as an interesting and novel 
target for prevention of lipoapoptosis, with some significant effects on PA-induced lipotoxicity. 
However, Pcyt1a knockdown of PA-treated cells did not completely restore cell viability or other 
lipotoxic markers to their basal levels. 
 
 
Figure 6-7. Knockdown of Pcyt1a expression in H4IIEC3 cells has no significant effect on PA-
induced CHOP expression. Knocking down Pcyt1a in H4IIEC3 had only slight effects on PA-mediated 
increases in CHOP abundance. H4IIEC3 hepatocytes were transfected with either non-targeted control 
siRNA (NTC), indicated as (-), or siPcyt1a, indicated by (+), and treated with 400 μM PA either alone or 
in combination with 400 μM OA for 8 h in independent experiments (representative blot shown). Levels 
of CHOP abundance were assessed using Western blotting techniques. Actin was the loading control and 
thapsigargin (Thaps) was used as a positive control. 
  
114 
 
 
  Fatty Acid NTC PA   NTC BSA   NTC OA   
siPcyt1a  
PA 
  siPcyt1a  BSA   siPcyt1a OA   
 
14:0 0.00 ± 0.00 
 
0.89 ± 0.02 
 
0.48 ± 0.03 
 
0.00 ± 0.00 
 
0.00 ± 0.00 
 
0.00 ± 0.00 
 
 
16:0 48.73 ± 0.62 
 
12.87 ± 0.14 
 
8.29 ± 0.10 
 
42.56 ± 0.41
a 
 
14.19 ± 0.15
a 
 
8.83 ± 0.14 
 
 
16:1 8.82 ± 0.24 
 
6.71 ± 0.10 
 
2.40 ± 0.08 
 
13.02 ± 0.17
a 
 
6.21 ± 0.07 
 
1.85 ± 0.04 
 
 
18:0 12.82 ± 0.58 
 
18.75 ± 0.55 
 
12.64 ± 0.42 
 
11.63 ± 0.12
a 
 
20.34 ± 0.43
a 
 
13.10 ± 0.25 
 
 
18:1w9 11.06 ± 0.07 
 
28.19 ± 0.74 
 
58.03 ± 0.05 
 
12.88 ± 0.15
a 
 
28.82 ± 0.29 
 
58.81 ± 0.20 
 
 
18:1w7 3.22 ± 0.02 
 
8.01 ± 0.42 
 
4.17 ± 0.08 
 
3.26 ± 0.04 
 
6.95 ± 0.02
a 
 
4.28 ± 0.02 
 
 
18:2 1.80 ± 0.08 
 
4.08 ± 0.14 
 
1.75 ± 0.05 
 
2.14 ± 0.02 
 
3.84 ± 0.02 
 
1.75 ± 0.01 
 
 
20:3w6 0.66 ± 0.33 
 
1.51 ± 0.03 
 
0.60 ± 0.01 
 
1.10 ± 0.01 
 
1.42 ± 0.02 
 
0.00 ± 0.00 
 
 
20:4 8.52 ± 0.07 
 
10.56 ± 0.03 
 
6.64 ± 0.07 
 
7.54 ± 0.11 
 
11.20 ± 0.02 
 
7.44 ± 0.08 
 
 
20:5  0.00 ± 0.00 
 
0.34 ± 0.17 
 
0.00 ± 0.00 
 
0.00 ± 0.00 
 
0.00 ± 0.00 
 
0.00 ± 0.00 
 
 
22:4w6 0.00 ± 0.00 
 
1.38 ± 0.01 
 
0.59 ± 0.01 
 
0.96 ± 0.03 
 
1.58 ± 0.06 
 
0.00 ± 0.00 
 
 
22:5w6 0.00 ± 0.00 
 
0.65 ± 0.42 
 
1.05 ± 0.01 
 
0.81 ± 0.01 
 
0.00 ± 0.00 
 
0.63 ± 0.31 
 
 
22:5w3 2.34 ± 0.09 
 
2.83 ± 0.03 
 
1.43 ± 0.01 
 
1.87 ± 0.03 
 
2.71 ± 0.01 
 
1.53 ± 0.01 
 
 
22:6 2.02 ± 0.01 
 
3.23 ± 0.01 
 
1.91 ± 0.04 
 
2.23 ± 0.04 
 
2.75 ± 0.04 
 
1.77 ± 0.02 
                                               
 
% SFA 61.55 ± 0.85 
 
32.52 ± 0.57 
 
21.42 ± 0.44 
 
54.19 ± 0.42
a 
 
34.52 ± 0.46
a 
 
21.93 ± 0.29 
 
 
% UFA 38.45 ± 0.44 
 
67.48 ± 0.98 
 
78.58 ± 0.15 
 
45.81 ± 0.26
a 
 
65.48 ± 0.32
a 
 
78.07 ± 0.38 
  
Table 6-3. Knockdown of Pcyt1a results in a small reduction in PA incorporation and overall 
phospholipid saturation in PA-treated hepatic cells (%composition). Phospholipid composition of 
either NTC control or siPcyt1a H4IIEC3 cells was measured following incubation with 400 μM PA, 400 
μM OA or corresponding amounts of BSA for 12 h. Phospholipids were separated by thin layer 
chromatography and analyzed by gas chromatography-flame ionization detection (GC-FID). Data 
represent mean fatty acid % ± SE of n=3. 
a
, p<0.05, NTC vs siPcyt1a cells with same treatment. SFA, 
saturated fatty acids; UFA, unsaturated fatty acids.  
 
Discussion 
Hepatic lipotoxicity in H4IIEC3 cells is characterized by disordered phospholipid metabolism 
resulting in increased saturation of membrane bilayers. Manipulating fatty acyl composition of 
phospholipids directly in intact living cells is currently a challenge that has not been resolved 
fully in a laboratory setting to date. Therefore, in this study we sought to determine if limiting 
PC synthesis or reducing phospholipid remodeling via inhibition of iPLA2 would suppress PA-
induced lipotoxic phenotypes, including ER stress and cell death, via reduction in phospholipid 
saturation.   
Newly synthesized phospholipid species have been previously shown to undergo significant 
remodeling within 1h (40, 45) and existing phospholipids are continuously recycled in this 
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manner. As such, remodeling may present an important avenue though which PA is incorporated 
into phospholipids in PA-mediated lipotoxicity. By inhibiting iPLA2, the major deacylation 
enzyme in the Lands’ cycle, we sought to prevent remodeling of synthesized phospholipids and 
subsequent reacylation of saturated fatty acids onto phospholipid backbones. We used 
PACOCF3, a pharmacological agent that has been demonstrated to specifically inhibit iPLA2 
activity (29, 41).  Our data indicate that this approach did have small, but significant, effects on 
phospholipid composition and lipotoxic markers. Pre-treatment of H4IIEC3 hepatic cells with 
PACOCF3 resulted in a significant decrease in the percent incorporation of PA into the 
phospholipid fraction after 6h and almost one third reduction after 24h. This correlated to 
decreases in other hallmark indicators of lipotoxicity including markers of ER stress (CHOP 
protein levels), ROS accumulation, caspase 3/7 activation and cell death (Fig. 6-4 and 6-5).   
Though our results suggest that inhibiting iPLA2 had significant effects on lipoapoptosis, other 
factors must also be considered when interpreting the response to PACOCF3 treatment. LysoPC 
has been previously implicated as a death effector in hepatic cells (28, 29), and inhibition of 
iPLA2 would also be expected to limit accumulation of this lipid intermediate. Kakisaka et al. 
demonstrated that intracellular LysoPC (16:0) accumulated with PA treatment and that cells 
supplemented with LysoPC alone underwent apoptosis in a concentration-dependent manner 
(28). LysoPC-mediated apoptosis was accompanied by increases in ER stress, p53 upregulated 
modulator of apoptosis (PUMA) and CHOP expression, and JNK phosphorylation, similar to PA 
treatment alone. They showed that inhibition of CHOP or JNK reversed LysoPC-induced 
lipoapotosis (28). However, this is in contrast to previous data that shows inhibition of CHOP or 
JNK can delay the onset of apoptosis but does not rescue hepatic cells from PA-mediated 
lipoapoptosis (36), indicating that PA and LysoPC may differ in their mechanisms of lipotoxic 
cell death.  
We also examined knockdown of de novo phospholipid synthesis though siRNA-mediated 
inhibition of Pcyt1a gene expression, the enzyme product (CCT) of which is responsible for 
activating the choline head group during the rate-limiting step of PC synthesis. Previous studies 
have demonstrated upregulated expression of this ER resident gene in human metabolic 
syndrome and obesity (6, 46); thus it presents a physiologically relevant target. As PC is the 
major constituent of membranes (1, 18, 19), reducing its synthesis should have a substantial 
impact on total phospholipid composition. Several studies have targeted the reacylation step in 
Lands’ cycle remodeling pathway as a means of modulating phospholipid composition. In 
particular, LPCAT3 has generated significant interest as it is more specific for incorporation of 
unsaturated as opposed to saturated fatty acids. One study demonstrated that activation of the 
liver X receptor (LXR) enzyme induced expression of LPCAT3 and ameliorates PA induced ER 
stress (22). Conversely, knockdown of LPCAT3 in this model, even in the presence of activated 
LXR, exacerbated PA-mediated ER stress and inflammation (22). Another group investigated the 
effect of sterol CoA desaturase 1 (SCD1), an enzyme responsible for desaturating saturated long 
chain fatty acids such as palmitate and sterate, and LPCAT3 in the context of PA-induced 
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lipotoxicity in HeLa cells (7). Reducing the ability of cells to desaturate toxic SFAs through 
SCD1 knockdown resulted in increased expression of LPCAT3 but also increased PA-mediated 
ER stress and lipotoxicity compared to untransfected cells only treated with PA. Knockdown of 
LPCAT3 in SCD1 deficient cells synergistically enhanced ER stress and lipoapoptosis (7).  Both 
of these studies focus on increasing incorporation of unsaturated fatty acids in phospholipids via 
LPCAT3 as a means of reducing PA apoptosis. To our knowledge, no previous studies have 
focused on reducing PC synthesis as a means for reducing PA-induced lipotoxicity. However, 
complete and prolonged inhibition of PC synthesis can itself result in ER stress (47) and 
therefore this line of investigation must be targeted with caution.  Our data demonstrate that 
siRNA targeted Pcyt1a knockdown (siPcyt1a) resulted in small, but statistically significant, 
improvements in several key markers of lipotoxicity including reductions in PA incorporation 
and overall phospholipid saturation (Table 6-3), markers of ER stress (Fig. 6-7), and cell death 
(Fig. 6-6).  
These results are encouraging, but do not reflect a full reversal of lipotoxic phenotypes. Although 
the knockdown efficiency was high (greater than approximately 90%, Fig. 6-5A), the ability to 
reduce lipotoxic markers was not correspondingly high. As Fig. 6-5B shows, siPcyt1a 
knockdown cells demonstrated a trend of reduced phospholipid levels, but the reduction was not 
significant. This could be the result of a number of potential limitations of the study design. First, 
while PC is the major component of membrane phospholipids, there is still a large constituent of 
other species that also comprise the phospholipid measurements shown in Fig. 6-5B and are not 
directly impacted by Pcyt1a knockdown. Additionally, the significant reduction in mRNA 
transcript levels may not necessarily correlate to as significant a drop in activity of the CCT 
enzyme.  Increased fatty acid levels are known to promote translocation and activation of this 
enzyme (44, 48-50), and this may provide a compensatory mechanism to partially recover PC 
synthesis in these conditions.  
Additional compensatory pathways may also play a role in limiting the reversal of lipotoxic 
phenotypes by Pcyt1a knockdown. In most tissues, the CDP-choline pathway accounts for the 
vast majority of PC synthesis. In the liver, however, there is a pathway to convert 
phosphatidylenthanolamine (PE) into PC though a series of thee methylation reactions catalyzed 
by the enzyme phosphatidylenthanolamine N-methyltransferase (PEMT), which can account for 
up to 30% of hepatic PC synthesis under normal conditions (51, 52). In rodent models fed a 
choline-deficient (CD) diet, which is designed to prevent normal PC synthesis, PEMT levels 
were significantly increased (53). Elevation of PEMT expression was also observed in liver-
specific CCT knockout mice fed a standard chow diet (54). An increased ratio of PC/PE has also 
been implicated as a contributing factor to ER stress in obesity (6) and to perturbations in ER 
calcium due to inhibition of the SERCA transporter (5, 6). Alternatively, decreases in PC/PE 
ratio have been linked to enhanced membrane permeability, organelle leakage, and increased 
plasma content of alanine aminotransferase (ALT, a clinical biomarker of hepatotoxicity) (55, 
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56). Therefore, increased flux though PEMT may mitigate the effects of Pcyt1a knockdown on 
phospholipid composition and explain the mixed results of this study.  
Abnormal phospholipid composition and fluidity has been observed in several diseased states 
and has been connected to dysfunction of the ER membrane. Our previous work (9) led to the 
hypothesis that inhibiting incorporation of PA into phospholipids by targeting pathways for 
phospholipid remodeling or PC synthesis would reduce PA-mediated lipotoxicity in an in vitro 
hepatic model. The results of this study indicate that methods designed to impede PA 
incorporation into phospholipids can provide some protective effects in conditions of acute PA 
oversupply. Either inhibition of remodeling by iPLA2 or inhibition of de novo PC biosynthesis 
via CCT provided modest protection against markers of lipotoxicity in our hepatic model.  
Neither intervention could by itself fully block PA incorporation into PL, most likely due to 
functional redundancy of PL synthesis and remodeling pathways. One interesting suggestion for 
a future study might be to combine inhibition of multiple PL metabolic pathways (e.g., 
PACOCF3 with Pcyt1a knockdown), although cell toxicity may become a concern with such 
combinations as phospholipids are necessary for cell survival. These findings suggest that 
modulating these or other phospholipid synthesis and remodeling pathways may represent an 
effective target for intervention in NASH and related liver diseases.  
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CHAPTER 7  
INTRAVENOUS INFUSION OF ETHYL PALMITITATE CAN RECAPITULATE ACUTE 
LIPOTOXIC PHENOTYPES IN AN IN VIVO RODENT MODEL 
Introduction 
There is a burgeoning epidemic of non-alcoholic fatty liver disease (NAFLD) largely due to 
increases in the prevalence of obesity around the world. NAFLD is currently the leading cause of 
referrals to US hepatology clinics (1), and cirrhosis stemming from NAFLD progression is the 
third leading cause of liver transplants (2). The startling increase in NAFLD incidence rate 
makes it a research priority to understand the mechanisms that drive simple steatosis and its 
progression into more acute and deadly forms of liver disease such as non-alcoholic 
steatohepatitis (NASH) and/or cirrhosis. 
The initial phase of NAFLD is characterized by increased accumulation of triglycerides in the 
liver, the fatty acid constituents of which can come from three main sources: de novo 
lipogenesis, diet, and circulating free fatty acids released from adipose tissue. Adipocytes are 
designed to store large amounts of excess fat, but non-adipose tissues such as the liver do not 
have the capacity to do so long-term. Excessive accumulation of lipids in the liver has been 
associated with organ dysfunction and hepatocyte cell death, known as lipotoxicity. In vitro 
experiments have demonstrated the distinctly different role that saturated versus unsaturated fatty 
acids play in lipotoxicity. Specifically, saturated fatty acids (SFAs) have been shown to cause 
widespread cellular stress and dysfunction while unsaturated fatty acids increase triglyceride 
accumulation but without changes in cell viability or function (3-6). These data indicate that 
elevations in circulating and/or hepatic SFAs may promote progressive liver damage in vivo.  
There are two main methods for increasing physiological levels of SFAs: feeding high saturated 
fat diets or direct intravenous infusion of SFA. Both of these methods have been used over the 
years, although alterations made in diet macronutrients to favor specific fatty acids have been 
historically more popular due to their inherently less difficult implementation. Several groups 
have focused specifically on developing in vivo models of NAFLD/NASH by increasing the 
relative proportion of SFAs in rodent diets, including the so-called “cafeteria diet rat” (7) and 
“fast food diet mouse” (8) models. The inclusion of high levels of saturated fats in these diets 
appears to trigger an inflammatory stress response that results in progression of NAFLD to 
NASH, which is not observed in rodents fed a standard high-fat diet (5, 7, 8).  
Other groups have developed methods for infusing saturated fatty acids directly into an animal’s 
bloodstream to recapitulate the acute lipotoxic effects of SFAs observed in vitro and determine if 
elevation of SFAs alone can lead to progressive liver disease. This method is inherently more 
difficult due to blood solubility issues, infusion rate constraints and the intricate animal surgeries 
required. However, the advantage is that this approach initiates SFA lipotoxicity more rapidly 
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and directly than dietary interventions. As a result, there are fewer confounding factors that must 
be considered as contributing to alterations in liver homeostasis. One recent study demonstrated 
that infusion of a lard oil emulsion mainly composed of SFAs effectively induced hepatic ER 
stress, inflammation and cellular cytotoxicity in rats (9). A similar experiment used direct 
palmitate infusion (as a 1:1 ratio of ethyl palmitate) to demonstrate inflammatory and apoptotic 
effects in islet β-cells of mice (10).  
In this preliminary study, we sought to recapitulate a progressive NASH-like liver state in vivo 
order to test the mechanistic hypotheses we generated in previously reported work regarding 
lipotoxicity in vitro (4). Our initial aim was to use a diet high in saturated fat to induce a NASH-
like phenotype in Sprague-Dawley rats, a model we chose due to some inherent physiological 
flaws with using other NASH models such as methionine and choline deficient (MCD) diet or 
ApoE -/- mice, as discussed in Chapter 2. Our goal was to determine the earliest time point at 
which markers of liver injury begin to manifest. The pilot study was conducted over 14 weeks by 
feeding the same Western AIN-76 diet used by Charlton et al. (8), but without the addition of 
fructose to drinking water. We sacrificed one animal every two weeks, and analyzed tissue and 
blood samples for markers of liver injury. Although the week-14 rat was removed from the study 
due to an unknown illness, the rat on the diet for 12 weeks showed large increases in adiposity, 
elevated liver triglycerides and some indicators of cellular dysfunction. However, markers of 
progressive NASH were inconclusive. 
In order to develop an acute model of in vivo lipotoxicity that would not require long-term diet 
interventions, we next examined the effects of direct fatty acid infusion into Sprague-Dawley 
rats. Though the expert assistance of the Vanderbilt Mouse Metabolic Phenotyping Center 
(MMPC), we were able to perform the necessary surgeries to enable continuous infusion of ethyl 
palmitate though a jugular vein catheter into conscious, unrestrained, and unstressed animals.  
Our preliminary data indicate that direct infusion of ethyl palmitate for 5 h results in changes in 
phospholipid composition, similar to our results in vitro, compared to vehicle infusions. These 
promising initial results will pave the way for future studies that will test hypotheses generated 
from our in vitro studies in a more physiologically relevant in vivo system.  
 
Methods 
Animals and surgical procedures  
For the feeding study, genetically unaltered male Sprague-Dawley rats (Jackson Laboratories, 
Bar Harbor, ME) were maintained in common cages (3-4 rats/cage) and had free access to 
standard rodent chow and water one week prior to initiation of the study. The animals were 
labeled and maintained on a high saturated fat, fructose and cholesterol diet with ~12% saturated 
fat (AIN-76 Western diet, Test Diet, St. Louis, MO) for the specified duration. Mice were 
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weighed two times per week and euthanized by barbiturate overdose. One lobe of the liver was 
tied off and either snap frozen using liquid nitrogen or preserved in 10% buffered formalin.  
For the lipid infusion studies, wild-type C57BL/6J mice were maintained in individual cages on 
a standard rodent diet with free access to food prior to catheterization surgeries. After surgeries, 
mice were housed individually and recovered for seven days, at minimum, to ensure they 
returned to within 10% of pre-surgical weight before initiating studies.  
Lipid emulsions 
Lipid emulsions for in vivo infusions were prepared using a protocol adapted and kindly 
provided by Dr. Kosei Eguchi of the University of Tokyo. The protocol is described briefly as 
follows. Mix 4.8% lecithin solution (in water), 10% glycerol (in water), and water at the ratio of 
1:1:1 (Designate as ‘Solution A’). To prepare the vehicle solution, mix ‘Solution A’ and water at 
the ratio of 3:1. To prepare the ethyl-palmitate solution, mix Solution A, ethyl palmitate (Sigma 
Aldrich), and water at the ratio of 15:4:1. Lastly, sonicate the vehicle solution and the ethyl-
palmitate solution until the ethyl-palmitate solution is completely emulsified by sonicating for 5 
minutes followed by 1 minute of vortex, repeated 9 times. 
Euglycemic clamp and lipid infusions 
Mice were fasted for five hours prior to initiation of each clamp study, and then externalized 
mouse catheters were attached to infusion syringes as shown in Fig. 7-1 one hour prior. Prior to 
the start of any infusions, an arterial blood sample was taken to evaluate arterial blood glucose 
concentration and hematocrit.  Venous infusion of saline-washed donor erythocytes (~1 μL/min) 
was administered during the clamp study to prevent a decline in hematocrit due to arterial 
sampling.  
In the first pilot study (Fig. 7-1A), ethyl palmitate was infused from t=1h until t=8h (3500 
μmol/kg prime followed by 7 μmol/kg/min continuous infusion) and erythocytes were infused 
from t=4h until t=8h. Blood glucose was measured every hour, nonesterified fatty acids (NEFAs) 
were measured at t=6.7 and 8h, and insulin was measured at t=6 and 8h.   
In the second pilot study (Fig. 7-1B), a euglycemic clamp with somatostatin was performed. At 
t=0h, somatostatin (20 μg/kg/min), glucagon (1-3 ng/kg/min) and insulin (0.8 mU/kg/min) were 
infused at rates based on previous methods employed in rodent studies (11). Glucose was infused 
at a variable rate to maintain euglycemia based on blood glucose levels measured every 10 
minutes. Ethyl palmitate was continuously administered starting at t=1h until t=6h (5h total 
infusion) at two different levels (37.5 or 75 μmol/kg/min).  Insulin, NEFAs and hematocrit were 
measured at the completion of the study. 
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In the third pilot experiment (Fig. 7-1C), ethyl palmitate or an ethanol (EtOH) emulsion vehicle 
control were infused for 5 hours per day over the course of 3 days at a rate of 37.5 μmol/kg/min. 
Arterial glucose and NEFA concentrations were measured on the third day without prior fasting.   
Plasma was stored at -20°C until analysis. Mice were sacrificed via cervical dislocation and liver 
tissue was excised and immediately snap-frozen in liquid nitrogen. Subsequently, the frozen 
tissue was stored in the -80°C freezer until use.  
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Figure 7-1. Schematic outline of experimental procedures and timeline. Arterial and jugular catheterization was 
performed for the sampling and infusion protocols of the ethyl palmitate (EP) infusion. Studies were performed seven days 
after catheterization surgeries to assess the effect of EP infusion on the liver. The first pilot study was a simple prime-
continuous infusion of EP (A). The second pilot study was performed with a euglycemic clamp to control blood glucose 
levels requiring the infusion of somatostatin (SRIF), glucagon and insulin in addition to medium (37.5 μmol/kg/min) or high 
(75 μmol/kg/min) rates of continuous EP infusion (B). The third pilot study used no clamp and infused EP 5h per day over 
three contiguous days (C).  
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Histology and lipid analysis 
Formalin-preserved liver tissue samples were embedded in paraffin and sectioned (5 μm thick). 
Deparaffinized, hydrated serial liver tissue sections were stained with hematoxylin-eosin (H&E) 
using standardized protocols from the Vanderbilt University Medical Center Department of 
Pathology. Animal pathologist Dr. Kelli Boyd analyzed H&E stained tissue sections for steatosis 
and markers of NASH, taking digital images with a microscope.  
Fatty acyl lipid analysis was performed on snap frozen liver tissue by the Vanderbilt Hormone 
Assay and Analytical Services Core using thin-layer chromatography (TLC) and gas 
chromatography-flame ionization detection (GC-FID) techniques. Briefly, lipids were extracted 
from snap frozen tissue by homogenizing the sample and using a modified Folch separation. An 
internal standard (1,2-dipentadecanoyl-sn-glycero-3-phosphocholine) for phospholipids was 
added to the lipid-containing chloroform phase. Total lipids were then extracted and separated by 
TLC using petroleum ether/ethyl ether/acetic acid (80/20/1, v/v/v) on silica plates. Spots 
corresponding to PLs, TAGs, and FFAs were visualized with rhodamine 6G in 95% ethanol and 
scraped individually into glass tubes for transmethylation. Transmethylation was performed 
using a boron trifluoride-methanol 10% (w/w) solution. Derivatized lipids were then analyzed 
using a GC-FID, where standardized calibration curves were used to analyze fatty acid content. 
TEM 
After catheterizing the animal and tying off and removing one large lobe, the liver was perfused 
with a 2.5% glutaraldehyde fixative solution in 0.1 M sodium cacodylate. After perfusing for 10 
minutes, the fixed organ was removed and tissue samples of approximately 2mm x 2mm were 
sectioned off and placed back into a tube containing 2.5% glutaraldehyde fixative solution in 0.1 
M sodium cacodylate buffer for 1 h at room temperature followed by 23 h at 4°C. Samples were 
postfixed in 1.25% osmium tetroxide and subsequently stained with 2% aqueous uranyl acetate. 
Embedded cells were then thin-sectioned and viewed on a Philips/FEI T-12 high-resolution 
transmission electron microscope.  
Glucose, insulin and NEFA analysis 
Plasma NEFA concentrations (NEFA C kit; Wako Chemicals, Richmond, VA) and glucose were 
determined spectrophotometrically as previously described (12). Insulin levels were determined 
though a double antibody method (13).  
 
Results 
Physiological changes in the liver were limited in rats fed high saturated fat “Western diet” over 
the course of 12 weeks.  
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Animals maintained on a high saturated fat, “Western” fast-food (FF) diet continued to gain 
weight over the time course of 12 weeks, with no indication of plateauing (Fig. 2A). Serum 
alanine aminotransferase (ALT), aspartate aminotransferase (AST), cholesterol and triglycerides 
were highly variable across different animals and only showed a slight trend toward increased 
cholesterol and triglyceride levels after 1012 weeks of FF diet feeding (Fig. 7-2).  
 
 
Figure 7-2. Change in weight and plasma biochemical markers over the 12-week time course. All 
animals on FF diet gained weight over 12 weeks. Measurements of triglycerides, cholesterol, AST and 
ALT were variable between rats, though it appeared that cholesterol and triglycerides increased at the end 
of the study while there was no clear pattern with AST and ALT. Alanine aminotransferase (ALT); 
Aspartate aminotransferase (AST). N=1 at each time point. 
 
FF diet fed rats exhibit indicators of increased liver damage and ER stress but no significant 
changes in phospholipid composition or NASH markers 
Although serum AST and ALT are used as clinical biomarkers for assessing liver damage, recent 
studies have found that neither is an accurate independent predictor of NASH in humans (14, 
15). Therefore, we sought to examine liver tissue samples collected from FF diet fed rats for 
markers of NASH and liver injury. Hematoxylin-eosin stained sections of liver tissue were 
examined for changes in liver morphology by a pathologist. Over the 12-week timeline, there 
was increased lipid droplet accumulation (steatosis) in the hepatic tissue, though largely 
microvesicular in nature (Fig. 7-3). At week 12 (rat #6) there was evidence of inflammatory 
and/or immune cell infiltration in portal areas (Fig. 7-3G, H) which may indicate early signs of 
increased liver damage. Masson’s trichome stains of the liver tissue (data not shown) did not 
show any indications of fibrosis associated with progressive NASH.  
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Figure 7-3. Hematoxylin-eosin (H&E) stained sections of liver tissue from FF diet fed rats. Increased 
lipid deposition was evident in H&E stained liver sections collected over the course of the experiment. 
There were no distinct markers of a NASH-like phenotype, but the Week 12 rat (#6) demonstrated 
various degrees of tissue injury ranging from mild (“Least”) to sites of more acute indicators of disease 
(“Most”) that had some did have some evidence of increased immune cell infiltration. N=1 at each time 
point. 
 
Transmission electron microscope (TEM) images of stained liver samples show changes in 
hepatic morphology after long-term FF diet feeding. After 12 weeks, hepatoctyes contained lipid 
droplets that were both more abundant and larger in size compared those from animals on the 
diet for only 2 weeks (Fig. 7-4 A vs. E). In Fig. 7-4, arrowheads point toward the ER membrane 
and, after 12 weeks on the FF diet, it can be observed that ER cisternae show increased dilation 
and distention, an indicator of ER stress (4, 6).  
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Figure 7-4. TEM images of rats on FF diet at week 2 versus week 12 showed increased triglyceride accumulation, indicators of ER membrane 
distention, and infiltration of immune cells. Cellular morphology in rat #1, wk 2 (A-D) and rat #6, wk12 (E-H) was observed by high-resolution imaging with 
transmission electron microscopy demonstrating increased triglyceride accumulation and ER dilation after longer duration on the diet (E-H). Immune cells were 
found in samples from rat #6, wk12 (G) but not in rat #1, wk2. Arrowheads point towards ER membrane. LD, lipid droplets. 
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ER stress in environments of high saturated fat, as shown here, has been previously linked to 
changes in phospholipid composition (4, 6, 16). However, there did not appear to be any clear 
trend in changes in phospholipid abundance (Fig. 7-5A) or composition (Table 7-1) over the 
course of the feeding study. Diacylglycerides and triacylglycerides exhibited trends of increasing 
accumulation for animals on the FF diet for longer periods of time (Fig. 7-5B and C), but again, 
there were no clear compositional changes in these lipid pools (Tables 7-2 and 7-3). Overall, the 
data from this study indicate that while there was progression in liver pathology over the 
duration of the feeding time course, there was no indication of NASH development or altered 
fatty acid composition in major lipid species. 
 
 
 
Figure 7-5. Rats on FF diet demonstrated a trend toward increased overall and saturated 
diacylglycerol and triglyceride accumulation, without changes in phospholipid levels. Absolute 
amounts of overall and saturated phospholipids (A), diacylglycerides (B) and triacylglycerides (C) were 
determined by thin layer chromatography (TLC) separation of lipid classes and analysis by gas 
chromatography flame ionization detection (GC-FID). N=1 at each time point. 
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Fatty 
Acid 
Rat#1, 
wk2 
  
Rat#2, 
wk4 
  
Rat#3, 
wk6 
  
Rat#4, 
wk8 
  
Rat#5, 
wk10 
  
Rat#6, 
wk12 
  
 
14:0 0.34 
 
0.41 
 
0.39 
 
0.42 
 
0.52 
 
0.43 
 
 
16:0 18.02 
 
17.52 
 
17.40 
 
16.57 
 
16.74 
 
15.67 
 
 
16:1 0.91 
 
1.22 
 
1.05 
 
1.48 
 
2.63 
 
1.83 
 
 
18:0 20.28 
 
18.86 
 
19.80 
 
20.30 
 
16.81 
 
19.36 
 
 
18:1w9 8.13 
 
9.51 
 
8.20 
 
8.73 
 
10.01 
 
9.20 
 
 
18:1w7 2.90 
 
4.47 
 
2.87 
 
2.93 
 
3.89 
 
3.15 
 
 
18:2 12.58 
 
11.58 
 
12.96 
 
13.68 
 
13.23 
 
11.18 
 
 
20:3w6 2.19 
 
2.85 
 
3.49 
 
3.98 
 
3.15 
 
3.20 
 
 
20:4 24.45 
 
24.80 
 
25.60 
 
24.55 
 
24.01 
 
26.80 
 
 
20:5 0.47 
 
0.44 
 
0.44 
 
0.60 
 
0.68 
 
0.55 
 
 
22:4w6 0.33 
 
0.35 
 
0.35 
 
0.32 
 
0.33 
 
0.35 
 
 
22:5w3 0.90 
 
0.62 
 
0.97 
 
0.81 
 
0.83 
 
0.73 
 
 
22:6 8.48 
 
7.36 
 
6.50 
 
5.64 
 
7.19 
 
7.54 
                             
 
% SFA 38.64 
 
36.79 
 
37.58 
 
37.29 
 
34.06 
 
35.46 
 
 
% UFA 61.36 
 
63.21 
 
62.42 
 
62.71 
 
65.94 
 
64.54 
  
Table 7-1. Phospholipid composition of liver tissue samples collected from individual rats at 
indicated time points. There were no observable changes in phospholipid composition over the course of 
the 12-week feeding study. Phospholipids were separated by thin layer chromatography and analyzed by 
gas chromatography-flame ionization detection (GC-FID). Data represent mean fatty acid %. N=1 at each 
time point. SFA, saturated fatty acids; UFA, unsaturated fatty acids.  
 
  
Fatty 
Acid 
Rat#1, 
wk2 
  
Rat#2, 
wk4 
  
Rat#3, 
wk6 
  
Rat#4, 
wk8 
  
Rat#5, 
wk10 
  
Rat#6, 
wk12 
  
 
16:0 39.32 
 
39.25 
 
42.03 
 
43.67 
 
38.43 
 
39.53 
 
 
18:0 30.41 
 
31.58 
 
20.84 
 
26.57 
 
27.93 
 
15.03 
 
 
18:1w9 16.90 
 
25.65 
 
29.83 
 
25.44 
 
28.04 
 
32.01 
 
 
18:1w7 0.00 
 
3.52 
 
3.64 
 
4.32 
 
5.60 
 
5.24 
 
 
18:2 5.68 
 
0.00 
 
3.66 
 
0.00 
 
0.00 
 
4.71 
 
 
20:4 7.69 
 
0.00 
 
0.00 
 
0.00 
 
0.00 
 
0.00 
                             
 
% SFA 69.73 
 
70.82 
 
62.86 
 
70.24 
 
66.36 
 
54.56 
 
 
% UFA 30.27 
 
29.18 
 
37.14 
 
29.76 
 
33.64 
 
45.44 
  
Table 7-2. Diacylglycerol composition of liver tissue samples collected from individual rats at 
indicated time points. There was no clear pattern in changes in diacylglycerol composition over the 
course of the 12-week feeding study. Diacylglycerides were separated by thin layer chromatography and 
analyzed by gas chromatography-flame ionization detection (GC-FID). Data represent mean fatty acid %. 
N=1 at each time point. SFA, saturated fatty acids; UFA, unsaturated fatty acids.  
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Fatty 
Acid 
Rat#1, 
wk2 
  
Rat#2, 
wk4 
  
Rat#3, 
wk6 
  
Rat#4, 
wk8 
  
Rat#5, 
wk10 
  
Rat#6, 
wk12 
  
 
14:0 3.21 
 
4.23 
 
4.11 
 
4.70 
 
3.64 
 
3.68 
 
 
16:0 31.93 
 
31.23 
 
30.11 
 
33.70 
 
31.64 
 
32.10 
 
 
16:1 4.21 
 
6.00 
 
4.59 
 
8.33 
 
8.89 
 
7.18 
 
 
18:0 2.15 
 
1.99 
 
1.56 
 
1.51 
 
1.63 
 
1.77 
 
 
18:1w9 44.41 
 
44.74 
 
46.10 
 
39.63 
 
43.52 
 
44.44 
 
 
18:1w7 4.81 
 
5.92 
 
3.92 
 
4.91 
 
5.02 
 
4.26 
 
 
18:2 8.48 
 
5.90 
 
7.85 
 
6.11 
 
5.17 
 
5.55 
 
 
18:3w6 0.00 
 
0.00 
 
0.12 
 
0.00 
 
0.00 
 
0.10 
 
 
18:3 w3 0.36 
 
0.00 
 
0.35 
 
0.30 
 
0.22 
 
0.22 
 
 
20:3w6 0.00 
 
0.00 
 
0.22 
 
0.18 
 
0.00 
 
0.13 
 
 
20:4 0.45 
 
0.00 
 
0.32 
 
0.24 
 
0.15 
 
0.23 
 
 
22:4w6 0.00 
 
0.00 
 
0.16 
 
0.00 
 
0.00 
 
0.11 
 
 
22:5w3 0.00 
 
0.00 
 
0.21 
 
0.14 
 
0.00 
 
0.00 
 
 
22:6 0.00 
 
0.00 
 
0.37 
 
0.25 
 
0.13 
 
0.22 
                      
 
% SFA 37.28 
 
37.44 
 
35.78 
 
39.91 
 
36.90 
 
37.55 
 
 
% UFA 62.72 
 
62.56 
 
64.22 
 
60.09 
 
63.10 
 
62.45 
  
Table 7-3. Triglyceride composition of liver tissue samples collected from individual rats at 
indicated time points. There was no clear pattern in changes in triglyceride composition over the course 
of the 12 week feeding study. Triglycerides were separated by thin layer chromatography and analyzed by 
gas chromatography-flame ionization detection (GC-FID). Data represent mean fatty acid %. N=1 at each 
time point. SFA, saturated fatty acids; UFA, unsaturated fatty acids. 
 
 
Pilot studies using a direct infusion of ethyl palmitate into mouse circulation yields promising 
initial results 
Since FF diet feeding requires a great length of time to recapitulate a NASH-like liver phenotype 
(8) and we were unable to achieve similar results in our rat study, we chose to investigate other 
methods of inducing lipotoxicity in vivo. Prior work by Eguchi et al. led us to experiment with 
direct infusion of ethyl palmitate into the systemic circulation of mice. These experiments were 
performed in collaboration with the Vanderbilt MMPC. 
In the first pilot experiment, ethyl palmitate (EP) was infused for 7 h at a relatively low rate (7 
μmol/kg/min) and compared to mice receiving a saline infusion as a control. EP mice 
demonstrated reduced blood glucose levels over the duration of the infusion (Fig. 7-6A), 
coincident with an approximate doubling of both plasma insulin and NEFA levels (Fig. 7-6B and 
C, respectively).  
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Figure 7-6. Mice infused for 7 h with ethyl palmitate (EP) in the first infusion pilot study. Mice 
receiving EP infusion had reduced blood glucose levels (A), but increased plasma insulin (B) and NEFA 
levels (C) compared to those with vehicle (saline) control infusions measured at 7h. N=1-2 at each time 
point.  
 
In the second pilot experiment, we examined whether high rates of EP infusion would result in 
acute changes to lipid composition similar to those observed in our in vitro experiments with 
palmitate-treated hepatocytes. Due to the reduced blood glucose and increased insulin levels in 
response to EP observed in the first pilot study, we used a euglycemic clamp with infusion of 
somatostatin, glucagon, insulin, and glucose to control these variables at basal levels.  EP was 
infused at two rates (37.5 μmol/kg/min and 75 μmol/kg/min) for 5 hours. Euglycemia (~120 
mg/dL) was better maintained than in the first pilot study (data not shown). However, the insulin 
levels still increased sharply in a dose-dependent manner (Fig. 7-7A). There was no detectable 
difference in plasma NEFA levels (Fig. 7-7B). Despite the lack of change in NEFAs, there were 
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detectable differences in the fatty acid composition of both the phospholipid and triglyceride 
pools in the liver tissue of these mice (Table 7-4 and 7-5, respectively). EP infusion resulted in 
increased palmitate incorporation and overall saturation of phospholipids compared to saline-
infused control mice. There also were slightly elevated amounts of phospholipids in those mice 
receiving a high EP infusion rate (~30.5 μg/mg tissue for the 75 μmol/kg/min EP infusion vs. 
~27 μg/mg tissue in control infusions). These data are similar to the results we have obtained 
from in vitro models of palmitate lipotoxicity (4). Additionally, there was increased triglyceride 
accumulation in EP-infused mice, which was primarily composed of saturated palmitate moieties 
(~64% and 38% saturated in 75 and 37 μmol/kg/min EP infusions, respectively) in contrast to 
control mice  (~27% saturated for both infusion rates). This is also reflective of the increased 
lipid accumulation that is usually present in steatotic and NASH livers (1). 
  
 
Figure 7-7. Mice were infused with EP for 5 h under a euglycemic clamp in the second pilot study. 
The euglycemic clamp was started by infusing somatostatin, glucagon, insulin and glucose 1 h prior to 
initiation of EP infusion. EP was infused at medium (37.5 μmol/kg/min) and high (75 μmol/kg/min) rates 
for 5 h while maintaining euglycermia. Mice receiving EP infusion had substantial increases in plasma 
insulin (A) but no changes in NEFA levels (B) compared to ethanol-emulsion (EtOH) vehicle controls. 
N=2-3. 
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  Fatty Acid 75 umol PA   75 umol Crtl   37.5 umol PA   37.5 umol Crtl   
 
16:0 28.77 ± 0.22 
 
23.06 
 
26.33 ± 0.32 
 
21.25 
 
 
16:1 0.86 ± 0.06 
 
0.59 
 
0.85 ± 0.08 
 
0.64 
 
 
18:0 16.39 ± 0.87 
 
17.05 
 
15.22 ± 0.12 
 
18.21 
 
 
18:1w9 8.65 ± 0.46 
 
8.86 
 
8.38 ± 0.04 
 
7.44 
 
 
18:1w7 1.21 ± 0.04 
 
1.41 
 
1.49 ± 0.00 
 
1.61 
 
 
18:2 15.12 ± 0.13 
 
16.24 
 
15.49 ± 0.11 
 
16.07 
 
 
20:3w6 1.25 ± 0.01 
 
1.28 
 
1.34 ± 0.09 
 
1.27 
 
 
20:4 13.11 ± 0.00 
 
13.93 
 
13.34 ± 0.41 
 
16.17 
 
 
20:5 0.75 ± 0.21 
 
0.96 
 
0.78 ± 0.03 
 
0.95 
 
 
22:5w3 0.91 ± 0.00 
 
0.84 
 
0.91 ± 0.11 
 
0.84 
 
 
22:6 12.98 ± 0.59 
 
15.78 
 
15.87 ± 0.88 
 
15.56 
 
                            
 
% SFA 45.16 ± 0.90 
 
40.11 
 
41.55 ± 0.34 
 
39.46 
 
 
% UFA 54.84 ± 0.79 
 
59.89 
 
58.45 ± 0.99 
 
60.54 
 
              
  μg PL/mg tissue 30.53 ± 0.19   27.05   28.77 ± 1.35   28.91   
 
μg SFA PL/mg 
tissue 
13.79 ± 0.42  10.85  11.96 ± 0.69  11.41 
  
Table 7-4. Phospholipid composition of liver tissue samples collected from mice receiving EP 
infusion for 5h in the second pilot study. Infusion of EP resulted in increases in both palmitate 
incorporation and overall phospholipid saturation compared to controls (Crtl). Phospholipids were 
separated by thin layer chromatography and analyzed by gas chromatography-flame ionization detection 
(GC-FID). Data represent mean fatty acid %. N=1-2. SFA, saturated fatty acids; UFA, unsaturated fatty 
acids.  
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  Fatty Acid 75 umol PA   75 umol Crtl   37.5 umol PA   37.5 umol Crtl   
 
14:0 0.78 ± 0.17 
 
1.51 
 
0.51 ± 0.08 
 
0.47 
 
 
16:0 59.33 ± 5.95 
 
22.12 
 
34.64 ± 5.43 
 
24.69 
 
 
16:1 2.32 ± 0.41 
 
1.32 
 
2.98 ± 0.48 
 
2.20 
 
 
18:0 3.77 ± 0.12 
 
3.15 
 
2.78 ± 0.41 
 
2.11 
 
 
18:1w9 15.13 ± 2.52 
 
33.51 
 
27.82 ± 2.16 
 
30.24 
 
 
18:1w7 1.44 ± 0.26 
 
2.49 
 
2.63 ± 0.16 
 
2.16 
 
 
18:2 10.59 ± 1.68 
 
24.90 
 
17.87 ± 2.90 
 
25.32 
 
 
20:3w6 0.35 ± 0.03 
   
0.57 ± 0.10 
 
1.23 
 
 
20:4 0.51 ± 0.17 
   
0.89 ± 0.06 
 
0.56 
 
 
20:5  1.73 ± 0.45 
 
1.91 
 
2.02 ± 0.27 
 
1.71 
 
 
22:4w6 0.29 ± 0.00 
   
0.42 ± 0.09 
 
1.27 
 
 
22:5w6 0.23 ± 0.23 
   
0.64 ± 0.06 
 
0.42 
 
 
22:5w3 0.76 ± 0.15 
 
1.73 
 
1.54 ± 0.20 
 
1.49 
 
 
22:6 2.77 ± 0.35 
 
7.37 
 
4.52 ± 0.57 
 
6.14 
                             
 
% SFA 63.88 ± 5.95 
 
26.78 
 
37.94 ± 5.45 
 
27.26 
 
 
% UFA 36.12 ± 3.13 
 
73.22 
 
62.06 ± 3.71 
 
72.74 
 
                μg TG/mg tissue 14.54 ± 0.69   3.32   10.70 ± 0.51   8.87   
 
μg SFA TG/mg 
tissue 
9.33 ± 1.35  0.89  4.03 ± 0.72  2.42 
  
Table 7-5. Triglyceride composition of liver tissue samples collected from mice receiving EP 
infusion for 5h in the second pilot study. Infusion of EP resulted in increases in both palmitate 
incorporation and overall saturation in triglycerides compared to controls (Crtl). Triglycerides were 
separated by thin layer chromatography and analyzed by gas chromatography-flame ionization detection 
(GC-FID). Data represent mean fatty acid %. N=1-2. SFA, saturated fatty acids; UFA, unsaturated fatty 
acids.  
 
The third pilot experiment sought to determine the effect of acute administration of EP infused 
over multiple days (Fig 7-1C). In this study, we infused mice at a rate of 37.5 μmol/kg/min EP 
for 5 hours per day for 3 consecutive days to simulate repeated acute exposure to high levels of 
saturated fatty acids. We used an ethanol (EtOH)-emulsion (no palmitate) as a control in this 
experiment to correct for any confounding effects that might be due to ethanol present in the EP 
infusion. Blood glucose on the third day of the experiment remained very similar for the duration 
of the last infusion despite no addition of somatostatin, glucagon, insulin or exogenous glucose 
(Fig. 7-8A). Surprisingly, there was again no change in plasma NEFA levels (Fig. 7-8B). Lipid 
analysis revealed changes in phospholipid composition, specifically increases in palmitate 
incorporation (~24.5% vs. 18%) and overall saturation (~42.5% vs. 37.5%) in EP mice compared 
139 
 
to EtOH-infused controls (Table 7-6). There were also similar changes in triglyceride 
composition (~32.5% vs ~17.3 % for percentage of PA and 37% vs 21% for overall saturation in 
EP vs. control mice, Table 7-7). The EtOH-emulsion infused mouse had similar levels of 
triglyceride accumulation as that receiving the EP lipid infusion, but this is not altogether 
unexpected as alcohol is known to have a pro-lipogenic effect (17).   
 
 
Figure 7-8. Mice infused for 5 h on 3 consecutive days with EP in the third pilot study. 
Measurements were taken the third day of the infusion study, and both EP-infused and control mice had 
similar blood glucose curves (A) and NEFA levels (B). N=1-2.  
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  Fatty Acid 37.5 umol PA   EtOH Crtl   
 
16:0 24.65 
 
18.13 
 
 
16:1 
  
0.95 
 
 
18:0 17.80 
 
19.33 
 
 
18:1w9 7.00 
 
10.62 
 
 
18:1w7 1.18 
 
1.97 
 
 
18:2 13.98 
 
13.98 
 
 
20:3w6 1.38 
 
2.00 
 
 
20:4 14.91 
 
16.67 
 
 
20:5 0.77 
 
0.99 
 
 
22:5w3 0.67 
 
0.70 
 
 
22:6 17.65 
 
14.66 
 
 
% SFA 42.46 
 
37.46 
 
 
% UFA 57.54 
 
62.54 
 
      
  μg PL/mg tissue 30.77   33.77   
 
μg SFA PL/mg 
tissue 13.06 
 
12.65 
  
Table 7-6. Phospholipid composition of liver tissue samples collected from mice receiving EP 
infusion for 5h on 3 consecutive days in the third pilot study. Infusion of EP resulted in increases in 
both palmitate incorporation and overall saturation in phospholipids compared to controls. Phospholipids 
were separated by thin layer chromatography and analyzed by gas chromatography-flame ionization 
detection (GC-FID). Data represent mean fatty acid %. N=1. SFA, saturated fatty acids; UFA, unsaturated 
fatty acids.  
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  Fatty Acid 37.5 umol PA   EtOH Crtl   
 
14:0 1.48 
 
1.08 
 
 
16:0 32.53 
 
17.28 
 
 
16:1 1.08 
 
2.90 
 
 
18:0 2.94 
 
2.71 
 
 
18:1w9 30.50 
 
46.70 
 
 
18:1w7 2.10 
 
3.47 
 
 
18:2 18.90 
 
16.27 
 
 
18:3 w3 
  
0.84 
 
 
20:3w6 0.69 
 
0.87 
 
 
20:4 1.38 
 
1.40 
 
 
22:4w6 
  
0.63 
 
 
22:5w3 1.39 
 
1.15 
 
 
22:6 7.02 
 
4.70 
 
 
% SFA 36.94 
 
21.08 
 
 
% UFA 63.06 
 
78.92 
 
      
  μg TG/mg tissue 10.40   11.27   
 
μg sat TG/mg 
tissue 3.84 
 
2.38 
  
Table 7-7. Triglyceride composition of liver tissue samples collected from mice receiving EP 
infusion for 5h on 3 consecutive days in the third pilot study. Infusion of EP resulted in increases in 
both palmitate incorporation and overall saturation in triglycerides compared to controls. There was no 
change in total amount of accumulated triglycerides most likely because ethanol (in EtOH emulsion 
control) is known to have a stimulatory effect on lipid synthesis in the liver. Triglycerides were separated 
by thin layer chromatography and analyzed by gas chromatography-flame ionization detection (GC-FID). 
Data represent mean fatty acid %. N=1. SFA, saturated fatty acids; UFA, unsaturated fatty acids.  
 
Discussion  
Wang et al. demonstrated that rats on a high SFA diet demonstrated increased liver injury and 
markers of endoplasmic reticulum (ER) stress, independently of obesity or changes in TNFα, 
insulin sensitivity and mitochondrial function, compared to rats on otherwise similar diets that 
were instead high in polyunsaturated fats, sucrose or starch (5). The “cafeteria diet” rat model 
went a step further to mimic human diet-induced obesity: male Wistar rats were fed a diet that 
consisted of food regularly consumed by humans in Western society including high-salt, high-
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fat, low fiber, energy-dense foods such cookies, chips and processed meats (7). The livers of 
these animals were characterized by significant increases in inflammation, macrophage 
infiltration and overall clinical markers of steatohepatitis after 16 weeks, features that were 
notably absent in animals fed low fat, high fat or standard chow diets (7). Similarly, the “fast 
food” (FF) mouse model was fed a diet based on the composition of typical Western fast food: 
high in saturated fat, cholesterol and fructose. FF mice were compared to mice fed standard 
chow or the widely used high fat (HF) diet consisting mainly of unsaturated fats (8). Although 
HF mice developed obesity, insulin resistance and simple hepatic steatosis after six months, they 
did not develop the pronounced features of progressive NASH, such as hepatocyte ballooning, 
fibrosis, inflammation and endoplasmic reticulum stress, observed in the FF mice (8). The 
inclusion of high levels of saturated fat in rodent diets appears to trigger dysfunctional hepatic 
metabolism leading to an inflamed NASH-like state.  
Overall, our results point toward high levels of hepatic steatosis and increasing inflammation and 
ER stress in FF diet fed rats. These animals demonstrated gradually increasing weight and a 
trend toward increased circulating levels of plasma triglycerides and cholesterol (Fig. 7-2). The 
limited data set produced only very small changes in levels of AST and ALT, two liver enzymes 
that have traditionally been used as surrogates to indicate liver injury. H&E histological stains of 
fixed liver tissue from these rodents demonstrated increased microvesicular steatosis and 
infiltration of inflammatory cells in certain aspects of the tissue section (Fig. 7-3). However, 
even at the last time point (12 weeks), histological markers of NASH were absenct. Additional 
staining with Masson’s trichome did not reveal any indicators of fibrosis, a metric often used to 
gauge more progressive forms of NASH.  
TEM imaging exposed wide swaths of large lipid droplet depositions that increased in density 
over the course of the study (Fig. 7-4). This was accompanied by indications of ER dilation and 
dissention, markers of ER stress that have been prominent in our studies with PA-treated hepatic 
cells (4), although chonic ER stress has also been linked to overnutrition in obesity (18).  
Additionally, we were able to identify small immune cell populations (Fig. 7-4G), which 
suggests progression from simple steatosis towards a more inflammatory, NASH-like state.  
Overall, however, the diet and timeline (12 weeks) was inadequate to promote a pathology with 
similarities to human NASH, so either the FF diet was not fed for a sufficient time to impart this 
effect or it did not have the same deleterious effects in rats as it did in the previous mouse studies 
by Charlton et al. that were conducted over a six month time course (8).  
In order to develop a more rapid method for inducing a NASH-like phenotype in rodent models, 
we examined several direct lipid infusion protocols. After investigating the effects of high 
saturated fat diets in the past, Nivala et al. (9) recently examined the effects of intravenous lipid 
infusions in rats. They compared infusions of lard (enriched in saturated fats) and soybean oil 
(enriched in unsaturated fats) by measuring their effects on ER stress and inflammation in the 
liver and adipose tissue (9). Both lipid infusions increased plasma free fatty acid levels, but the 
lard treatment increased SFA concentrations including palmitate (16:0) by over two-fold and 
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stearate (18:0) by four-fold compared to control and soybean oil treatments. After only four 
hours of infusion, livers of the lard-infused animals were already showing significantly elevated 
markers of ER stress, including phosphorylated PERK, spliced-XBP1 and CHOP, as well as 
markers of inflammation, including Interleukin-1β (IL-1B), macrophage inflammatory protein-
1α (MIP-1a) and TNFα. We expected to achieve similar results by direct infusion of palmitate in 
order to recapitulate the effects observed to our previous in vitro studies.  
Typical lipid infusates are emulsified triglycerides that contain a mixture of fatty acid residues 
(10). Additionally, they are often infused with the anticoagulant herapin, which serves to activate 
lipoprotein lipases in order to release the free fatty acids from the infused triglycerides but can 
have the same effect on endogenous triglycerides and lipoproteins in circulation (19). These two 
issues are significant confounding factors that complicate the interpretation of prior studies.  In 
contrast, infusion of unesterified fatty acids can be technically challenging due poor plasma 
solubility. Furthermore, protein overload and elevated oncotic pressure can result when fatty 
acids are complexed to albumin. Recently, Eguchi et al. performed an infusion of ethyl palmitate 
to study its effects on β-cell dysfunction.  Ethyl palmitate is a 1:1 mixture of palmitate esterified 
to ethanol that is easily solubilized, emulsified and administered intravenously (10) and is rapidly 
hydrolyzed to free palmitate in the blood (20). Our lipid infusion procedures were based on this 
work.  
The first pilot study pointed towards increased plasma NEFA levels in EP infused mice, which 
we postulated would recapitulate the palmitate-mediated lipotoxicity observed in our in vitro 
experiments (Fig. 7-6). Following this experiment, we decided to increase the EP infusion to 
both a moderate (37.5 μmol/kg/min) and high (75 μmol/kg/min) rate and to apply a euglycemic 
clamp to prevent the depressed blood glucose levels observed in the first pilot study (Fig. 7-6A). 
Interestingly, this resulted in almost 5- and 10-fold changes in plasma insulin levels but no 
change in NEFA concentrations despite the use of somatostatin, glucagon and a defined rate of 
insulin in the clamp (Fig. 7-7). Somatostatin is often used in animal research to prevent insulin 
secretion from the pancreas. In speculation, the EP infusion may pose a significant physiological 
stressor that counteracts the effects of somatostatin. Another possibility is that the insulin was 
ineffectively cleared from circulation as fatty acids have been reported to cause impaired insulin 
clearance (21). Insulin’s precursor is cleaved into insulin and c-peptide.  Future measurements of 
c-peptide could point toward whether increased secretion (higher levels of c-peptide) or reduced 
clearance (similar levels of c-peptide between EP infusion and control) is contributing to the 
elevated insulin levels. Nevertheless, the substantial increase in insulin is a likely explanation for 
the lack of change in NEFA levels, since insulin is a strong stimulator of fatty acid uptake by the 
liver and other insulin-responsive tissues (22). 
Despite the fact that there was no change in plasma NEFA levels in either the 5-hour infusion 
(pilot 2) or 5 hours on 3 contiguous days (pilot 3), there were still interesting changes in the 
phospholipid composition of EP infused mice compared to controls (Table 7-5 and 7-7). There 
was evidence of increased palmitate incorporation into lipids and increased saturation of both 
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phospholipids and triglycerides. Further study is needed to assess whether these changes in lipid 
compositoin correlate to increased ER stress levels characteristic of in vitro models of palmitate 
lipotoxicity (4, 23, 24), as well as physiologically relevant indicators of metabolic syndrome (18, 
25). 
Overall, our initial results show that we can effectively modulate fatty acid composition of the in 
vivo liver using ethyl palmitate infusions. Transitioning our work from a purely in vitro model 
into more physiological relevant in vivo models is an important step in demonstrating the validity 
of our previous results and to test hypotheses generated from these studies. Further work is 
needed to verify these initial results and to understand the unexpected changes in insulin and 
NEFA levels that occursed in response to ethyl palmitate infusion. This will require a larger 
study size and may involve infusion of other fatty acids such as oleate that have not been shown 
to exert toxic effects in vitro.  
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CHAPTER 8  
CONCLUSIONS AND FUTURE WORK 
Conclusions 
Saturated fatty acids, such as palmitate (PA), have long been known to induce lipotoxicity in a 
variety of cell types, characterized by increased ER stress, ROS accumulation and subsequent 
cell death, while monounsaturated fatty acids, such as oleate (OA), have been shown to exert a 
protective effect when co-supplemented in PA-treated cells. The mechanism though which 
saturated fatty acids disrupt normal cellular metabolism and function has not been fully 
elucidated.  The purpose of this dissertation was to investigate the role that different pathways of 
lipid metabolism play in initiating, or preventing, the downstream cascade that culminates in 
hepatocellular lipoapoptosis.  
In Chapter 3, we investigated the hypothesis that dysregulated phospholipid metabolism and 
oversaturation of lipid bilayer membranes play a contributing role in the ER stress that is 
characteristic of PA-treated hepatic cells. Our results demonstrate that palmitate supplementation 
resulted in highly significant increases in PA incorporation and overall saturation in membrane 
phospholipids as well as indicators of increased phospholipid synthesis though the Kennedy 
pathway. This was correlated to elevated expression of markers of ER stress, such ER dilation 
and CHOP protein levels, and increases in apoptotic cell death. Addition of OA to PA-treated 
hepatic cells restored the saturation of phospholipids toward basal levels, which resulted in 
reduced ER stress and cell death. Cells co-treated with OA were also characterized by increased 
triglyceride (TG) synthesis, a pathway that has been postulated to detoxify palmitate and to be 
responsible for the protective effect exerted by OA in PA-treated cells.  
Our interest in the longstanding hypothesis that increased TG synthesis is the main mechanism of 
OA-mediated rescue led us to investigate the effect of inhibiting TG synthesis in Chapter 4. By 
knocking down the final step in the TG synthetic pathway (DGAT), we were able to significantly 
reduce TG accumulation in hepatic cells in response to all fatty acid combinations we tested. 
Most interestingly, despite severely impaired TG synthesis, OA supplementation in PA-treated 
cells still exerted a powerful rescue effect. Our results demonstrated that although the cells were 
inhibited in their ability to produce triglycerides, the phospholipid incorporation of PA and 
overall saturation were still restored back to basal levels. These results define a significant role of 
phospholipid metabolism and saturation in lipotoxicity, and shed doubt on the hypothesis that 
increased TG synthesis is the lone driving force responsible for OA’s protective effect on PA-
treated cells. 
The hypothesis that re-routing PA away from phospholipid incorporation and toward less toxic 
lipid pathways would reduce lipotoxicity was further explored in Chapter 5. We investigated the 
effect that modulations of β-oxidation would have in hepatic cells. Our data demonstrated that 
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increased PA disposal though fatty acid oxidation by stimulating β-oxidation via AICAR did 
result in reduced PA incorporation into phospholipids and reduced markers of lipotoxicity. In 
this chapter, we again demonstrated that methods designed to reduce PA incorporation in 
membrane phospholipids, and therefore limit oversaturation of the bilayer, were protective 
against PA-mediated lipotoxicity.  
Since dysregulated phospholipid metabolism and composition seems to play a significant role in 
PA-induced lipotoxicity, in Chapter 6 we sought to investigate direct methods for modulating PA 
incorporation into these species. We examined approaches for inhibiting PA incorporation by 
either knocking down the initial step of phosphatidylcholine synthesis or though 
pharmacological inhibition of phospholipid remodeling. Both methods demonstrated small, but 
significant, reductions in markers of PA lipotoxicity, though neither was fully protective. The 
limited efficacy was likely due to the inherit limitations when targeting only specific 
phospholipids, such as phosphatidylcholine, and only a particular pathway of phospholipid 
metabolism at a time. However, these results demonstrate that methods designed to target 
phospholipid metabolism show promise in reversing PA-mediated lipotoxicity and may play a 
role in preventing the progression of hepatic diseases such as NASH.  
We are currently designing and testing in vivo rodent models to recapitulate findings and 
mechanisms developed in our in vitro models. Thus far, our initial results show interesting trends 
that correlate to increased saturation of phospholipids in response to PA treatment like those 
demonstrated in this dissertation. We will continue to pursue this line of experimentation in the 
hopes of better understanding the role that saturated fatty acids and phospholipid metabolism 
play in a more physiologically relevant model of lipotoxicity. 
Overall, this dissertation provides further evidence to support the hypothesis that phospholipids 
play an integral part in the mechanisms of lipotoxicity. Our work is relevant in a field where 
other groups are exploring the role that phospholipid metabolism plays in disease (1-4). In our 
hepatic models, we saw that increasing saturation of membrane phospholipids though PA 
treatment was detrimental to cell survival, while interventions designed to prevent PA 
incorporation and phospholipid saturation provided beneficial effects. Oleate co-treatment 
rescued the lipotoxic phenotype, not simply though increased flux into triglycerides, but though 
its phospholipid desaturation effect. Although our experiments designed to more directly 
modulate PA incorporation into phospholipids demonstrated only modest success, this deserves 
further investigation as it may prove clinically relevant in disease states such as obesity (1) and 
NASH (5) where disordered phospholipids have been identified as a possible contributing factor. 
Interventions that modulate phospholipid saturation may relieve the characteristic ER stress and, 
therefore, downstream inflammation and cell death observed in these conditions. 
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Future work 
The majority of the work presented in this dissertation demonstrates correlative data, where a 
treatment results in changes in specific outputs. We link the outputs together by probable 
mechanisms but don’t have concrete evidence to fully define them. For example, our data shows 
significant changes in phospholipid composition in response to fatty acid treatment and we link 
this to changes in ER stress, a mechanism that has been demonstrated in other model systems. 
However, it would be more novel and interesting to develop a method to initiate direct and 
quantitative changes in ER phospholipid composition. Directly manipulating only ER 
phospholipid saturation levels and monitoring whether other markers associated with 
lipotoxicity, such as ER stress, Ca
2+
 efflux, ROS and cells death, also change as predicted would 
more definitely demonstrate the validity of our hypothetical mechanisms. We have performed 
some initial work in this area, as discussed in Chapter 6, but due to the modest changes imparted 
by these interventions, more approaches need to be investigated. Manipulating fatty acid 
reacylation enzymes in the Lands’ cycle that demonstrate substrate specificity based on 
saturation and/or chain length may prove to be a very interesting avenue of research. For 
example, prior work in this area has focused on LPCAT3, a reacylation enzyme more specific for 
mono- and polyunsaturated long chain fatty acid, and has shown that modulating its activity has 
effects on phospholipid saturation and other markers of lipotoxicity (2, 3). 
A large majority of this dissertation work was done in an immortalized rat hepatoma cell line 
(H4IIEC3), which has both its advantages and disadvantages. Immortalized cell lines are easier 
to work with and maintain in continuous culture so that many experiments can be completed in a 
timely fashion. They allow us to quickly optimize conditions, new treatments and assays without 
the large expense of both time and money that is incurred with freshly isolated primary 
hepatocytes. However, the disadvantages are also significant due to the fact that these cells are 
immortalized, cancer-derived, and grown in culture, and therefore may not recapitulate some 
important aspects of the in vivo hepatic physiology that we seek to understand. Some key 
experiments were done in primary hepatocytes as confirmation studies, but continued work in 
these and other model systems needs to be done to further solidify mechanisms that have been 
determined using H4IIEC3 cells.  
In addition to continuing work in primary cells, moving into in vivo systems such as the rat or 
mouse would be an important next step in translating our experiments and hypothesized 
mechanisms into a more realistic model of NASH. There is a variety of diet-induced and 
genetically manipulated models of rodent NAFLD/NASH (see Chapter 2), but determining the 
most appropriate one to study is not always simple. Our work in Chapter 7 demonstrates our 
lab’s first exploration into in vivo models of hepatic lipotoxicity. Although diet manipulation did 
not appear to be as successful for short-term experiments in wild-type animals, direct infusion of 
ethyl palmitate following the method of Eguchi et al. (6) has shown interesting preliminary 
results. Continuing to optimize and complete these studies will allow us to demonstrate the 
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validity of our in vitro results in an in vivo whole animal model, which represents a large step 
toward understanding human liver disease progression.  
Other possible avenues of work that would be of interest in future studies include investigating 
the role and significance of myelin bodies. These interesting features found only in PA-treated 
cells are associated with disordered phospholipid metabolism and the significance of their 
biogenesis in environments of SFA supplementation may provide clues as to the phenotype and 
mechanism of lipotoxicity. Investigating the role that other ER proteins, such as SERCA, play in 
modulating ER stress in both basal conditions and under SFA stress would also be a nice 
extension of this work. Finally, examining the effects of treatments that have been the subject of 
clinical trials, such as metformin and bile acid derivatives (see Chapter 2), in both the in vitro 
and in vivo context of SFA toxicity, would also propel the findings of this dissertation into a 
better clinical understanding of lipotoxicity and hepatic disease progression.   
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APPENDIX OF DETAILED PROTOCOLS  
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Propidium Iodide Viability Assay 
Purpose: 
To measure the nonviable population of H4IIEC3 cells in response to various treatments 
in 96 well plates. This protocol is specific for adherent cells. 
Mechanism 
Propidium iodide (PI) is an intercalating dye and will only bind to double stranded DNA 
longer than 4-5 base pairs.  Since PI cannot cross the cell membrane, it is useful when 
trying to discriminate dead from live cells in a population.   
Materials: 
● Propidium Iodide powder stock 
● HBSS buffer 
● Low glucose DMEM (Media w/out phenol red) 
● 96 well plate- opaque, clear bottom.  
Note:  for best results seed cells at least 48 hours prior to experiment. 2x10^4 cells/well  
Procedure: 
● Dye preparation- dissolve PI in HBSS to make a stock solution of 1 mg/mL (1.5 mM) 
● 1 hour prior to adding PI dye- add 70% ethanol solution to appropriate wells for a 
positive control.   
● Remove media from cells.   
● Do not wash, could result in losing dead cells. 
● Add 100 uL of Low glucose DMEM (or other media) that does not contain phenol red.  
This will react with the dye and result in measurement errors.   
● Add .333 uL of PI stock (5 uM final concentration)* 
○ *Alternatively make stock of 5 uM PI by adding 33.3 uL of PI stock to 10 mL of 
DMEM 
● Incubate for a minimum of 1 h.  
● Measure fluorescence 
○ Ex 535, Em 617  
○ For FL 600 use ex: 530, em: 645, bottom read, sensitivity: 100 
Ordering Information 
Invitrogen:  http://products.invitrogen.com/ivgn/product/P1304MP?ICID=search-product  
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Reactive Oxygen Species (ROS) Assay 
Purpose: 
To measure the levels of reactive oxygen species (ROS) in H4IIEC3 cells using H2DCFA 
in 96 well plates.   
 This protocol is specific for adherent cells. 
Materials: 
● H2DCFA (Invitrogen) 
● DMSO 
● HBSS buffer 
● 96 well plate- opaque, clear bottom. 
Procedure: 
● 30 minutes prior to adding H2DCFA dye- add Hydrogen Peroxide controls.  Normally 
we use .5-1 mM concentration (final).   
● To make H2DCFA stock solution- dissolve H2DCFA powder in DMSO to make 10 mM 
solution. 
● Dilute H2DCFA in HBSS to make 10 uM working solution.  H2DCFA is light sensitive 
and the tube should be wrapped in tin foil to prevent any degradation due to light.   
● Vortex for 30 seconds. 
● Remove media from cells.   
● Wash 2x with HBSS. 
● Add 100 uL of H2DCFA mixture to cells. 
● Incubate for 30-45 minutes.  
● To measure ROS- H2DCFA fluorescence, set excitation wavelength to 485 nm and 
emission wavelength to 530 nm.  Set sensitivity of reader to 150.  – specific FL-600 plate 
reader 
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Apo-ONE Caspase 3/7 Reagent Apoptosis Detection 
Purpose: 
To measure apoptosis in H4IIEC3 cells by detecting the activities of caspase-3 and -7. 
This protocol is specific for adherent cells. 
Mechanism 
The Apo-ONE kit is used to measure apoptosis in cells by measuring caspase activity.  
The kit contains a lysis buffer which permeabilizes the cell population to facilitate dye 
introduction to caspases 3/7.  When the nonfluorescent dye comes in contact with the 
caspases, quenching groups are removed from the dye and return it to its fluorescent 
rhodamine state.  This protocol should be used when it is necessary to confirm apoptosis 
and when cell metabolism differences due to different treatments prevents use of cell titer 
blue dye (resazurin). 
Materials: 
● Apo-ONE Caspase 3/7 Kit 
● 96 well plate (opaque, clear bottom) 
● Low Glucose DMEM 
Prior to experiment: 
● 48 hs before assay, seed 2x10^4 cells per well in a 96 well plate (black, clear bottom) 
Procedure: 
● Dye preparation-  add 100 uL Substrate into 9900 uL Buffer provided in the kit- good for 
24-48 hs.   
● 30 minutes prior to adding ApoONE Dye- add staurosporine positive controls.   
● Remove media from cells.   
● Wash 2x with HBSS 
● Add 100 uL of Low glucose DMEM (or other media) that does not contain phenol red.  
This will react with the dye and result in measurement errors.   
● Add 100 uL of Apo ONE stock. 
● Incubate for a minimum of 1 hours.  
● Wavelengths- excitation 499, emission 521 
○ For FL-600 plate reader 
○ Use 485 filter for excitation and 5 
○ Bottom Read 
○ Set Sensitivity to 125 
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JC-1 Analysis of Mitochondrial Potential 
Purpose: 
To identify mitochondrial impairments as a function of mitochondrial potential. This 
protocol is specific for adherent cells 
Mechanism: 
The JC-1 dye accumulates in mitochondria in monomeric (green) form.  The increase in 
mitochondrial potential causes the dye to form aggregates characterized by a shift from 
green to red fluorescence.  Therefore a ratio of red to green fluorescent emissions (using 
the same excitation) indicates the relative mitochondrial potential.  
Materials: 
 JC-1 Dye (Invitrogen T-3168) 
 96 well plate, black, clear bottom 
 Plate reader 
 Ethanol 
 Media 
Prior to experiment: 
 48 hs before assay, seed 2x10^4 cells per well in a 96 well plate (black, clear bottom) 
 Stock solution is 5 mg in 1 mL of ethanol ( 5mg/mL concentration) 
Dye loading:   
 Treatment final concentration is 10 ug/mL 
 Make secondary stock concentration of 110 ug/mL 
 Calculate total volume needed.  For a 96 well plate you will need 1950 uL – 2000 uL. 
 For 2000 uL add 44 uL of 5 mg/mL stock to 1956 uL DMEM in a small tube.   
 VORTEX VIGOROUSLY.  JC-1 is tough to dissolve.  Pre-warm media ahead of time. 
 Add 20 uL of 110 ug/ml of secondary stock directly on top of 200 uL media with 
treatments. 
 Incubate for 1 hour 
 Rinse 3 times with PBS 
 Add 100 uL DMEM back to wells 
 Excite dye at 485 nm and measure fluorescence at 530 nm (green) and 590 nm (red) 
Data Analysis: 
 Ratio Red/Green signals, increase in this ratio indicates higher relative mitochondrial 
potential.  
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Protocol for [3H]-Palmitate Beta oxidation Measurement (Shiota Lab) 
1. Plate cells on 6 well dishes 
a. ~5 x 10^4 cells/well 
b. 2-3 mL of media total 
c. Allow proliferation for 2 days until confluent 
2. Cell Incubation 
a. Total of 2mL/well of buffer (media+reagents) 
3. Incubate for 24 hours 
4. Label 2 tubes/sample (well) for later use 
5. Deprotenization 
a. Remove 1.5 mL of media separately from each well and place in appropriate tube 
b. Add 75 uL of 60% PCA 
i. Precipitates out protein from the media (i.e BSA).  
ii. This step removes ~99% of un-oxidized [3H]-PA from sample 
c. Shake and vortex thoroughly 
d. Allow samples to rest on ice for 2 hours (or overnight in 4C) 
e. Centrifuge @3000 RPM for 30 mins 
6. Wash out each well with ice cold PBS x5 for protein analysis  
i. Need to remove any remaining BSA because this causes problems with 
protein analysis 
ii. Can put in freezer like this for later use 
7. Neutralization 
a. Remove 1.2 mL of deproteinized buffer from step 6  
i. DO NOT GET ANY OF PRECIPITATE at the bottom. This is unwanted 
protein! 
b. Add 5 uL of S160 Universal pH indicator dye 
c. Add ~40 uL of 5M K2CO3 to each sample 
i. Want dye color in sample to turn from red (acidic) to green (neutral) 
ii. Used 36 uL/sample 9/11/12 
d. Allow neutralized samples to sit in 4C overnight  
i. Make sure they are still green in the morning 
e. Centrifuge @3000 RPM for 30 mins 
8. Make Separation Columns 
a. Supplies: 
i. 2mL glass pipette for each sample 
ii. Glass wool 
iii. AG 1-X8 Resin (Bio-Rad 140-1441) 
b. Pack glass wool into narrowing of pipette 
1. Don’t want it too compact or nothing will flow though 
c. Soak in H2O 
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d. Pipette in Resin/water solution (~0.2g/mL) 
i. Resin should settle into ~2inches above glass wool stopper 
ii. Excess water should flow though 
1. Don’t want resin leaking out (something wrong with glass wool 
packing) 
2. Resin will remove last remaining un-oxidized [3H]-PA  
e. Allow columns to remain in water until right before using 
9. Applying sample to columns 
a. Set up columns flush columns with water to ensure no resin is leaking and water 
is actually flowing though column  
b. Place scintillation vials (PerkinElmer) below tips to catch eluting water after 
flushing (1/sample) 
c. Apply 0.8 mL of each sample to column 
i. Allow sample to fully elute before next step 
d. Flush column with 0.6 mL of water x2 
i. Total volume in glass receptacle is 2 mL 
e. Add 8 mL scintillation fluid (EcoLume) that amplifies radiation from [3H] – total 
volume 10mL 
f. Cap tightly and shake vigorously 
g. Read in scintillation counter. Subtract nonspecificity controls as background. 
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Metabolite extraction from animal cells 
Introduction 
This protocol describes the extraction of intracellular metabolites from cultured animal 
cells. This is a biphasic extraction protocol, with non-polar metabolites partitioning into a 
chloroform phase and polar metabolites partitioning into a methanol/water phase. 
Required Materials and Equipment 
 Cells plated on a 100 mm dish 
 Ice-cold PBS (20 mL) 
 Ice-cold PIPES buffer (2 mL, contains 3 mM PIPES and 3 mM EDTA in MilliQ water at 
pH 7.2) 
 Methanol pre-cooled to -80ºC and stored on dry ice (2 mL) 
 Chloroform pre-cooled to -20ºC (4 mL) 
 Cell scraper 
 15 mL centrifuge tube 
 Internal standard cocktails (optional) 
 Benchtop centrifuge (Forma 5678 with model 815 fixed angle rotor) 
 Eppendorf tubes 
 Evaporator (Pierce Reacti-Vap) 
 Vortexer with attachment to hold 15 mL tubes, placed inside -20ºC freezer 
 
Protocol 
 Remove media from dish 
 Wash cells twice with ice-cold PBS 
 Add 1 mL pre-cooled methanol to dish  
 Place dish in dry ice container for 1 min 
 Scrape cells into 15 mL centrifuge tube 
 Add 1 mL pre-cooled methanol to dish  
 Remove remaining cells from dish into the same 15 mL tube 
 Add internal standard cocktails to tube (optional) 
 Add 2 mL pre-cooled chloroform 
 Vortex tube for 30 min at -20ºC  
 Add 2  mL of ice-cold water 
 Vortex sample for 5 min at -20ºC 
 Centrifuge at 3,000 rpm (~1,000g) for 20 min at lowest temperature setting 
 Collect aqueous (upper) phase in two 2 mL Eppendorf tubes (label the tubes!) 
 Collect organic (lower) phase in two 2 mL Eppendorf tubes (label the tubes!) 
 Evaporate all extracts to dryness using aeration at room temperature 
 Store samples at -80ºC 
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Western Blotting (Young Lab) 
Lysate Buffer:  
Ripa Buffer ........................1mL 
PMSF ................................20uL 
Inhibitor Cocktail  .............10-20uL 
Naorthovanadate ...............10uL 
 
1. Aspirate 
2. Wash 1-3xs with PBS 
3. Turn on side in ice to make  sure all remaining PBS drains out or accumulates in bottom 
4. Aspirate out all remaining residual PBS 
5. Add 75 uL Lysate buffer along whole top edge (6-cm plate) 
6. Swirl around plate for ~1-2 mins to make sure lysate buffer encounters all cells on plate 
7. Scrape all cells off with scrapper (THOROUGHLY) 
8. Use pipette tip remove lysis/cell solution from plate 
9. Aliquot into small eppendorf tube 
10. Allow samples to sit 30-45 mins on ice 
11. Centrifuge @13,200rpm for 20 mins @4C 
12. Remove supernatant (make sure not to get the protein pellet at the bottom!) and put into 
fresh, prechilled tubes  
Protein Assay 
13. Need Reagent A &B from BioRad kit 
14. Make A/B Solution: (50:1 A:B) so that there will be enough for 200uL/well 
15. Add 25 uL of each BSA to 96 well plate for concentrations shown below. Only need to 
use 2 wells for each conc of BSA 
 
16. Vortex extracted sample 
17. Dilute by factor of 10 (i.e at 9uL of sample to 81uL PBS) 
18. Vortex each sample/PBS mixture to ensure homogeneity and then add 25uL of each 
sample per well. Need to use 3 wells per sample.  
19. Add 200 uL A/B solution on top of each well (Do it all at the same time so the reaction 
happens at the same time 
1 2 3 4 5 6 7 8 9
A
B
C
D Sample 1 Sample 2 Sample 3 Sample 4 Sample 5…
E
F
G Sample Sample Sample Sample Sample 
H
1500 ug/uL 2000 ug/uL
25 ug/uL 
(5uL 125 + 
125 ug/uL 250 ug/uL 500 ug/uL 700 ug/uL 1000 ug/uLBSA
Samples
Samples
0 ug/uL
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20. Cover with foil and put on shaker for ~5 mins 
21. Incubate for ~25 so total time from reaction addition of A/B to reading is 30 mins 
22. Put in plate reader 
 
Sample Preparation 
23. Use concentration information from printout to create a table for necessary dilutions, as 
shown below, to find appropriate QS to get required #of samples. Need ~30ug 
protein/sample run and the final Sample+PBS+SDS buffer solution volume needs to be 
divisible by #samples and <45uL (well capacity) 
 
      
 
24. Add 10 uL of SDS PAGE buffer per 30uL of sample solution (with 1% of BME added)---
it’s the blue solution sitting out (no refrigeration needed) 
→Example: If have an avg conc of 5ug/uL from BCA assay, 5uL are need to get to 25 ug of 
total protein. If want 4 samples total for different WB then you will need 5ul X 4 
samples=20uL total. If desired QS volume is 60uL, then add 40 uL PBS to the 20uL of 
sample. Since final PBS/sample volume is 60uL, add 20 uL of SDS-PAGE buffer to each. 
Overall, there is 80uL total volume for 4 samples, so 20uL of final solution will be used for 
each WB 
 
25. Heat on block @95C for 10 mins 
26. Store at -20C until ready to load on to gels (Best if use fresh) 
a. Reheat at 95C for 5 mins after take out of freezer 
 
Running Gel 
27. Get gel set up in electrophoresis contraption 
28. Make sure to fill up inner space between 2 gels with 1XTGS (Running Buffer) and also 
up to the level of the base of the gel in the total container. Note: if only doing one gel, put 
gel sized spacer and thin smaller plastic slip (faces out) on other side of clamp to keep 
everything together 
29. Clean out wells of gel. Use 70uL of surrounding Running buffer solution to pipette into 
each well and try to blow out debris. Use pipette tip to straighten out any sagging well 
walls. 
Conc (ug/uL) Conc Undiluted uL for 30 ug 4 samples PBS to 30uL
(6) 8 hr PA 0.89 8.92 3.36 13.45 16.55
(7) 6 hr PA 0.90 9.05 3.32 13.26 16.74
(8) 6hr BSA 0.93 9.33 3.21 12.86 17.14
(9) 4 hr PA 0.82 8.19 3.66 14.66 15.34
Control 0.85 8.49 3.53 14.13 15.87
Thaps 1.02 10.19 2.94 11.77 18.23
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30. Pipette Ladder (BioRad Dual Color #161-0374) and samples into wells in SPECIFIC 
ORDER. Write down the order that you put in samples as shown below. BE SPECIFIC. 
31. Top off chamber between gels with more running buffer (until it spills over the sides) 
32. Run gel @80V for 15-20 mins until ladder looks separated 
a. NOTE: Keep the electrophoresis chamber during Running VERY COLD!! Need 
to surround chamber with a lot of ice 
33. Once ladder has separated as desired, run gel at 150-180V for ~40-45 more mins until 
ladder looks to be in good position (good separation for the kDa weight you’ll be looking 
at with protein of interest). Don’t let ladder run off gel! Always want protein levels to be 
even on running gel….Sloping=BAD! 
 
Transferring to Membrane 
   
34. Activate PVDF membrane by the following method: 
a. Wet in MeOH ~5-10sec each side. 
i. Make sure membrane is completely immersed and wetted 
ii. Do NOT want to overactive membrane in MeOH…it will be destroyed! 
iii. Use clean, non-perforated tweezers to hold membrane—Do NOT touch 
directly! 
b. Fan off excess 
c. Immediately submerge in Transfer Buffer (TB), flipping over with flathead 
tweezers several times (until “oil like” drops disappear). Soak in TB for >15 mins. 
35. In medium sized basin filled with TB and presoaked sponges/filter paper, assemble the 
transfer sandwich in the following order from BOTTOM to TOP: 
BLACK SIDE OF TRANSFER BRACKET 
SPONGE 
THICK FILTER PAPER 
GEL 
MEMBRANE (DO NOT MOVE ONCE IT IS IN CONTACT WITH GEL) 
THICK FILTER PAPER  
SPONGE 
WHITE SIDE OF TRANSFER BRACKET 
36. Place membrane on top of gel. CAREFULLY roll out any air bubbles. Make sure that gel 
and membrane do not move in relation to each other or membrane picture will be ruined. 
37. Put filter paper and sponge on top of that. Roll fiber pad sandwich somewhat more 
vigorously. 
38. Put red plastic part on top and close white clasp to complete the sandwich. 
39. If only doing one gel, make an identical sandwich but with no gel or membrane 
40. Place sandwich with actual membrane/gel in back of tank by black side (black part of 
sandwich faces black and white faces red) 
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41. Place sandwich with no membrane in red side, same orientation (order doesn’t matter if 
both have gels/membranes in them) 
42. Put ice pack into back of tank (but no actual ice-this would change the concentration of 
TB) 
43. Fill up tank with pre-cooled TB to fill line 
44. Place tank in 4C (fridge) surrounded by ice (NEED THIS VERY COLD!) 
45. Attach leads and run at 300mA for 2.5 hours 
a. Make sure that measurement instrument reads some watts to ensure that gels are 
being registered as resistance 
46. Remove transfer tank from 4C and take out membrane/gel and place in separate holders 
after cutting excess/marking membranes 
 
Blocking 
47. Place container with ~5mL Blocking buffer on rocker at RT for ~1 h 
48. Remove Blocking buffer and save for later use  
49. Wash with TBST for ~10 mins on shake plate 
 
Antibodies and Imaging 
50. Dissolve 5uL Primary Antibody in 5mL of new blocking buffer 
a. Label tube with type, initials, date, dilution factor, species-can use 4-5 times 
b. Make sure that 1:1000 dilution is appropriate (some require less) 
51. Pour antibody solution over membrane  
52. Incubate overnight on rocker at 4C  
a. Make sure this is appropriate for your antibody. Ex. Actin does not need to be 
incubated overnight. Incubating at RT for 1 hour is sufficient.  
53. Remove antibody---put back in tube & put back in 4C for later use 
54. Wash membrane with TBST @RT 2-3xs at RT for ~5-10 min each 
55. Make solution of 1:1 Blocking Buffer:TBST 
a. Make secondary antibody by making 1:10,000 dilution of antibody into above 
solution (i.e 1uL in 10mL of solution) 
b. Use anti-species secondary of whatever the species the primary antibody came 
from 
56. Incubate on rocker @RT for 60 mins  
57. Discard Secondary antibody 
58. Wash x3 TBST (~10mL) for 10 mins each on rocker. Keep in TBST for trip to imaging 
center. 
 
Imaging 
59. Add ~3mL of 50/50 mix of both chemiluniescence chemicals 
60. Incubate 1 min 
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61. Remove membranes from reaction chemicals using tweezers and place inside plastic 
sheet protector in exposure snap case. Position as desired. Close case. 
62. Go over to Light Hall 731 (Bring film!) 
63. Place exposure sheet outside of plastic sheet protector and membrane. Snap lid close and 
exposure sheet/membrane for desired time (i.e CHOP= ~1min) 
64. Remove sheet from snap case and place directly in chemical machine. Wait for developed 
image to emerge from back. Check to see exposure level and adjust next exposure time 
(+/-). Repeat until image looks satisfactory. 
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RNA Extraction and cDNA synthesis 
 Direct lysing (from a 96/24 well plate)  
1. Wash with 1 vol PBS x 3 
2. Add Buffer RLT to well (75 μL for 96-well/12-well plate or 350 μL for 24 well plate 
or bigger) 
3. Scrap cells using lifter 
4. Collect lysate into RNA-ase free microcentrifuge tube 
5. Vortex or pipet to mix, ensuring no visible clumps 
 RNA isolation (Using RNeasy mini kit) 
Before starting: - β-Mercaptoethanol (β -ME) must be added to Buffer RLT before use. β 
-ME is toxic; dispense in a fume hood and wear appropriate protective cloting. Add 10 μl 
of β -ME per 1 ml Buffer RLT. RLT buffer is stable for 1 month after addition of β -ME. 
1. Homogenize the sample: Pipet the lysate/Buffer RLT mixture directly onto a 
QIAshedder (Cat No. 79656) spin column placed in a 2 ml collection tube, and 
centrifuge for 2 min at full speed (13200 rpm) 
2. Add one volume 70% ethanol and mix thoroughly (one volume = same amount of 
Buffer RLT added) 
3. Transfer sample, including any precipitate that might have formed, to an RNeasy mini 
column placed in a 2 mL collection tube (no greater than 700 μL) 
4. Close the tube gently and centrifuge for 15 s at  8000xg (10,000 rpm). Discard 
flow though.  
5. Add 350 μl of Buffer RW1 to the RNeasy mini column 
6. Close the tube gently and centrifuge for 15 s at  8000xg (10,000 rpm). Discard 
flow though.  
a. Buffer RW1 is NOT compatible with Bleach so be careful discarding flow 
though 
7. Prepare DNAse solution (Components Cat. No. 79254) 
a. Buffer RDD  70 μl / sample 
b. DNAse  10 μl / sample 
8. Add the DNAse solution (80 μl / sample) to the RNeasy spin column membrane and 
place on the benchtop (@20-30ºC) for 15 min 
9. Add 350 μl of Buffer RW1 to the RNeasy spin column 
10. Close the tube gently and centrifuge for 15 s at  8000xg (10,000 rpm). Discard 
flow-though.  
11. Pipet 500 μl Buffer RPE onto the RNeasy column 
12. Close the tube gently and centrifuge for 15 s at  8000xg (10,000 rpm). Discard 
flow-though.  
13. Add 500 μl Buffer RPE solution to the RNeasy column 
14. Close the tube gently and centrifuge for 2 min at  8000xg (10,000 rpm). Discard 
flow-though.  
15. Place RNeasy spin column in a new 2mL collection tube.  
16. Close tube gently and centrifuge at full speed for 2 mins to dry membrane 
17. Transfer the RNeasy column to a new 1.5 ml collection tube. 
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18. Add 30-50 μl of RNease-free water directly onto the RNeasy column  
19. Close the tube gently and let it sit for 1 min. Then centrifuge for 1 min at  8000xg 
(10,000 rpm) to elute RNA 
20. Remove and discard the RNeasy column, and close the 1.5 ml collection tube 
a. RNA is not stable! Keep it in ice while working with it in downstream steps 
21. Measure the RNA concentration using Nanodop  
a. Nanodrop 
i. Open Nanodrop software 
1. Make sure Nanodrop is plugged in because wavelengths will 
be measured when software is opened 
ii. Click on Measure DNA/RNA 
iii. Click on Measure RNA at the top right 
iv. Must run blank first (2 uL RNAse free water) 
v. Run Samples 
1. Remember to record name of sample for easy recall  
2. Use 1-2uL of sample per test 
3. Do duplicates, if not triplicates 
NOTE: If the RNA needs to be stored, this should be done at -80C. This should be avoided; the 
cDNA should be prepared as soon as possible.  
 
 cDNA synthesis (Using iScript cDNA synthesis kit) 
1. After measuring the RNA content in all the samples, determine the amount of RNA 
template to be used in the cDNA synthesis (it should be as close to 1μg as possible). 
NOTE: The initial RNA amount to use as a template should be the same for all of the 
samples; it will be limited by the sample with less total isolated RNA. 
2. For each sample: 
a. In a nuclease-free 1ml tube add the following reagents: 
Components Volume per 
reaction 
5x iScript reaction mix 4 μl 
iScript reverse 
transcriptase 
1 μl 
Nuclease-free water X μl 
RNA template Y μl 
Total volume 20 μl 
X and Y depend on the amount of RNA quantified in the sample 
3. Transfer the tubes to a thermocycler and use the following protocol (40 min): 
a. 5 minutes at 25C 
b. 30 minutes at 42C 
c. 5 minutes at 85C 
d. Hold at 4C 
4. Store the cDNA at -20C 
  
168 
 
qPCR 
Primer Preparation 
 QuickSpin the tubes in which the dry oligos were delivered 
 Add the appropriate amount of water (pH around 7 according to manufacturer’s 
instructions) to make 100 M solution (should be on the sheet) 
 Shake and quickspin again 
 To make the working primer mixture, add 2.5 L (each) of the sense and anti-sense 
primers to 95 L of water (or desired concentration) 
 
cDNA Preparation 
 Want 25 ng of cDNA/well 
 Add water to appropriate cDNA so final concentration of mixture is 3.125 ng/uL 
 Add 8 uL of cDNA+H20 mixture to wells 
 
qPCR Plate Preparation 
1. Calculate the number of replicates that are needed. Typically, 3 technical replicates per 
sample per primer are needed. Make a little bit extra to account for liquid adherence 
(multiply by 3.5 for 3 replicates).  
 
2. Add to wells in the following order (per well): 
 10 L of 2X SYBR Green Mix 
 8 L of cDNA Sample 
 2 L of primer mixture 
 
3. Stick film to top of plate 
4. Centrifuge for 5 minutes  
5. Run PCR on the instruments at the core.  
 
Notes 
1. Make sure to have some wells with just H20+SYBR Green and some with 
H20+primers+SYBR Green for controls 
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Protocol for siRNA transfection (IDT DNA) 
1. Seed cells at appropriate density on plate ( 
a. 0.5 million cells/ 6-cm dish 
b. ~1.00 million cells/96 well plate 
2. Allow to attach for 24 hours 
3. Add siRNA via transfection steps below 
Transfection (make 2mL aliquots): 
a. Dilute concentrated siRNA stocks (20μM) to appropriate concentrations with DNA-, 
RNA-, and nuclease-free water (2 μM, 0.2 μM) 
b. Couple siRNA and Lipofectamine to OPTI-MEM (separately) 
 
  μL reagent 
μL Opti-
MEM 
25 nM 
siRNA 
25μL of 2uM siRNA 
soln 175 μL 
RNAiMAX 
8μL Lipofectamine-
RNAiMAX 192 μL 
 
c. Couple Lipofectamine/Opti-MEM to  siRNA/Opti-MEM by carefully mixing each 
siRNA into the respective individual lipofectamine-containing tube. Pipette up and down 
gently to mix. 
d. Incubate at room temp for 5+ mins 
e. Add lipofectamine/siRNA complex mixture to Antibiotic-Free (AF) media (contains 
glutamine and FBS)  
a. 1.6 mL AF media + 0.4 mL lipofectamine/siRNA complex = 2 mL total volume 
f. Add to cells (150 μL media/well in 96 well plate) 
g. Incubate for 24 hours 
h. Remove siRNA and replace with fresh, complete media 
i. Incubate 24-48 hours 
j. Extract RNA using RNeasy kit (Qiagen) or add treatments using AF media 
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Protocol for Lipid Transmethylation (GC-MS) 
 
1. Extract cells using protocol “metabolite extraction from mammalian cells” 
2. Dry down non-polar (lipid) fraction from chloroform in glass tube 
3. In glass tube, add 2 ml 5% sulfuric acid:methanol (v:v) made fresh 
4. Add 0.5 ml Toluene 
5. Add 30 ul (0.2 mg) C15: or C17:0 Internal Standard 6.67 ug/ul (Make internal standard 
from stock;weigh out a precise amount around 100 mg and dissolve in weighed out 
amount of heptanes, approximately 15 ml, (SG of heptane is 0.684 so 15 ml = 10.26 g) to 
give final concentration of 6.67 mg/ml)  
6. 25ul of a 0.2% BHT in methanol soln is added (final conc’n = 0.0025%, ie.80x dilute) 
7. Vortex and heat at 95°C for 2+ hours ~ occasional vortex 
8. Add 3 ml H20 and shake to quench reaction 
9. Extract with 2-3ml hexane 2x – spin to get good separation 
10. Remove hexane and pool and dry under nitrogen, occasionally clean walls by swishing 
11. Resuspend in desired amount of hexane (0.2-0.4 mL typically) and thoroughly swish to 
clean walls 
12. Dilute to desired concentration for running on GC 
13. Transfer to GC vials and run “Fatty acid Alex” 
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TLC Protocol: 
Preparing Samples-  
1. Extract cells from plates using “Metabolite Extraction for Mammalian Cells” protocol 
2. Centrifuge for 15 mins at 2500 rpm 
3. Aspirate off top fraction (methanol) 
4. Vortex remaining chloroform fraction and transfer to 2mL sample tubes 
5. Dry down using N2 and heat (37 C) – or the vacuum dryer (Shiota lab – for radioactive 
samples) 
6. Bring back up in 30-35uL chloroform (step 9) 
Preparing Tank and Plates 
7. Fill up tank with ~120 mL of tank solution: 
i. 800 mL Pet Ether 
ii. 200 mL Ethyl Ether 
iii. 10 mL Acetic Acid 
b. Make sure to saturate filter liners (Heavy Filter Paper) as tank solution is being 
poured in 
c. Do NOT fill up past the point where the sample will be on the plate; The samples 
will be ruined if directly in contact with bulk liquid  
d. Wait at least 5 mins before using tank to make sure environment is completely 
saturated 
8. Situate plate (silica with inorganic binder) so that the edge with most glass showing is at 
the top. 
a. Want the greatest possible SA contact of topping with liquid in tank 
9. Mark off spot ~1” from the bottom on the surface (scratch or with pencil) 
10. Add 30-35 uL chloroform to dried sample & vortex 
11. Using syringe, take up sample and squeeze out liquid across 2 cm on plate (2.5 cm if 
using only 4 samples) 
a. Leave at least 1 cm between samples so they do not bleed together 
b. Do NOT scratch plate! 
12. Rinse sample vial with 30-35 mL additional chloroform and squeeze out over top of 
initial respective sample spot on plate 
13. Place plate with silica/chalky side facing toward the center of the tank (away from 
respective filter paper) 
14. Let run for ~20-30 mins until liquid is 1” from top of plate 
15. Remove plate from liquid and spray with Rhodamine 6G spray (DO NOT SHAKE 
SPRAY!) 
16. Allow sprayed plate to dry under hood 
17. Visualize with UV if necessary 
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Scintillation counting and analysis for radioactive tracers 
18. There will be 5 spots per sample (in order): Phospholipid (PL), Diacylglyceride (DAG), 
Free fatty acid (FFA), Triglyceride (TG), Cholesterol ester (CE). Scrape each spot into an 
individually labeled vial for scintillation counting 
19. Add 10 mL of scintillation liquid to each labeled scintillation vial 
20. Close tightly (dangerous substance) and shake vigorously for 30 seconds  
21. Count with scintillation counter  
22. Analyze sample lipid partitioning (with 3H-PA) as follows: 
a. Sum up all counts for each sample (i.e. add up counts of 
PL+DAG+FFA+TG+CE) 
b. Divide the counts for each fraction and divide by total of all fractions summed 
together 
 
 
 
